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1 Introduction 
1.1 Vascular remodeling 
The vessel wall is composed of the intima formed by the endothelial cells, the media 
built of vascular smooth muscle cells (VSMC) and the outer adventitia containing 
fibroblasts and extracellular matrix [1].  
1.1.1 Structure of the vessel wall 
The endothelial cells form the inner monolayer of a vessel, the intima. As the only 
cells of the vasculature, the endothelial cells have direct contact to the blood in the 
vessel. The endothelium not only provides a barrier between blood and underlying 
cell layers, but also plays a role in the regulation of the vascular tone. Endothelial 
cells secret vasodilating substances such as nitric oxide (NO) or prostacyclin (PGI2) 
as well as vasoconstricting substances like platelet activating factor (PAF) and 
endothelin-1. The endothelium also regulates the traffic of the cellular elements in the 
blood, like erythrocytes, thrombocytes and leukocytes through interaction of these 
cells with endothelial cellular adhesion molecules at the surface of the endothelium. 
VSMCs form the media of the vessel wall. They regulate the vessel tone, the blood 
pressure and the distribution of the blood flow. Although the VSMC have the ability to 
proliferate, under physiological conditions the proliferation as well as the metabolic 
rates are very low. 
The outer layer of the vessel contains fibroblasts and extracellular matrix forming a 
very stable fibrious connective tissue. Its main function is the stabilization of the 
vessel under varying pressure. 
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1.1.2 Characteristics of vascular remodeling 
Structural changes in the three layers of the vessel wall are generally designated as 
vascular remodeling. Thereby, changes in cellular proliferation, in cell migration and 
apoptosis as well as changes in the composition of the extracellular matrix occur. 
Besides physiological vascular remodeling which takes place during embryonic 
development and vasculogenesis, vascular remodeling is also associated with a 
variety of diseases like atherosclerosis, ischemic diseases, systemic and pulmonary 
hypertension and tumor growth [2, 3].  
One of the first events in pathophysiological vascular remodeling is an endothelial 
dysfunction which is associated with a decrease in NO availability leading to a 
change in the vascular tone due to increased contractility of the smooth muscle cells 
[4]. This change in the vascular tone can subsequently activate the endothelium 
resulting in the recruitment of leukocytes und inflammatory processes. Damage of the 
endothelium can lead to the coagulation cascade and the formation of thrombin. 
Subsequently VSMC become activated, which results in a change in their phenotype. 
They proliferate and synthesise growth factors and components of the extracellular 
matrix, which can lead to a thickening of the media. 
1.1.3 Examples for vascular remodeling 
1.1.3.1 Pulmonary hypertension 
One pathological process accompanied by strong vascular remodeling is pulmonary 
hypertension [2]. Pulmonary hypertension is characterized by a thickening of the 
smooth muscle cell layer. Consequently, the vessels become stiff and show 
increased vasoconstriction. This eventually results in the elevation of pulmonary 
artery pressure and pulmonary vascular resistance and can subsequently cause 
heart right ventricle hypertrophy and failure. Pulmonary hypertension is also often 
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associated with the formation of so called plexiform lesions [5]. In this case 
disordered proliferation and migration of endothelial cells take place together with 
neoangiogenesis. Smooth muscle cells transdifferentiate into myofibroblasts 
altogether forming the plexiform lesions and finally resulting in luminal narrowing.  
1.1.3.2 Atherosclerosis 
Another disease accompanied by vascular remodeling is atherosclerosis 
characterized by a strong decrease of the vessel lumen due to the formation of an 
atherosclerotic plaque (Fig. 1). Rupture of this plaque can lead to thrombosis and 
subsequently to stroke or heart failure [6]. A lesion in the endothelium leads to 
recruitment of thrombocytes, T-lymphocytes and monocytes, the latter can transform 
into foam cells by uptake of low density lipoproteins (LDL) and oxidized LDL (oxLDL) 
[7]. Growth factors and cytokines released by foam cells as well as blood-borne 
factors like thrombin lead to VSMC proliferation and migration. Activated VSMC form 
together with foam cells then so called fatty streaks. 
 
Fig. 1   Schematic overview about the progression of atherosclerosis. 
Starting from early stages (fatty streaks) atherosclerosis progresses by continued inflammatory 
processes and lipid accumulation to early atherosclerotic lesions finally resulting into either rupture of 
the plaque or plaque stabilization (modified from 
http://en.wikipedia.org/wiki/File:Endo_dysfunction_Athero.PNG, used under the GNU Free 
Documentation License). 
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Continued lipid uptake and proliferation then finally result in advanced lesions with a 
fibrious cap sealing off the plaque. The cap can either become thick, stabilizing the 
plaque, or can rupture, exposing the plaque content to the blood and resulting in a 
platelet aggregation and clot formation. 
1.2 Role of reactive oxygen species in the vasculature 
Reactive oxygen species (ROS) have been originally described as cytotoxic 
molecules responsible for bacterial killing in host defense produced by phagocytic 
cells including neutrophils, monocytes and macrophages [8, 9]. These species 
include superoxide anion radicals (O2-.), hydrogen peroxide (H2O2) and hydroxyl 
radicals (OH.). Single electron reduction of molecular oxygen results in superoxide 
anion radical formation. Although this highly reactive molecule is membrane 
impermeable, it can use anion channels in the cell membranes for transmigration [10, 
11]. Spontaneously or catalized by the superoxide dismutase (SOD), superoxide 
anion radicals are transformed into H2O2, which is less reactive than superoxide 
anion radicals. On the other hand, H2O2 diffuses more easily and has a longer half life 
time than O2-. H2O2 is then either enzymatically metabolized by catalase or 
glutathione-peroxidase (GPx) or is converted in a Fenton reaction with transition 
metals like ferrous ions (Fe2+) into highly reactive hydroxyl radicals. Superoxide anion 
radicals can also react with NO, which is produced in endothelial cells by NO 
synthase, forming peroxynitrite leading to a decrease in the NO bioavailability (Fig. 
2). More recently, it has been appreciated that also non-phagocytic cells, including 
vascular cells, can produce ROS at low levels which play a role as signaling 
molecules in a wide spectrum of physiological and pathophysiological responses [12], 
including endothelial dysfunction, vascular remodeling and atherosclerosis. In 
endothelial cells, low levels of ROS appeared to be required for proliferation and 
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growth and to be implicated in tube formation and angiogenesis [13, 14]. Exposure to 
higher doses of ROS can also elicit an apoptotic response, modulate vascular tone, 
impair the endothelial barrier functions, promote thrombosis and mediate vascular 
remodeling processes [15-17]. Increased and sustained production of ROS is 
associated with the pathogenesis of various cardiovascular diseases including 
diabetes, hypertension, atherosclerosis, heart failure and ischemia reperfusion [16-
18].  
1.3 Structure and function of NADPH oxidases 
The structure and function of the NADPH oxidase were primarily described in 
neutrophils, where it is composed of the two membrane-bound subunits p22phox and 
NOX2 – previously known as gp91phox forming the flavocytochrome b558 as the 
catalytic core of the NADPH oxidase [8, 19, 20]. Other important components are the 
cytosolic subunits p40phox, p47phox, p67phox and the small GTP-binding protein 
Rac. Dormant in resting neutrophils, p47phox becomes phosphorylated after 
stimulation with pathogens like bacterial lipopolysaccharids [20, 21]. This  
phosphorylation leads to a change in their conformation and subsequently 
O2-
. NO
H2O2
Cu, Zn SOD
Mn SOD
EC SOD
Catalase
GPx
ONOO.
OH. + NO2H2O
Fe2+
 
Fig. 2   Reactive oxygen and reactive nitrogen species in vascular cells. 
Schematic overview of reactive oxygen and nitrogen species in the vasculature. SOD: superoxide 
dismutase. Cu (II): Copper II ions as cofactor for SOD. GPx: Gluthation peroxidase. Fe(II) Iron II ions 
as cofactor for the GPx. (adapted from [22]) 
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translocation and association with the flavocytochrome b558 at the membrane. In 
addition, loading of Rac with GTP and interaction of active Rac with p47phox and 
p67phox triggers the translocation of Rac to the flavocytochrome b558 at the 
flavocytochrome b558 in the right direction for electron transfer [23, 24]. The finally 
activated oxidase releases large amounts of superoxide in the well characterized 
respiratory burst (Fig. 3). 
The physiological significance of the phagocytic NADPH oxidase is illustrated by 
chronic granulomatous disease (CGD) caused by mutations in any of the genes 
encoding gp91phox, p22phox, p47phox or p67phox subunits of the NADPH oxidase. 
Phagocytes of patients suffering from CGD are unable to produce O2-., and these 
patients are therefore highly susceptible to bacterial and fungal infections. The other 
membrane-bound component of the flavocytochrome b558, p22phox, is a 22-kDa 
membrane protein. As described, p22phox forms together with NOX2 the catalytical 
core of the phagocytic NADPH oxidase [25, 26]. Moreover, upon stimulation, 
p22phox gp91phox
p40phox
p47phox
p67phox
P P P
O2 O2.-
NADPH NADP+
Rac GTP
RhoGDI
Rac GDP
Rac GTP
GEF
Active
p22phox gp91phox
p40phox
p47phox
p67phox
Resting Activation
Extracellular
Intracellular
 
Fig. 3   Schematic overview of the structure and activation of the phagocytic NADPH 
oxidase. 
In resting phagocytic cells, gp91phox forms together with p22phox a membrane bound 
flavocytochrome b558. The cytosolic factors p40phox, p47phox and p67phox form a cytosolic compex. 
In activated phagocytic cells, the cytosolic complex translocates to the membrane upon 
phosphorylation of p47phox. Activation of Rac leads to the fully activation of the NADPH oxidase. 
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p22phox binds to p47phox to assemble the active oxidase [20]. Expression of 
p22phox is ubiquitous and has been shown in all vascular cell types underlining the 
essential function of this component for the assembly and activation of NADPH 
oxidases. Interestingly, several polymorphisms in the p22phox gene were identified. 
A polymorphism in the p22phox promoter revealed higher promoter activity and has 
been associated with hypertension [27]. Furthermore, increased levels of p22phox 
and other NADPH oxidase subunits have been identified in the vascular wall after 
balloon angioplasty, as well as in atherosclerosis, hypertension, diabetes and other 
disorders and have been associated with elevated ROS levels in these disorders [18, 
28-31]. 
Recently, a NOX2-containing NADPH oxidase has been described to be functionally 
active in endothelial cells together with the other components of the neutrophil 
enzyme, which have also been identified in these cells [32, 33]. In contrast to 
neutrophils, endothelial cells produce ROS already under basal conditions. Exposure 
of endothelial cells to different stimuli including endothelin-1 (ET-1), angiotensin-II 
(AngII), tumor necrosis factor α (TNFα), thrombin, platelet-derived growth factor 
(PDGF), insulin growth factor-1 (IGF-1), interleukin-1 α (IL1-α), vascular endothelial 
growth factor (VEGF), transforming growth factor-β (TGF-β), LDL or oxLDL, results in 
ROS production [34-37]. However, ROS levels achieved in vascular cells are 
significantly lower than in leukocytes, suggesting that important differences exist 
between neutrophil and endothelial NADPH oxidases, for example expression levels 
or functional regulation [32]. In recent years, homologues of NOX2 (NOX1-NOX5) as 
well as homologues of p47phox (p41nox or NOXO1) and p67phox (p51nox or 
NOXA1) were discovered to be expressed in different cell types including vascular 
cells suggesting the presence of different NADPH oxidase forms in these cells 
(Fig. 4, 5) [8, 38, 39]. In addition to the NOX2-containing NADPH oxidase, NOX4 has 
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been recently found to be expressed in certain types of endothelial cells suggesting 
that it may play a role in endothelial ROS generation [40]. Interestingly, high levels of 
NOX2 mRNA have been found in veins whereas the amount of NOX4 mRNA was 
found to be elevated in arteries compared to veins suggesting that the abundance 
and the potential functional role of the NOX proteins may also differ in different 
vascular beds [29]. Only very recently, NOX1 has been detected in certain 
endothelial cells [41, 42]. However, it is unclear whether its cofactors NOXO1 and 
NOXA1 are expressed in endothelial cells. So far, NOX3 has been only found in the 
inner ear [43, 44] and fetal tissue. NOX5 has been described to contain an amino 
terminal calmodulin-like domain with four binding sites for calcium (EF hands) [45]. In 
addition, two related proteins, called DUOX1 and DUOX2, mainly expressed in 
thyroid tissue, have NOX-homologous regions as well as regions with peroxidase 
activity [20, 46]. It has been suggested for NOX5 that calcium-binding induces a 
conformational change to intramolecular interactions between the N-
NOX2 
(gp91phox)
NOX3
NOX1
NH2 COOH
NOX4
Transmembrane
helices
FAD NADPH 
Binding domain
NOX5 
EF-hands
 
Fig. 4   Schematic overview of the NOX homologues NOX1 to NOX5. 
Simplified structures of the NOX homologues NOX1 to NOX5 showing homologue domains. Red: 
transmembran helix. Green: FAD binding domain. Blue: NADPH binding domain. EF-hands: calcium-
binding motives. 
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terminus and the C-terminal catalytic domain which may result in enhanced ROS 
production upon addition of free calcium or ionomycin [45, 47]. To date four splice 
variants named NOX5α, NOX5β, NOX5γ and NOX5δ (GenBankTM AF353088, 
AF325189, AF353089 and AF325190, respectively) which differ in the sequence of 
their EF hands, have been described [45]. NOX5α was found in spleen and NOX5β 
in testis [45] whereas the cellular presence of NOX5γ and NOX5δ has not been 
shown, yet. In addition, expression of NOX5 protein has been described in a prostate 
carcinoma cell line [48] and in malignant B-cell hairy leukemic cells [49], while NOX5 
mRNA was found in the stomach [50] as well as in cardiac fibroblasts [51].  
1.4 Endoplasmic reticulum stress and unfolded protein response 
Most of the newly discovered homologues to NOX2 (NOX1 - 5) have been 
associated with intracellular membrane systems, especially the endoplasmic 
reticulum (ER) [52-56]. There is evidence for the interaction between NOX1 and 
NOX4 with the protein disulfide isomerase (PDI), an ER-localized thiol 
oxidoreductase assisting in redox protein folding [56-58]. 
SH3TPR TPR TPR TPR AD SH3 PB1
PB1NOX2Rac
p40phox
PRR
p47phox
SH3TPR TPR TPR TPR AD PB1 C
C
N
N
Rac PRR
NOXO1
p67phox
NOXA1
B
SH3 SH3 PRRN C
SH3 SH3 PRRN CAIR
phosphorylation
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p22phox
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NOXO1
PtdIns(4)P
PtdIns(5)P
PtdIns(3,5)P2
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A
 
Fig. 5   Schematic overview of NOXO1 and NOXA1 in comparison with their 
homologues p47phox and p67phox. 
A. Schematics of p47phox and NOXO1. NOXO1 is lacking the autoinhibitory region (AIR) of p47phox. 
B. Schematics of p67phox and NOXA1. NOXA1 is lacking the N-terminal located SH3 domain. PX: 
phosphoinositide binding domain; SH3: Src homology 3 domain; AIR: autoinhibotory region; PRR: 
proline rich region; TPR: tetratricopeptide repeat; AD: activating domain; PB1: Phox and Bem1 domain 
(adapted from [59]). 
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Pathophysiological processes such as atherosclerosis are associated with the 
accumulation of oxysterols which induces ER-stress, which is characterized by a 
disturbance in the normal ER function leading to an accumulation of mis- or unfolded 
proteins, and triggers the unfolded protein response (UPR) (Fig. 6) [16, 55, 60]. The 
UPR is characterized by a general attenuation in protein synthesis with a 
simultaneous increase in UPR genes such as specific transcripton factors, 
chaperones and proteins of the protein degradation machinery for an increased ER- 
associated degradation of proteins. Prolonged UPR results finally in apoptosis [61, 
62].  ER-stress is associated with an accumulation of misfolded proteins. This 
accumulation results in an increased binding of the binding brotein (BiP or GRP78) to 
these proteins. Under physiological conditions, BiP is bound to the PRKR-like 
endoplasmic reticulum kinase (PERK), the ER-membrane located inositol requiring 
element 1 (IRE1) and the activating transcription factor 6 (ATF6) inhibiting their 
ER
BIP
PERK IRE1 ATF6
golgi
nucleus
eIF2α eIF2α-P
XBP1ATF4 ATF6
(p50)
XBP1 mRNA splicing
(general translation
attentuation)
(selective
translation)
UPRE UPR genes
 
Fig. 6   Schematic overview of the unfolded protein response (UPR). 
Accumulation of unfolded proteins leads to higher requirement of BiP leading to the activation of the 
kinase PERK, IRE1 and ATF6. PERK activation leads to increased ATF4, IRE1 activation to increased 
XBP1 activation. ATF4, XBP1 and ATF6 binds to UPR elements in UPR-gene promoters (adapted 
from http://biochemistry.utoronto.ca/volchuk/images/UPR.jpg).  
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activation. Dissociation of BiP activates PERK, IRE1 and ATF6. Under non-stress 
conditions, ATF6 is anchored in the ER-membrane by an N-terminal transmembrane 
domain. Upon ER-stress, ATF6 translocates to the Golgi compartment, where the 
active cytosolic part is released. It travels to the nucleus activating the transcription of 
UPR genes including the X-box binding protein 1 (XBP1) [62]. The ER-
transmembrane glycoprotein IRE1 contains both kinase and RNase activities in the 
cytoplasmic domain. ER-stress leads to autophosphorylation and activation of IRE1 
RNase activity which initiates the splicing of XBP1 mRNA generating a mature XBP1  
mRNA to be translated (Fig. 7A). This splice variant of XBP1 is a potent transcription 
factor whereas the product of the unspliced mRNA has been suggested to inhibit 
transcription [61, 62]. XBP1 induces UPR genes including PDI. The ER 
transmembrane protein kinase PERK phosphorylates the α-subunit of the translation 
initiation factor 2 (eIF2α) leading to reduced formation of translation initiation 
complexes and subsequently general attenuation of translation. 
ER lumen
nucleus
UPRE UPR genes
unstressed stressed
PERK
ATF4
eIF2α
P
eIF2α
AUG AUG ATF mRNAAUG
general translation
attentuation
P P
ER lumen
XBP1 mRNA
unspliced
XBP1 mRNA XBP1 mRNA
spliced
XBP1s
nucleus
UPRE UPR genes
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IRE1
P P
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Fig. 7   Activation of ATF4 and XBP1 by unfolded protein response. 
A. Activation of ATF4 expression by ER-stress. PERK getting activated and phosphorylates eIF2α 
leading to an increase in ATF4 translation. B. ER-stress leads to activation of IRE1. IRE1 processes 
specifically the mRNA of XBP1. Spliced XBP1 mRNA is translated into the active form of XBP1 
whereas unspliced XBP1 mRNA is translated into an inactive protein (adapted from [63]). 
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Paradoxically, translation of mRNAs having a lower requirement for eIF2α and the 
translational initiation complex are enhanced including the activating transcription 
factor ATF4 which induces UPR genes (Fig. 7B) [62]. Prolonged ER-stress leads to a 
phosphorylation cascade initiated by IRE1 resulting in activation of JNK and 
mitochondria/Apaf1-dependent caspases ending in apoptosis. This process has been 
associated with ROS and NOX4 expression has been recently associated with this 
response in SMCs [55].  
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1.5 Aims 
Although initial evidences have been provided that a NOX2 containing NADPH 
oxidase is expressed and functionally active in endothelial cells, the differential 
expression and potential functions of the novel NOX homologues have not been fully 
understood. Thus the overall aim of this study was to better characterize the 
expression, regulation and function of NOX homologues (NOX1 – NOX5) in different 
endothelial cell models. The hybridoma cell line Ea.Hy926 which is derived from 
human umbilical vein endothelial cells fused with the lung carcinoma cell line A549 
was used as a model for endothelial cells from larger vessels. In contrast, human 
microvascular endothelial cells HMEC1 were used as a model for endothelial cells 
from smaller, capillary vessels. 
Hereby, specific aims were formed: 
1. It was aimed to analyze the expression levels of NOX1, NOX2, NOX4 
and NOX5 and their interaction with p22phox as well as the expression 
levels of the p47phox and p67phox homologues NOXO1 and NOXA1 in 
human endothelial cells.  
2. It was aimed to characterize the functional role of the NOX homologues 
in endothelial cells, specifically to analyze their contribution to the basal 
ROS production and proliferation. 
3. Since ER-stress and thrombin induced cellular stress have been 
associated with increased ROS generation, it was aimed to investigate 
whether NOX1, NOX2, NOX4, NOX5 as well as p22phox participate in 
cellular stress induced by thrombin, tunicamycin or thapsigargin. 
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2 Material and Methods 
2.1 Materials 
2.1.1 Equipment list 
Device Product name company 
Analytical balance B 301 S Sartorius 
Autoclave big KSG 116-2-ED KSG 
Autoclave small KSG 25-2-3 KSG 
Balance BP 4100 S Sartorius 
Bunsen burner Vulcan Heraeus 
Centrifuges Biofuge fresco Heraeus 
 Biofuge pico Heraeus 
 Biofuge stratos Heraeus 
 Megafuge 1.0 R Heraeus 
 Varifuge 3.0 R Heraeus 
Deep-freezer (-70°C) Hera freeze Heraeus 
Fluorescence microscope IX50 Olympus 
 Hg-Lamp U-RFL-T Olympus 
 Camera Controller Hamamatsu 
 Filtermodule improvision 
Orbit 
improvision 
 Hg-Lamp U-RFL-T Olympus 
Liquid-N2-Dewar Locator 6 Plus Thermolyne 
Freezer (-20°C) comfort Liebherr 
Freezer big (-20°C) comfort Liebherr 
Fridge big profi line Liebherr 
Fridge small Premium Liebherr 
Fridge-freezer combination   Liebherr 
Gel documentation system  Gel Doc 2000 BioRad 
Heating block Thermomixer comfort Eppendorf 
Heatingplate CM1850 Leica 
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Hybridization oven Herahybrid 12 Heraeus 
Hypoxia bench  Hypoxia Workstation IUL Instruments 
Incubator Hera Cell Heraeus 
Incubator Binder WTC Binder 
Isopropanol freezing box Qualifreeze Qualilab 
Laboratory dishwasher  G7783CD Mielabor Miele 
laminar airflow cabinet 
(hood) 
Hera Safe Heraeus 
Luminometer AutoLumat plus Berthold Technologies 
Magnetic stirrer with heater MR3001 Heidolph 
Magnetic stirrer without 
heater 
MR3000 Heidolph 
Microscope HAL 100 Zeiss 
Microscope Axiovert 25 Zeiss 
Microwave   Whirlpool 
Millipore water supply Milli-Q synthesis Millipore GmbH 
Mini-table-top-centrifuge Capsulefuge PMC-060 TOMY 
pH Meter pH 540 GLP WTW 
Photometer U-2001 
Spectrophotometer 
Hitachi 
Platereader Tecan Safire Tecan 
Power supplies Power Pac  200 BioRad 
 Power PAC 300 BioRad 
 Power Pac 3000 BioRad 
Pump CVC 2000 vacuubrand 
Roller mixer RM5 Assistent Karl Hecht KG 
Rotator   Fröbel Labortechnik 
GmbH 
SDS-PAGE hardware Mini-Protean 3 BioRad 
Shaker Duomax 1030 Heidolph 
 IKA-Schüttler MTS2 
electronic 
IKA-Werke 
 Polymax 1040 Heidolph 
Shaker-incubator  C24 Incubator Shaker New Brunswick 
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Scientific 
Stand-dewar   KGW Isotherm 
Thermocycler iCycler BioRad 
 PCR System 9700 PE Applied Biosystems 
 Rotor-Gene 6000 Corbett 
 SDS 7700 Applied Biosystems 
Transfer hardware Mini Protean 3 BioRad 
UV-Stratalinker Stratalinker 1800 Stratagene  
Vacuum pump   Neuberger 
Vortexer   
 Reax top Heidolph 
 Vortex-Genie 2 Scientific Industries 
Water bath Grant SUB 
 “no name”  Memmert 
2.1.2 Chemicals   
Name Company 
Acetic acid  Carl Roth GmbH   
Actinomycin D  Sigma  
Agar  Carl Roth GmbH   
Agarose NEEO Ultra quality  Carl Roth GmbH   
Alamar Blue  Biosource  
Ammonium persulfate  Carl Roth GmbH   
Ampicillin  Calbiochem  
Amidoblack  Carl Roth GmbH 
BAPTA Sigma 
Bovine serum albumin  Sigma  
Brilliant Blue G250 Carl Roth GmbH 
Calciumchlorid-Dihydrate Merck 
Chloroform  Merck  
Coumaric acid  Sigma  
DCF  MoBiTec /Invitrogen 
Diethylpyrocarbonate (DEPC)  Carl Roth GmbH 
diaminobenzidine Sigma 
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Dihydroethidium (DHE) MoBiTec /Invitrogen 
Dimethylsulfoxide (DMSO) Carl Roth GmbH 
Dithiothreitol  (DTT) Carl Roth GmbH    
Ethylene diamine tetraacetic acid (EDTA) Carl Roth GmbH   
Ethylene glycol tetraacetic acid (EGTA) Carl Roth GmbH   
Ethanol Merck  
Ethidium bromide  Carl Roth GmbH    
Formaldehyde 37%  Merck  
D-(+)-glucose Sigma 
Glycine Carl Roth GmbH  
Glycerol  Carl Roth GmbH   
Guanidinethiocyanate Carl Roth GmbH  
Hank’s balanced salt solution (HBSS) Gibco  
Hydrochloric acid  JT Baker  
Hydrogen peroxide  Merck  
Igepal CA-630 Sigma 
Ionomycine Sigma 
Isoamylalcohol  Merck  
Isopropanol  JT Baker  
Kanamycine sulfate Calbiochem 
Lucigenin Sigma 
Luminol Sigma 
Magnesium carbonate hydroxide Sigma 
Magnesium chloride-hexahydrate Carl Roth GmbH  
Magnesiumsulfat-heptahydrat Applichem 
Maleic acid Sigma 
Manganese-(II)-chloride Merck 
Mayer's hemalum solution Merck 
β-mercaptoethanol  Carl Roth GmbH   
3-(N-morpholino)propanesulfonic acid (MOPS) Carl Roth GmbH  
N-nitro-L-arginine  Calbiochem  
Non-fat dry milk powder  Merck  
PBS-tablettes GibCo /Invitrogen 
Phenylmethanesulfonyl fluoride (PMSF) Sigma 
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Ponceau S  Carl Roth GmbH   
Potassium acetate Merck 
Potassium carbonate Merck 
Potassium chloride Merck 
Potassium dihydrogene Phosphate Merck 
Potassium hydrogencarbonate Merck 
Potassium hydroxide Carl Roth GmbH  
Phorbol 12-myristate 13 Acetate  Sigma  
Roti-aqua-phenol  Carl Roth GmbH   
Rotiphorese gel 30% Carl Roth GmbH   
P38 MAP kinase inhibitor (SB202190) Calbiochem   
SDS ultra pure  Carl Roth GmbH   
Sodium acetate  Merck  
Sodium chloride  Carl Roth GmbH   
Sodium citrate  Carl Roth GmbH   
Sodium dihydrogen phosphate  Sigma  
Sodium fluoride  Merck  
Sodium orthovanadate  Merck  
Sucrose Sigma 
Sulfuric acid  Carl Roth GmbH   
TEMED  Carl Roth GmbH   
Thapsigargin Sigma 
Thrombin  Haemochrom Dignostik  
Tricine Carl Roth GmbH  
Trifluoroacetic acid Sigma 
Tris ultra Carl Roth GmbH  
Triton® X-100 Sigma 
Trypan blue (C.I. 23850) Merck 
Tryptone Carl Roth GmbH  
Tunicamycin Sigma 
Tween® 20 Sigma 
Vitamin C  Sigma  
Xylenecyanol  Carl Roth GmbH   
Yeast extract  Carl Roth GmbH   
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2.1.3  Cell culture reagents 
Cell culture media and additives  Company  
Dulbecco's Modified Eagle Medium (DMEM) Gibco, PAA 
Fetal calf serum (FCS) Pan Biotech  
HAT supplement  Gibco  
MCDB 131  medium  Gibco  
Endothelial basal medium PAA 
Penicillin / streptomycin  Gibco  
SmBm-2 medium  Cambrex / Lonza  
SmGm-2 single Quot  Cambrex / Lonza 
Trypsin-EDTA  Gibco, PAA 
PBS PAA 
HBSS with Mg/Ca Gibco, PAA 
2.1.4 Kits   
Name Company  
ABI PRISM BigDye Terminator v1.1 Cycle Sequencing 
Kit 
Applied Biosystems 
BrdU proliferation assay  Roche  
Jetstar Plasmid Maxi Kit Genomed 
Nucleo Seq sequencing clean-up kit  Macherey-Nagel  
Qiagen RNeasy Mini Kit Qiagen 
Qiagen Plasmid Maxi Kit  Qiagen  
siSTRIKE™U6 Hairpin Cloning System (Human)-
Neomycin 
Promega 
SuperScript™III Reverse Transcriptase Invitrogen 
Expand High FidelityPLUS PCR System Roche 
Phusion™ High-Fidelity DNA Polymerase NewEngland Biolabs 
qPCR MasterMix (Plus) for SYBR© green I Eurogentec 
2.1.5 Plasticware   
Item Company  
T75 flasks  Greiner  
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10 and 6 cm dishes  Sarstedt  
6-, 24- and 96-well plates  Greiner  
2, 5, 10 and 25 ml pipettes  Sarstedt  
1.5 and 2 ml reaction tubes  Sarstedt  
15 ml and 50 ml tubes  Sarstedt  
Cryovials  Greiner  
2.1.6  Bacteria  
For amplification of plasmids, chemical transformation was performed with competent 
bacteria of the following stems: 
Subcloning 
Bacteria stem Genotype 
DH-5α F-φ80lacZM15 (lacZYA-argF)U169 recA1 endA1 
hsdR17(rk-, mk+) phoAsupE44 thi-1 gyrA96 relA1 λ- 
XL-1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ 
proAB lacIqZM15 Tn10 (Tetr)] 
JM109 (e14–(McrA–) recA1 endA1 gyrA96 thi-1 hsdR17 (rK– mK+) 
supE44 relA1 (lac-proAB) [F´ traD36 proAB lacIqZM15]) 
Mutagenesis 
XL-10 Ultracompetent 
cells 
(TetrD(mcrA)183 D(mcrCB-hsdSMR-mrr)173 endA1 supE44 
thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZDM15 
Tn10 (Tetr) Amy Camr]) 
TOP10F´ F´ {lacIq Tn10 (TetR)} mcrA (mrr-hsdRMS-mcrBC) 
Φ80lacZM15 lacΧ74 recA1 araD139 (ara-leu)7697 galU 
galK rpsL (StrR) endA1 nupG 
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2.1.7 Plasmids   
2.1.7.1 Overview 
The following vectors and plasmids were used:   
Plasmid name Reference 
Cloning vectors  
pCR2.1-Topo-TA  Invitrogen 
Expression vectors  
pcDNA3.1- Invitrogen 
pcDNA3.1p22phoxS Djordjevic et al. 2005 
psDNA6.1ECFP Djordjevic et al. 2005 
pcDNA6.1hp22phoxECFP Djordjevic et al. 2005 
pcDNA3.1NOX4S Djordjevic et al. 2005 
pFLAG-p22YN Petry et al. 2006 
pCMV-NOX4YC Petry et al. 2006 
pcDNA3.1-NOX2YC Petry et al. 2006 
pcDNA3.1-NOX2 Petry et al. 2006 
pcDNA3.1-YC Petry et al. 2006 
pcDNA3.1-YN Petry et al. 2006 
pCDNA3.1-NOX5β Banfi et al. 2004 
pcDNA3.1-NOX5S BelAiba, Djordjevic, Petry et al. 2007 
pCMV-NOX5β-YC BelAiba, Djordjevic, Petry et al. 2007 
pCMV-NOX5S-YC BelAiba, Djordjevic, Petry et al. 2007 
pCMVSPORT6-ATF4 RZPD 
pCMVSPORT6-XBP1 RZPD 
pEF/myc/ER/YFP Petry et al. 2006 
pER-CFP Petry et al. 2006 
pER-DsRed T.Kietzmann, Kaiserslautern 
pCMV-hPDI T.Kietzmann, Kaiserslautern 
pCMV-hPDImut T.Kietzmann, Kaiserslautern 
Gene silencing plasmids  
pSTRIKE-None Petry et al. 2006 
pSTRIKE-p22phox Petry et al. 2006 
pSTRIKE-NOX2 Petry et al. 2006 
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pSTRIKE-NOX4 Petry et al. 2006 
pSTRIKE-NOX1 Petry et al. 2006 
pSTRIKE-NOX5 BelAiba, Djordjevic, Petry et al. 2007 
pSTRIKE-ATF4 Unpublished 
pSTRIKE-XBP1 Unpublished 
Reporter gene constructs  
pGL3B-p22phox1.2Kluc M. Weitnauer 
pGL3P-p22phox-XBPluc M. Weitnauer, K. Diemer 
pGL3-Promoter Promega Corporation 
pGL3-Basic Promega Corporation 
2.1.7.2 Expression vectors  
To obtain pcDNA3.1p22phoxS (p22S) the full length cDNA fragment encoding human 
p22phox derived from pBShp22phox (provided by Dr. M. Dinauer, Indianopolis, USA) 
was digested with EcoRI, blunt-ended with mung bean nuclease and the fragment was 
ligated into pcDNA3.1 in sense and antisense direction resulting in p22S.  The human 
NOX4 full length cDNA was cut out from pCMV4-SPORT-NOX4 (RZPD, Accession 
number NM-016931) by AvaI, and blunted using Klenow fragment. It was then inserted 
into pcDNA3.1 linearised with EcoRV resulting in pcDNA3.1NOX4 sense construct 
(NOX4S). 
The plasmid pCMVERCFP encoded for an endoplasmatic localization sequence fused 
to the cyan fluorescent protein (CFP) and the pEFERYFP plasmid were a gift from Dr. 
M. Grez (Frankfurt a. M., Germany). For the p22phoxYN and the YFP-p22phox 
constructs, polymerase chain reaction (PCR) with primers adding appropriate 
restriction sites was performed on the pcDNA3.1- p22phoxS plasmid to amplify the 
human p22phox coding sequence and cloned either into the pCMV-FLAG-bJunYN 
vector (kindly provided by Dr. T. Kerppola, Ann Arbor, MI) or pEYFP-C1 (BD 
Biosciences Clontech), resulting in pCMV-FLAG-p22phoxYN, encoding for a FLAG-
p22phoxYN chimera, and pEYFP-C1-p22phox plasmid encoding for the YFP-p22phox 
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chimera, respectively. The pcDNA3.1-YN was created by cutting the YN-fragment 
from pCMV-FLAG-bJunYN with BamHI and subcloning it into pcDNA3.1. For the 
NOX4YC and the YFP-NOX4 fusion constructs, the cDNA encoding for human NOX4 
was amplified by PCR from pcDNA3.1-NOX4S using specific primers for adding 
appropriate restriction sites and cloned into the pCMV-HA-bFosYC vector (kindly 
provided by Dr. T. Kerppola) or pEYFP-C1 resulting in pCMV-NOX4YC encoding for 
NOX4YC and in pEYFP-C1-NOX4 encoding for YFP-NOX4. The full-length human 
NOX2 cDNA was derived from pBShgp91phox and subcloned into pcDNA6.1CFP 
resulting in pcDNA6.1hgp91phoxCFP encoding for CFP-NOX2. For the NOX2YC 
fusion construct, the YC-fragment was cut from pCMV-HA-bFosYC and subcloned into 
pcDNA3.1, resulting in pcDNA3.1-YC. For NOX2YC and for NOX2 expression vectors, 
NOX2 was amplified from pcDNA6-ECFP-NOX2 by PCR using primers adding 
appropriate restriction sites and subcloned either in pcDNA3.1 or into pcDNA3.1-YC, 
resulting in pcDNA3.1-NOX2 and pcDNA3.1-NOX2YC, respectively. All other 
expression plasmids were already in the lab or purchased from the company listed in 
the table above.  
2.1.7.3 Luciferase reporter plasmids 
The plasmid containing the full p22phox-promoter (pGL3B-p22phox1.2Kluc) was 
based on the pGL3-Basic vector containing a multiple cloning site adjacent upstream 
to the luciferase coding sequence, whilst the plasmids containing only small part 
upstream of the putative promoter sequence were based on the pGL3-Promoter 
plasmids containing a SV40 promoter driving the transcription of the luciferase gene 
(Fig. 8). Both the pGL3B-p22phox1.2Kluc and the pGL3P-p22phox-XBPluc were 
already present in the lab, and were cloned from HEPG2 genomic DNA using 
polymerase chain reaction with primers attaching approbiate restriction sites at the 5´-
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end and at the 3´-prim end and were subcloned into the pGL3-Basic or pGL3-
Promoter. 
BA
 
Fig. 8   Luciferase reporter plasmid maps. 
For luciferase reporter gene assay, two types of vectors were used: pGL3-Basic (A) contained a 
multiple cloning site 5’ to the luciferase coding sequence to enable the analysis of full promoters whilst 
the pGL3-Promoter (B) vector had a multiple cloning site in front of an SV40 promoter 5’ to the 
luciferase gene thus enabling analysis of enhancer sequences (©Promega Cooperation, 
www.promega.com, used with permission). 
2.1.7.4 Gene silencing vectors 
Selective gene silencing can be achieved by using short double stranded interfering 
RNAs (siRNA) which match the sequence of the gene to be silenced. This is done by 
either direct transfecting siRNA duplexes into the cell or via endogenous production of 
siRNA. In this study, in vivo expression of siRNA was conducted by the transfection of 
an expression vector (psiSTRIKE, Promega) which produced siRNA as fold-back 
stem-loop structures (short hairpin RNA, shRNA) that were transcribed from a U6 
promoter thanks to a linker sequence (5’- TTC AAG AGA -3’) joining the sense to the 
antisense sequence. The oligos also had terminal PstI sites which enabled sticky end 
ligation to the psiSTRIKE vector (supplied linearised with PstI). This enzyme was later 
used for confirmation of insert. Two oligonucleotides with the same sequence as the 
target siRNA sequence were synthesized and annealed to form a DNA insert 
containing the hairpin siRNA target sequence. Upon annealing, the oligonucleotides 
formed ends that were compatible with the ends of the linearised psiSTRIKE vector 
thus facilitating a "sticky end" ligation (Fig. 9). The oligonucleotides were designed 
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using the siRNA Target Designer program on the Promega website and a random 
sequence was used as control siRNA. 
  
siRNA vector
sense antisenseHuman U6 Promoter
loop
siRNA
Duplex
RISCsiRNA
mRNA
RISCsiRNA
Cleaved mRNA
expression
processing
cleavage
 
Fig. 9   Principle of gene silencing using the siStrike system. 
A double stranded oligonucleotide containing the sense and antisense of the to be silenced target RNA 
is linked into the target psiSTRIKE vector under the control of the human U6 promoter. After 
transfection, RNA polymerase III produces short hairpin RNA (shRNA) which is then processed to short 
interfering RNA (siRNA) with the effect of silencing mRNA homologous to the target sequence in the 
RISC complex (adapted from http://www.abcam.com) 
The following oligonucleotides were generated: 
Name Sequence (5’-> 3’) 
siCtr-F ACCGTCTCCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGAATTTTTC 
siCtr-R TGCAGAAAAATTCTCCGAACGTGTCACGTTCTCTTGAAACGTGACACGTTCGGAGA 
siNOX4-F ACCGCCTCTACATATGCAATAATTTGTGTAGTTATTGCATATGTAGAGGCTTTTTC 
siNOX4-R TGCAGAAAAAGCCTCTACATATGCAATAACTACACAAATTATTGCATATGTAGAGG 
sip22-F ACCGGCCCTTTACCAGGAATTATTTGTGTAGTAATTCCTGGTAAAGGGCCTTTTTC 
sip22-R TGCAGAAAAAGGCCCTTTACCAGGAATTACTACACAAATAATTCCTGGTAAAGGGC 
siNOX2-F ACCGAATCTCACCTTTCATAAATTTGTGTAGTTTATGAAAGGTGAGATTCTTTTTC 
siNOX2-R TGCAGAAAAAGAATCTCACCTTTCATAAACTACACAAATTTATGAAAGGTGAGATT 
siNOX1-R TGCAGAAAAAGCACCGGTCATTCTTTATACTACACAAATATAAAGAATGACCGGTG 
siNOX1-F ACCGCACCGGTCATTCTTTATATTTGTGTAGTATAAAGAATGACCGGTGCTTTTTC 
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siXBP1-F ACCGAAGTAGACATGGAATTTATTTGTGTAGTAAATTCCATGTCTACTTCTTTTTC 
siXBP1-R TGCAGAAAAAGAAGTAGACATGGAATTTACTACACAAATAAATTCCATGTCTACTT 
siATF4-F ACCGGTGGCCAAGCACTTCAAATTTGTGTAGTTTGAAGTGCTTGGCCACCTTTTTC 
siATF4-R TGCAGAAAAAGGTGGCCAAGCACTTCAAACTACACAAATTTGAAGTGCTTGGCCAC 
 
 
2.1.8 Oligonucleotides 
2.1.8.1 Cloning primers 
Restriction sites underlined 
Name Restriction 
enzyme 
Sequence (5´-> 3´) AT(°C) 
BiFC vectors 
 
  
p22phoxYN F (EcoRI) ATGAATTCAGGGCAGATCGAGTGGGCC 
55 
 R (XbaI) CCTCTAGACACGACCTCGTCGGTCACC 
p47phoxYC F (EcoRI) AGGAATTCCGATGGGGGACACCTTCATCCGTC 
58 
 R (KpnI) TCGGTACCGACGGCAGACGCCAGCTTC 
p47phoxYN F (EcoRI) ATGAATTCGATGGGGGACACCTTCATCCG 
58 
 R (XbaI) TATCTAGAGACGGCAGACGCCAGCTTC 
p67phoxYC F (EcoRI) ATGAATTCGGATGTCCCTGGTGGAGGCCATC 
58 
 R (KpnI) TAGGTACCGACTTCTCTCCGAGTGCTTTCC 
gp91phoxYC F (XhoI) ATCTCGAGGCCACCATGGGGAACTGGGCTGTGAATG 
59 
 R (XhoI) TACTCGAGcGAAGTTTTCCTTGTTGAAAATGAAATG 
Nox5SYC F (EcoRI) ATGAATTCAAATGGAGAACCTGACCATCAGGGCTG 
59 
 R (KpnI) TAGGTACCGAAATTCTCTTGGAAAAATCTGAAGCCG 
Nox4YC F (ApaI) ATGGGCCCGCCGCCATGGCTGTGTCCTGGAGGAGC 
59 
 R (KpnI) CCGGTACCGCTGAAAGACTCTTTATTGTATTC 
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Expression vectors  
F-N4-SacI-w/oATG F (SacI) AAGAGCTCGGGCTGTGTCCTGGAGGAGC 
59 
R-Nox4-KpnI-STP  R (KpnI) TTGGTACCTCAGCTGAAAGACTCTTTATTGTATTC 
2.1.8.2 RT-PCR primers 
Target Sequence (5´->3´) AT(°C) P 1roduct length 
p22phox 
CAGATCGAGTGGGCCATGT 
57 571 
TCGTCGGTCACCGGGATG 
NOX1 
GTCTTCTGGTATACTCACCACC 
54 228 
GAATGACCGGTGGAAGGATCCAC 
NOX2 
CATGTTTCTGTATCTCTGTGA 
57 614 
GTGAGGTAGATGTTGTAGCT 
NOX4 
CCATGGCTGTGTCCTGGAGGAGCTG 
57 389 
AGTTGAGGGCATTCACCAGATGGGC 
GAPDH 
TATGACAACAGCCTCAAGAT 
58 316 
AGGTCCACCACTGACACGTT 
NOX5 
ATGAGTGGCACCCCTTCACCATCAG 
65 501 
TTCGAGTGGTTTGTGAGCCTGCTGAC 
NOX5α 
/NOX5γ  
GGCCCTGAAGGCTGTAGAGGCA 
65 326/451 
GCGCAGCTCATCCGGGTCAATG 
NOX5β/ 
NOX5δ  
CAGGACGGTACTCCGCTGACACCTT 
65 
577/661 
GCGCAGCTCATCCGGGTCAATG 
 
2.1.8.3 qPCR primers 
Target Sequence (5´-> 3´) Product length 
NOX1 CACCCCAAGTCTGTAGTGGGAG 
91 
 
CCAGACTGGAATATCGGTGACA 
GAPDH GAAGGTGAAGGTCGGAGTC 
226 
 
GAAGATGGTGATGGGATTTC 
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2.1.8.4 Sequencing primers 
Primer-Name Sequence (5´->3´)  
R-YC-Seq CCCGCGGCCGCTTACTTGTACAG  
Sp6 CATACGATTTAGGTGACACTATAG  
M13 Forward (-20) GTAAAACGACGGCCAG  
M13 Reverse CAGGAAACAGCTATGAC  
CMV-F CGCAAATGGGCGGTAGGCGTG  
BGH-R TAGAAGGCACAGTCGAGG  
2.1.9 DNA modifying enzymes  
2.1.9.1 DNA polymerase I, large (Klenow) fragment  
DNA polymerase I, Large (Klenow) Fragment is a DNA polymerase that contains 3´5´ 
exodeoxyribonuclease activity. It is used to fill-in 5´ overhangs to make blunt-ended 
vectors and/or inserts.  
2.1.9.2 Calf alkaline phosphatase  
Alkaline phosphatases catalyse the dephosphorylation of 5’ phosphates from DNA and 
RNA. Once dephosphorylated, the 5'-hydroxyl end cannot be ligated to a 3'-hydroxyl 
end of double-stranded DNA. In this way, dephosphorylated ends can be prevented 
from religating to themselves or to other dephosphorylated DNA molecules, increasing 
the efficiency of the ligation reaction.  
2.1.9.3 T4 DNA ligase  
T4 DNA ligase can be used to join DNA fragments with staggered or blunt ends and to 
repair nicks in double-stranded DNA having 3'-hydroxyl and 5'-phosphate ends. The 
enzyme is isolated from E. coli lambda lysogen NM989. It catalyzes the formation of a 
phosphodiester bond between adjacent nucleotides only if one nucleotide carries a 5´-
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phosphate residue and the other carries a 3´-hydroxyl terminus. It was therefore used 
to clone inserts into the multiple cloning sites of cloning vectors.  
2.1.10 TOPO cloning 
For some clonings the TOPO-TA cloning kit (Invitrogen) was used in accordance to 
the manual (Fig. 10). The target vector pCR2.1-TOPO is supplied linearized with the 
following charactisticts: 
- Single 3´-thymidine (T) overhangs for TA Cloning 
- Topoisomerase I covalently bound to the vector (referred to as "activated" 
vector)  
The PCR itself was performed with the Taq polymerase containing Expand High 
FidelityPLUS PCR System (Roche). The Taq polymerase has a nontemplate-
dependent terminal transferase activity that adds a single deoxyadenosine (A) to the 
3´ ends of PCR products. The pCR2.1-TOPO vector contains a single overhanging 3´ 
deoxythymidine (T) residue which allows PCR inserts to ligate efficiently with the 
vector. Topoisomerase I from Vaccinia virus binds to duplex DNA at specific sites and 
cleaves the phosphodiester backbone after 5′-CCCTT in one strand [64-67]. The 
energy from the broken phosphodiester backbone is conserved by formation of a 
covalent bond between the 3′ phosphate of the cleaved strand and a tyrosyl residue 
(Tyr-274) of topoisomerase I. The phospho-tyrosyl bond between the DNA and 
enzyme can subsequently be attacked by the 5′ hydroxyl of the originally cleaved 
strand, reversing the reaction and releasing topoisomerase [68]. The TOPO-TA 
cloning was used as a first cloning step of the NOX5 and NOX4 for the pCMV-
NOX5SYC and pEGFP-NOX4.  
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Fig. 10   Schematic overview over the TOPO cloning principle. 
The TOPO target pCR2.1-TOPO vector contains a single 3´-T-overhang covalently bound to the 
Topoisomerase I. Adding of a PCR product or other DNA-sequence containg a single 3´-A-overhang 
and incubation results in a ligation of the PCR product and the pCR2.1-TOPO vector and a release of 
the Topoisomerase I (adapted from www.invitrogen.com). 
2.1.11 Solutions 
All solutions were prepared with doubledestilled water if not otherwise stated. 
2.1.11.1 Northern blot solutions 
DEPC Water      
500 µl DEPC were added to 900 ml dH2O and left overnight with slightly opened lid 
at room temperature. The solution was then autoclaved. 
 
GT    
Guanidine thiocyanate 4 M   
Na-citrate   25 mM 
N-Lauryl Sarcosine  0.3% 
      
MOPS buffer (10x)    
MOPS   0.2 M 
Sodium acetate   80 mM   
EDTA   10 mM 
The pH were adjusted to 7.0. 500 µl DEPC was added to 900 ml 10x MOPS buffer 
and left overnight with slightly opened lit. The solution was then autoclaved. 
SSC (20x)    
NaCl   3 M 
Sodium citrate   0.3 M 
500 µl DEPC were added to 900 ml 20X SSC and left overnight with slightly opened 
lit. The solution was then autoclaved. 
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Premix for RNA probes 
Formamid   10 ml  
Formaldehyd 37%   3.5 ml   
10 X MOPS   2.0 ml  
Ethidium Bromide   0.03 µg   
The solution was aliquoted and stored at - 20°C.  
  
Blue marker for RNA probes (10x)    
Glycerine   1 ml  
Bromphenolblue   1.6 mg   
Xylenecyanol   1.6 mg  
EDTA pH 8.0   1 mM 
DEPC H20   2 ml  
The solution was stored at 4 °C.  
 
Hybridisation solution   
20 X SSC 25% 
Formamid 50% 
10 X Blocking reagent 20% 
N-Lauryl Sarcosinate 0.01% 
SDS  0.02% 
   
Washing solution  
Maleic acid  0.10 M  
NaCl  0.15 M  
The pH was adjusted to 7.5.  
  
Blocking 
solution 
     
10X Blocking solution (Roche) was diluted 1:9 in washing solution.  
Detection solution  
Tris   0.1 M  
NaCl   5 M  
The pH was adjusted to 9-9.5. 
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2.1.11.2 Western blot solutions 
Running gel (volume for one gel) 
Percentage  8% 10% 12%  
H20 (ml)  3.4 2.8 2.1  
30% acrylamid 
(Rotiphorese gel) (ml) 
 2.7 3.3 4  
1M Tris pH 8.8 (ml)  3.7 3.7 3.7  
10% SDS (µl)  100 100 100  
For polymerization, 80 µl ammoniumpersulfate and 10 µl of TEMED were added. 
 
Stacking gel 
Percentage   5%   
H20 (ml)   2.14   
30% acrylamid (ml)  0.488   
1M Tris pH 6.8 (ml)  0.375   
10% SDS   30   
For polymerization, 15 µl ammoniumpersulfate and 3 µl of TEMED were added. 
 
Laemmli buffer (3x)   
Tris pH 6.8   187 mM   
SDS   6%   
Glycerol   30%   
Bromphenol blue   0.06%   
DTT   15 mM   
EDTA   60 mM   
      
 
Running buffer 
    
Tris   25 mM   
Glycine   200 mM   
SDS   0.5%   
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Transfer buffer     
Tris   25 mM   
Glycine   200 mM   
Methanol   20%   
      
Stripping buffer     
SDS   2%   
Tris pH 6.8   62.5 mM   
β-
Mercaptoethanol 
  0.07%   
      
Enhanced chemiluminescent reagent 1 (ECL1)  
Tris pH 8.8   100 mM   
Luminol   2.5 mM   
Coumaric acid   0.4 mM   
      
Enhanced chemiluminescent reagent 2 (ECL1)   
Tris pH 8.8   100 mM   
H2O2   0.15%   
 
Phospho-buffer   
Tris pH 7.4 50 mM 
NaCl 300 mM 
10% Triton 100  1% 
500mM EDTA  2 mM 
500mM EGTA  2 mM 
125 mM Na4P2O7  10 mM 
100mM Na3VO4  0.5 mM 
chymostatin, antipain, leupeptin, 
pepstatin, and aprotinin 
2µg / ml each 
PMSF  1mM 
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2.1.11.3 Solutions and media for molecular biology 
SOC medium Final (%) in H2O  
Yeast extract  0.5%  
Tryptone   2%  
NaCl   0.05% 
After dissolving in 950 ml of water, 10 ml of 250 mM KCl solution (final concentration 
2.5 mM) were added and pH was adjusted to 7.0. The solution was then autoclaved 
and thereafter 20 ml of sterile 1 M solution of glucose (final concentration 5 mM) and 
5 ml of sterile 2 M MgCl2 (final concentration 0.5 mM) were added. 
 
LB medium 
 
Yeast Extract 0.5 % 0.5% 
Tryptone 1% 
NaCl 1% 
The pH was adjusted to 7.2 and the solution autoclaved. 
 
LB plates    
Agar 1.5%   
Antibiotic (Ampicilin or Kanamycin) 1%    
Agar was added to LB medium prior to autoclaving. After cooling to 45-50°C 
antibiotic was added, mixed and plates were poured. 
 
TSS 
NaCl 1% (w/v) 
Tryptone 1% (w/v) 
Yeast Extract 0.5% (w/v) 
MgCl2  30 mM 
PEG 4000 10% 
DMSO  5% 
The pH was adjusted to 6.5 with NaOH, buffer sterile filtered and stored at 4°C.  
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TAE (50x stock in 1 litre H2O) 
Tris 242 g 
Glacial acetic acid 57.1 ml 
EDTA 0.5M pH 8.0 100 ml 
Water Add 1000ml 
In the 1x working solution was 40mM Tris acetate and 1mM EDTA. 
 
6x Gel loading dye (in H2O) 
Bromophenol blue 0.25% (w/v) 
Sucrose 40 % (w/v) 
2.1.11.4 Solutions for luciferase reporter gene assay 
Luciferase lysis buffer  
Tris pH 7.8 5 mM 
trans-CDTA 0.4 mM 
99.5% Glycerol 50% 
DTT 2 mM 
Triton-X 100 5% 
DTT and Triton-X 100 were added after autoclaving and buffer was stored at -20°C.  
Luciferase substrate  
Tricine pH 7,8  20 mM 
(MgCO3)4. Mg(OH)2.5H2O  1.07 mM 
MgSO4  2.67 mM 
EDTA  0.1 mM 
DTT  33.3 mM 
D-Luciferin  460 mM 
ATP  580 mM 
The pH was adjusted to 7.8. The solution was stored in 12 ml aliquots at -70°C. 
Before use the solution was warmed to 37°C and protected from light at all times.  
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2.1.11.5 Solutions for immunofluorescence and immunohistochemistry 
M/A solution   
Methanol  50%  
Acetone  50%  
Store at -20°C.  
  
Blocking solution   
BSA  5% 
In PBS   
  
Citrate buffer   
Citric acid pH 6.0  0.01 M  
in water.   
2.1.11.6 Solutions for cell culture 
HEPES-buffered phosphate (HBSS) 
HEPES  25 mM  
NaCl  140 mM  
Na2HPO4  0.75 mM  
The solution was adjusted to pH 7.5 and sterilised by filtration.  
2.1.12   Antibodies 
Primary antibodies were prepared in 5% non-fat dry milk powder or 5% BSA diluted in 
Tris buffered salt solution containing 0.3% Tween 20 (TBS-T). 
TBS-T    
Tris pH 7.5   50 mM 
NaCl   150 mM 
HCl (37%)   0.3%  
Tween    0.3%  
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2.1.12.1 Primary antibodies 
Antibody Isotype Company Dilution 
   
WB 
(in 5% milk) 
IF 
(in 5% milk) 
β-Actin Goat polyclonal Santa Cruz 1/1000  
α-Actin Mouse monoclonal Dako IHC: 1:100 
f-actin Alexa Fluor488-
coupled phalloidin  Molecular Probes  1:1000 
ARNT Mouse monoclonal Abcam 1:1000  
ATF4 Rabbit polyclonal Santa Cruz 1:500  
Calnexin Mouse monoclonal BD Biosciences 1:1000  
Calreticulin Mouse monoclonal Upstate 1:1000 1:1000 
eIF2α Mouse monoclonal Cell Signaling 1:2000  
Flag Mouse monoclonal Sigma 1:4000  
GFP Rabbit polyclonal Molecular Probes 1:1000 1:200 
GFP Mouse monoclonal Roche 1:1000 1:200 
gp91phox/NOX2 Rabbit polyclonal upstate 1:500 1:100 
HA Mouse monoclonal Roche 1:1000  
NOX1 Rabbit polyclonal Eurogentec, peptide: CAESFEMWDDRDSH 1:1000 1:100 
NOX1 Goat polyclonal Santa Cruz 1:500  
NOX2 (cl. 49) Mouse monoclonal Kindly provided by Dr. D. Roos, Amsterdam 1:500  
NOX4 Rabbit polyclonal Eurogentec, peptide: CSYGTRFEYNKESFS 1:500 1:100 
NOX4 Goat polyclonal Santa Cruz 1:500  
NOX5 Rabbit polyclonal 
Davids Biotechnologie 
GmbH; peptide: 
QTRTQPGRPDWSKVF 
1:500 1:100 
NOX5 Rabbit polyclonal Eurogentec, peptide: TRAYWHNHRSQLFC 1:500 1:50 
p22phox Rabbit polyclonal 
Eurogentec, peptides: 
CEQWTPIEPKPRERPQ 
YPRGKRKKGSTMERWC 
1:500 1:100 
p22phox (cl. 449) Mouse monoclonal Kindly provided by Dr. D. Roos, Amsterdam 1:250  
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Phospho-p38 
MAP Kinase Rabbit monoclonal Cell Signaling 1:1000  
p38 MAP Kinase Rabbit monoclonal Cell Signaling 1:1000  
PDI Mouse monoclonal Stressgene 1:10000 1:2000 
p-eIF2α Rabbit monoclonal Cell Signaling 1:1000  
XBP1 Rabbit polyclonal Santa Cruz 1:500  
 
2.1.12.2 Secondary antibodies 
Western blot 
Antibody Company Dilution 
Goat anti mouse HRP conjugated Calbiochem 1:10000 
Goat anti rabbit HRP conjugated Calbiochem 1:10000 
Rabbit anti goat HRP conjugated Calbiochem 1:10000 
   
Immunofluorescence 
Antibody Company Dilution 
Mouse IgG Alexa Fluor 488 Molecular Probes/Invitrogen 1:200 
Mouse IgG Alexa Fluor 594 Molecular Probes/Invitrogen 1:200 
Rabbit IgG Alexa Fluor 488 Molecular Probes/Invitrogen 1:200 
Rabbit IgG  Alexa Fluor 594 Molecular Probes/Invitrogen 1:200 
Goat  IgG Alexa Fluor 488 Molecular Probes/Invitrogen 1:200 
Goat  IgG Alexa Fluor 568 Molecular Probes/Invitrogen 1:200 
Goat  IgG Alexa Fluor 594 Molecular Probes/Invitrogen 1:200 
   
Immunohistochemistry 
LSAB2 Systems HRP Dako 
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2.2 Methods 
2.2.1 Cell biology methods 
2.2.1.1 Cells 
2.2.1.1.1 Ea.Hy926  
The human endothelial cell line Ea.Hy926 (kindly provided by Dr. U. Foerstermann, 
Mainz, Germany) is a permanent cell line established by hybridization of human 
umbilical vein endothelial cells with the permanent human cell line A549 [69]. This 
cell line is well characterized for its endothelial phenotype and biology, and 
expresses markers of highly differentiated vascular endothelium, including factor VIII-
related antigen, which is maintained for more than 100 cumulative populations. Cells 
were grown in DMEM medium with 1 g/l glucose, containing 10% FCS, 100 U/ml 
penicillin and 100 g/ml streptomycin. Since Ea.Hy926 cells need to be cultured in 
selective medium to maintain the endothelial phenotype, medium was supplemented 
with 1.5x Hypoxanthine, Aminopterin, Thymidine (HAT) and cells were maintained at 
37°C under the humidified atmosphere of 5% CO2. Cells were cultured in T75 flasks 
and passaged twice a week by trypsinisation. First, cells were briefly rinsed and then 
incubated with 2 ml of 0.05% trypsin containing 0.53 mM EDTA•4Na for 1-2 minutes 
at 37°C. The digestion was stopped by adding complete medium and cells were 
subcultured in the ratio 1:3 in T75 flasks or were approbiated seeded in dishes or 
plates. Prior to stimulation cells were starved from serum in DMEM medium 
containing 1.5x HAT, 100 U/ml penicillin and 100 g/ml streptomycin for 16 h.  
 
 
Materials and Methods 
 40
2.2.1.1.2 HMEC-1 
The permanent endothelial cell line, HMEC-1 is derived from human dermal 
microvascular endothelial cells transfected with a pBR-322-based plasmid containing 
the coding region of the simian virus 40 A gene product, large T antigen. They are 
immortalised cells which have retained all the morphological, phenotypic and 
functional characteristics of normal human microvascular endothelial cells [70]. 
The cells were grown at 37°C, 5% CO2 in MCDB or EBM medium supplemented with 
10% FCS, 100 U/ml penicillin, 100 U/ml streptomycin, 10 mM L-glutamine, 0.5 g 
hydrocortisone and 50 pg epidermal growth factor. The culture medium was changed 
every two days and the cells were trypsinised at 90% confluency to prevent 
senescence as described before.  
2.2.1.1.3 Other cell lines  
The human cervix carcinoma cell line HeLa (ATCC CCL-2), the human embryonic 
kidney cell line HEK293 (ATCC CRL-1573) and the colon carcinoma cell line CaCo2 
(ATCC HTB-37) were cultured in DMEM with 1 g/l glucose, 10% fetal calf serum, 100 
U/ml penicillin, and 100 g/ml streptomycin. The human hepatocellular carcinoma 
cell line HepG2 (ATCC HB-8065) cultured in DMEM with 4.5 g/l glucose, 10% fetal 
calf serum, 100 U/ml penicillin, and 100 g/ml streptomycin. Pulmonary artery 
smooth muscle cells (PASMC) were purchased from Lonza and grown in the 
provided SmBm medium supplemented with 5% foetal bovine serum and the 
“SmGm-2 Single Quot” supplement containing insulin, human fibroblast growth 
factor-B and epidermal growth factor. PASMC were used only up to passage 12 in 
order to maintain the phenotypic characteristics of PASMC. All cells were grown at 
37°C and 5% CO2 and passaged twice a week.  
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2.2.1.2 Storage of the cells 
To store the cells in liquid nitrogen, confluent cells were detached by trypsinisation 
and centrifuged at 1000 rpm for 5 minutes. Cells were then resuspended in 
precooled culture medium containing 10% DMSO and transferred to cryovials. To 
allow gradual freezing, vials were then placed in a cold isopropanol freezing box and 
kept for one day at -70°C. Thereafter, cells were frozen at -70°C and kept for at least 
24 h to acclimate to extreme cold. Finally, cells were transferred to and stored in 
liquid nitrogen (-196°C). 
2.2.1.3 Transfection of endothelial cells 
Ea.Hy926 cells were transfected using the Effectene transfection reagent. The 
Effectene reagent is a non-liposomal lipid formulation that spontaneously forms 
micelle structures that show no variations in size or batch. In the first step of 
transfection, DNA is highly condensed by interaction with DNA-condensation buffer 
(Buffer EC) with the help of the Enhancer solution in a ratio 1:8 (DNA : Enhancer). 
Then, Effectene reagent is added in a ratio 1:10 (DNA : Effectene) in order to coat 
condensed DNA molecules and produce Effectene-DNA complexes, thus allowing 
transfer of DNA into eukaryotic cells. When performing transfections, Ea.Hy926 cells 
were seeded one day before the experiments in 96-well plates or 10 cm dishes to 
achieve 50-70% confluency on the following day. Per one well of 96 well plates 
0.3 µg of plasmid DNA was diluted in DNA-condensation buffer EC to a total volume 
of 5 µl, 2.4 µl Enhancer solution and 3.0 µl of Effectene reagent was used. For a 10 
cm dish 4.5 µg of DNA were mixed with 180 µl of EC buffer and 36 µl Enhancer 
solution and incubated for 3 minutes. Then 45 µl Effectene reagent was added, the 
mixture vortexed for 10 seconds and incubated for 8 minutes at room temperature to 
allow the formation of the transfection complex. Thereafter, the growth medium from 
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the plate was gently aspirated, 100 µl of serum containing media per one well of a 96 
well plate or 5 ml per 10 cm dish was added to the cells. The transfection complex 
was filled up to a total volume of either 50 or 500 µl, mixed by pipetting and 
immediately added to the cells. The transfection efficiency was about 60%.  
HMEC-1 were transfected using the SuperFect reagent. SuperFect transfection 
reagent is an activated dendrimer with a defined spherical architecture, with branches 
radiating from a central core and terminating at positively charged amino groups. Net 
positive charge allows them to bind to negatively charged receptors on the surface of 
eukaryotic cells (e.g. sialylated glycoproteins). Once inside the cell, SuperFect 
reagent buffers the lysosome after it has fused with the endosome, leading to pH 
inhibition of lysosomal nucleases and stability of SuperFect–DNA complexes. For 
transfection experiments, cells were plated one day before transfection. A ratio of a 
total of 1 µg of DNA to 5 µl Superfect per well was used in each transfection. After 
2 h of incubation with the transfection complex, the medium was changed, and the 
cells were further cultured. Before stimulation, cells were serum-starved 16 h prior to 
stimulation. 
2.2.1.4 Transfection of HEK293 and HeLa cells  
The calcium phosphate method was used to transfect HEK293 and HeLa cell lines. 
This method is based on the method described in the Maniatis’ laboratory manual 
[71].  
A precipitate containing calcium phosphate and DNA is formed by slowly mixing a 
HEPES-buffered phosphate solution with a solution containing 2.5 M calcium chloride 
and DNA. These DNA precipitates are then taken into eukaryotic cells by an 
endocytic-type mechanism.  
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DNA was diluted to the required concentration with water and calcium chloride was 
added. The solution was mixed well and centrifuged down. HEPES was then added 
while vortexing the mixture vigorously. After spinning down, it was incubated for 10 
minutes. Then, medium of the cells were changed against fresh medium and 
transfection mixture was added to the cells. 
2.2.1.5 Luciferase Assay  
The luciferase reporter gene assay makes use of the firefly luciferase enzyme gene 
to catalyse the chemiluminescent redox reaction of luciferin to oxyluciferin. By placing 
the luciferase gene under the control of a promoter or enhancer sequence, it can be 
used to study gene activation under different stimuli or to investigate the effect of a 
protein on the activity of a particular promoter or enhancer. The procedure described 
here is based on the Promega manual for Luciferase activity.  
Cells were transfected with a plasmid containing the luciferase gene which is under 
control of the promoter under investigation. After cell lysis, the proteins are mixed 
with a substrate containing luciferin and ATP. Firefly luciferase is a monomeric, 
61 kDa-enzyme that catalyzes luciferin oxidation using ATP Mg2+ as a cosubstrate. 
Light is produced by converting chemical energy of luciferin oxidation through an 
electron transition, forming oxyluciferin. The light produced is directly proportional to 
the amount of luciferase present and is therefore a measure of promoter activity in 
the luciferase vector.  
Cells (HEK293 or Ea.Hy926 cells) were plated in 24-well plates at 50-60% confluency 
and transfected the next day. After transfection the cells were left in serum 
supplemented medium for 24 hours. Then the cells were stimulated with either 
Tunicamycin (2 µg/ml) or Thapsigargin (2.5 nM) for 8 hours or left unstimulated. The 
medium was aspirated and passive lysis buffer optimised for luciferase extraction 
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was then added (HEK293: 500 µl, Ea.Hy926: 400 µl). The plates were placed on a 
shaker for 30 minutes and centrifuged at 500 g for 5 minutes at 4°C to deposit cell 
debris to the bottom of the wells. Then 150 µl lysed cells were transferred to 
measuring tubes or the lysate was stored at -20°C for later analysis.  
To measure the luciferase activity, samples were loaded on a luminometer (Berthold 
Technologies, Pforzheim, Germany). The luminometer was programmed to inject 
100 l of luciferase substrate and to measure average luminescence for 5 s at 37°C. 
Finally, protein content of the total lysate was determined by performing Bradford 
assay. 
2.2.1.6 DCF fluorescence measurement 
The generation of reactive oxygen species (ROS) was measured using the 
fluoroprobe 5-(and-6)-chloromethyl-2‘,7‘-dichlorodihydrofluorescein diacetate, acetyl 
ester (CM-H2DCFDA (DCF)). Fluorescent dyes, like fluorescein, are chemically 
reduced to colorless, nonfluorescent products easily reoxidized in the presence of 
ROS to fluorescent compounds. Dichlorodihydrofluorescein diacetate passively 
diffuses into the cells where its diacetate groups are cleaved by cellular esterases, 
giving a more polar compound that stays trapped in the cells. The carboxylated 
analogue of H2DCFDA passes even easier through the membranes and has better 
retention in the cells, since it has two negative charges at physiological pH. 
Moreover, thiol-reactive chloromethyl groups react with gluthatione and other thiols, 
further preventing the leakage of the dye from the cells (Fig. 12).  
Subsequent oxidation of DCF gives a fluorescent product that remains trapped in the 
cells and indicates ROS production. DCF is sensitive to H2O2, but it also detects 
peroxynitrite (ONOO-) that is formed in a reaction between NO. and O2.-. Endothelial 
cell express eNOS and produce high amounts of NO.. Therefore, when measuring 
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ROS in endothelial cells, the contribution of ONOO--dependent DCF oxidation was 
excluded by preincubating the cells for 30 minutes with the eNOS inhibitor N-ω-nitro-
L- arginine methyl ester (L-NAME, 10 µM), and by adding L-NAME to HBSS. To 
determine DCF fluorescence in a microplate reader (Tecan), endothelial cells were 
grown in 96-well plates to 80% confluence, or transfected as described above, and 
made quiescent in serum free medium for 16 h. Cells were then treated, washed with 
HBSS and incubated in the dark with DCF (8.5 µM) dissolved in HBSS for 10 minutes 
at 37°C. Cells were then washed with HBSS to remove excess dye, and fluorescence 
was monitored using 480 nm excitation and 540 nm emission wavelength. In some 
experiments, cells were preincubated with various inhibitors or antioxidants for 
30 minutes and then exposed to stimuli. To evaluate ROS levels, background 
fluorescence of unloaded cells was subtracted from DCF fluorescence. Moreover, 
DCF fluorescence was standardized to the number of viable cells using the 
alamarBlue test. Continued cellular growth maintains a reduced environment in the 
cells, and therefore causes the redox indicator from alamarBlue to change from the 
oxidized, nonfluorescent, blue form to the reduced, fluorescent, red form. Therefore, 
to determine the number of viable cells, cells were incubated with alamarBlue in 
Esterases
Thiol reactive group
  
Fig. 11   Structure of 5-(and-6)- chloromethyl-2',7'- dichlorodihydrofluorescein diacetate, 
acetyl ester (CM-H2DCFDA). 
Explanations are given in the text. 
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HBSS at 37°C to allow the indicator to change from blue to the fully reduced red 
form. The absorbance was then measured at the wavelength of 580 nm. 
2.2.1.7 Dihydroethidium fluorescence measurement 
Generation of ROS was visualized by the fluoroprobe dihydroethidium (DHE), which 
is also called hydroethidine. DHE passively diffuses into the cells exhibiting blue 
fluorescence. After oxidation, predominantly with O2.-, DHE is oxidized to ethidium, 
giving a more polar compound that intercalates within DNA and stains the nucleus in 
fluorescent red (Fig. 13). To evaluate the levels of ROS, endothelial cells were grown 
in 96-well plates to 80% confluence, and growth-arrested in serum free media for 16 
h. Cells were then stimulated, washed with HBSS and incubated in the dark with 
DHE (50 µM) for 10 minutes at 37°C. Cells were washed with HBSS again to remove 
excess dye. Then DHE fluorescence was analyzed using 480 nm excitation and 640 
nm emission wavelength and the ROS levels were analyzed and standardized as 
described for the DCF fluorescence. 
+
O2-.
Dihydroethidium Ethidium
 
Fig. 12   Structure of the dihydroethidium. 
After oxidation with O2-., DHE is converted to the polar compound ethidium that intercalates into DNA. 
2.2.1.8 Bimolecular fluorescence complementation (BiFC) 
To study the interaction of proteins in situ the bimolecular fluorescence 
complementation (BiFC) was used. In this technique, the coding sequence for the 
yellow fluorescent protein (YFP) is genetically divided into two non-fluorescent 
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fragments, YC and YN which are fused to the codingsequence of the protein of 
interest. As a result a fusion protein of the protein and the YC or YN fragment is 
encoded. When two interacting YC/YN-fusion proteins are expressed in one cell, the 
original YFP fluorophore is reconstituted upon interaction of the two binding partners 
in a finally irreversible manner and the interaction can be monitored using 
fluorescence microscopy. 
For the BiFC experiments HeLa cells were used. The cells were seeded on glass-
bottom dishes (Willco Wells, Berlin, Germany) before transfection to achieve 50% 
confluency. Then the cells were cotransfected with NOX2YC/p22phoxYN, 
NOX4YC/p22phoxYN, NOX5βYC/p22phoxYN and NOX5SYC/p22phoxYN or 
NOX5βYC/YN, NOX5SYC/YN, NOX2YC/YN and NOX4YC/YN as negative controls. 
The cells were grown for 24 h, then the media was changed for a HEPES-buffered 
DMEM (Gibco) and the cells were cooled down several hours to promote fluorophore 
formation. The fluorescence complementation was then monitored in a fluorescence 
microscope (Olympus, Hamburg, Germany) and images were obtained using the 
Openlab Modular Software for Scientific Imaging (Improvision, Tübingen, Germany). 
2.2.1.9 Proliferation assay with BrdU incorporation 
Cellular proliferation requires DNA replication. Therefore, monitoring of DNA 
synthesis is an indirect marker of the rate of proliferation in response to different 
stimuli. To asses proliferative activity of endothelial cells we used 5-bromo-
2‘deoxyuridine (BrdU) labeling. BrdU is an analogue of the DNA nucleoside 
thymidine, and is incorporated in newly synthesized DNA of proliferating cells. The 
incorporated BrdU is detected by an immunoassay, using a peroxidase-conjugated 
antibody that specifically recognizes BrdU bound to denaturated DNA. The bound 
antibody is detected by a peroxidase-catalysed colorimetric reaction, using 
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tetramethyl-benzidine (TMB) as a substrate. Cells were seeded in 96-well plates to 
achieve 50% of confluency. In the experiments where DNA synthesis of transfected 
cells was investigated, cells were transfected on the following day with corresponding 
vectors, and starved from serum overnight 24 h after transfection. On the following 
day, cells were exposed to stimuli as described in the figure legends.  
To asses proliferation, cells were then incubated with BrdU (10 µM) for 16 h. 
Thereafter, cells were fixed for 30 minutes and then incubated for one hour with the 
peroxidase-conjugated antibody against BrdU. Immunodetection was performed by 
adding the colorimetric substrate TMB. When the blue color developed, the reaction 
was stopped with 1 M H2SO4. Absorbance was measured in an ELISA reader (Tecan 
Safire) at 450 nm with a reference wavelength at 690 nm. 
2.2.1.10 In vitro matrigel angiogenesis assay  
To determine the capability of endothelial cells to form capillaries, BD matrigel (BD 
Biosciences) was used. BD Matrigel Basement Membrane Matrix is a solubilized 
basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) 
mouse sarcoma, a tumor rich in extracellular matrix proteins. Its major component is 
laminin, followed by collagen IV, heparan sulfate proteoglycans, entactin and 
nidogen. It also contains TGF-β, fibroblast growth factor, tissue plasminogen 
activator, and other growth factors which occur naturally in the EHS tumor, however, 
in this study we used growth factor-reduced Matrigel. When plated onto matrigel, 
endothelial cells spontaneously form capillary-like structures which are a measure of 
angiogenic activity. Since the matrigel matrix gels rapidly between 22°C and 35°C, all 
plates and pipette tips were kept at -20°C and all work was performed on ice. The 
matrigel itself was thawed overnight on ice at +4°C.  
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Matrigel (150 l) was added to each well of a 48-well plate by tilting the plate to one 
side and pipetting slowly and continuously to avoid air bubbles from forming inside 
the gel. Any bubbles were removed immediately with a hot needle. The plate was 
then tilted slightly in all directions to cover the bottom of the well completely. When all 
wells were coated with matrigel, the plate was warmed to 37°C for 20 minutes.  
The cells were plated out in 6 cm dishes and transfected the next day. After 24 h the 
cells were trypsinised and counted. They were then suspended at 24000 cells/250 l 
medium without FCS in the case cells were stimulated or with FCS otherwise for 
each well. They were then added to the polymerised matrigel and the plate tilted 
gently in all directions to ensure a uniform cell cover over the entire matrigel surface. 
The cells were then incubated at 37°C and 5 % CO2 for 30 minutes to let the cells 
settle down. Cells were stimulated and were incubated for 4 h to allow capillary 
structure formation.  
After the experiment, calcein AM staining was used to visualise the tube-like 
structures, since it gives a strong fluorescence signal with minimal background 
staining. The medium was removed from the plates by placing them upside down on 
a stack of paper towels and tapping gently to avoid disturbing the tube structures. 
The wells were then washed twice with warm (37°C) HBSS. Calcein AM solution (8 
µg/ml in HBSS) was then added to each well (100 l) and the plates were incubated 
for 30 minutes at 37°C, 5% CO2. The labeling solution was then removed and the 
plates washed twice with warm HBSS. The washing solution was then removed and 
the plates were viewed under a fluorescence microscope at 40X magnification. 
Pictures were taken and analyzed using ImageJ
 
software. Total tube length was then 
measured and used as a measure of angiogenesis.  
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2.2.1.11 Immunofluorescence  
The cellular localization of proteins can be visualized by using specific antibodies 
against the proteins of interest, which are detected by secondary antibodies 
conjugated with a fluorescent label which can be visualized under a fluorescent 
microscope. This method is based on the one in the Maniatis laboratory manual [71]. 
Cells were plated out to ~50 % confluency onto glass coverslips inside a 24-well 
plate. After stimulation, they were washed twice with PBS (5 minutes each time) and 
then fixed with cold methanol/acetone (MA) solution at -20°C for 10 minutes. The MA 
solution was then aspirated and the plates left to dry at room temperature for 5 
minutes. The coverslips were then blocked with blocking solution (5% BSA in PBS) 
for 1 hour at room temperature. Primary antibody (35 l) diluted in blocking solution 
was then pipetted onto parafilm and the coverslips placed face-down over the 
droplet. Incubation was carried out in a humidified chamber overnight at 4°C. The 
cover slips were then placed into the 24-well plate and washed 3 times with PBS for 
5 minutes each. As negative control, one coverslip was incubated in blocking solution 
alone. The secondary antibody (30 l) was pipetted onto parafilm and the coverslips 
placed face down onto it. Incubation with secondary antibody was carried out for 1 h 
at room temperature in the dark. The samples were then washed 3 times with PBS 
for 5 minutes  and checked under the fluorescence microscope. They were then fixed 
onto glass slides with fluorescent mounting medium. 
2.2.1.12 Immunohistochemistry  
To localize proteins in tissue sections, immunohistochemistry was performed on 
tonsil sections using LSAB2 Systems HRP (Dako) in accordance with the 
manufacture’s manual with specific antibodies against NOX5, p22phox and smooth 
muscle cell actin.  
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The samples were deparaffinised by subsequent treatment with 100% xylol, 100% 
ethanol, 96% ethanol, 70% ethanol, 50% ethanol. They were then washed for 3 times 
with PBS and then washed with citrate buffer in a pressure cooker for 4 minutes. The 
samples were then washed in cold water and then 3 times in PBS, 5 minutes each 
time. To block endogenous peroxidase activity, the samples were then treated with 
3% H2O2 for 5 minutes and washed again 3 times with PBS.  
Blocking was performed using 4% BSA for 30 minutes at room temperature. Then the 
slides were left to drip the excess solution. Incubation was performed with the 
primary antibody diluted in 1% BSA. As negative control, one sample was incubated 
in 1% BSA alone. The samples were then washed for 3 times with PBS and 
incubated in streptavidin-HRP conjugated secondary antibody for 30 minutes at room 
temperature. The samples were then washed for 3 times in PBS and incubated with 
diaminobenzidine (DAB) for 10 minutes. After washing with PBS for 3 times, the 
samples were counterstained with Mayer’s Hämalaun solution. The samples were 
then washed with tap water before taking pictures with a light microscope.  
2.2.2 RNA-Methods 
2.2.2.1 Preparation of total RNA  
Total RNA from endothelial cells was purified using guanidine thiocyanate-acid 
phenol extraction. For RNA extraction, cells were plated in 10 cm dishes. At the end 
of the experiment, cells were washed with ice cold PBS and plates were frozen on 
liquid nitrogen. Thereafter, cells were lysed in 800 µl GT-DTT buffer, which denatures 
cellular and nucleoprotein complexes and releases RNA. The lysate was incubated 
for 30 minutes on ice with 800 µl phenol and 200 µl chloroform-isoamyl alcohol (24:1) 
to remove contaminating chromosomal DNA from the RNA preparation. Moreover, 80 
µl of 2 M sodium-acetate buffer (pH 4) was added to maintain the pH of the 
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denatured cell lysate during acid extraction and to provide the salt necessary for RNA 
precipitation with isopropanol. After centrifugation for 30 minutes at 13000 rpm, DNA 
and proteins remained in the lower organic phase, while RNA was present in the 
upper aqueous phase. After separation of phases, RNA was purified by two 
isopropanol precipitations at -20 °C for 2 h. Finally, the pellet of RNA was diluted in 
DEPC treated H2O, heated at 65 °C for 10 minutes and RNA concentration was 
measured in a Hitachi spectrophotometer model U-2001. Alternatively, total RNA was 
purified using the RNeasy Mini Kit (Qiagen) in accordance with the manufacturer’s 
manual. 
2.2.2.2 Northern blot  
10 to 15 µg of total RNA were mixed with RNA Premix (containing ethidium bromide) 
in a 1:1 ratio and 10x RNA blue marker was added to the mix. Samples were heated 
at 65°C for 10 minutes and loaded on 1.3% denaturating agarose gels containing 
1.1% formaldehyde. The gel was run in 1X MOPS buffer on 40 V for 4 h. After 
separation, loading of the gel was confirmed by staining the gel with ethidium 
bromide and checking the 18S band under the UV light. Then, RNA was transferred 
from the gel to a nylon membrane (Porablot, Macherey Nagel) for 24 h using capillary 
transfer in 20X SSC buffer. After the transfer was controlled by UV detection of 
incorporated ethidium bromide, transferred RNA was cross-linked by UV irradiation in 
Stratalinker 1800 (Stratagen). Northern membranes were then incubated in 
hybridization solution for 2 h at 65°C. Northern hybridizations were carried out with 
digoxigenin(DIG)-labeled antisense RNA for human p22phox at 65°C for 16 h which 
was present in the lab [72]. Then, membranes were washed 2 times in 2X SSC 
solution containing 0.1% SDS and then 2 times in 0.1 SSC solution containing 0.1% 
SDS at 65°C. Membranes were blocked for 30 minutes in 1X blocking solution and 
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then incubated for 1 h with anti-DIG antibody conjugated with alkaline phosphatase 
(Roche) diluted 1:10000 in blocking solution. After washing the membranes in 
washing solution, detection was performed by using the chemiluminescent substrate 
CDP-Star (Roche) diluted 1:100 in detection buffer. Blots were scanned and 
analyzed using GelDoc software (BioRad).  
2.2.2.3 cDNA synthesis from RNA 
Reverse transcriptase (RT) reaction involves the use of an RNA-dependent DNA 
polymerase to produce a library of cDNA from mRNA extracted from cultured cells or 
tissue. The technique is based on RNA denaturation and hybridisation to short non-
specific DNA sequences (random hexamers). The cDNA thus produced can be used 
to clone genes or to analyze the mRNA expression of a specific gene by PCR or 
quantitative PCR. Reverse transcription was performed on 1 to 5 g total RNA using 
random hexamers. After addition of dNTPs, the reaction mixture was warmed to 
65°C to denature any RNA secondary structures. After cooling on ice a mix 
consisting of reverse transciptase buffer, DTT and Superscript III© was added to the 
reaction tubes. The tubes were vortexed and spun down. They were then incubated 
at 25°C for 5 minutes to allow the hexamer primers to hybridize with the RNA. This 
was followed by incubation at 55°C for 60 minutes to allow the reverse transcriptase 
Table 1 Reverse transcription mixes for Superscript III (Invitrogen) 
Primer hybridization mix   
RNA  1 - 5 g  
pdN6 (100 ng/l)  1 l  
dNTP mix (10mM)  1 l  
H
2
O-DEPC up to  13 l  
  
Reverse transcriptase master mix   
5X RT Buffer  4 l  
DTT (100 mM)  1 l  
Superscript III (200 U/l)  1 l  
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to work. The enzyme was then inactivated at 70°C for 15 minutes. The RNA was 
destroyed by incubation with RNAse H at 37°C for 20 minutes. The cDNA thus 
produced was then stored at -21°C.  As negative control, RT reaction for each 
sample was performed without adding reverse transcriptase. 
2.2.3 DNA Methods 
2.2.3.1 Polymerase chain reaction (PCR)  
Polymerase chain reaction (PCR) is a technique used to produce a large number of 
copies of a specific DNA sequence. The technique relies on oligonucleotide 
complementary hybridization.  
First, the template DNA is denatured at high temperature to get single strands at the 
initiation denaturation step, followed by the annealing of two short oligonulcetoides 
(~25 bp), so called primers, to the DNA sequence flanking the region of interest at a 
lower temperature. This annealing step is followed by the elongation of the strands by 
the DNA polymerase starting at the 3´ site of each primer. This leads to an extension 
of the 3´ end of the primer resulting in a complentary strand of the template.  This 
step is followed by another denaturation step and the newly synthesized strands act 
as templates for the next cycle of elongation (Fig. 11). As the number of products is 
doubled with each cycle, the number of PCR products increase in a logarithmic 
manner.  
The precision with which PCR amplifies the selected DNA sequence is known as 
fidelity. The fidelity of a PCR reaction depends primarily on the annealing 
temperature (TA) at which the primers hybridise to the template and magnesium 
concentration.  
A temperature higher than the optimal TA reduces the hybridisation rate of the 
primers to the template, resulting in a reduced product yield. On the other hand, if the 
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temperature is too low the specificity of the primers decreases resulting in an 
unspecific binding and subsequently amplification of unspecific PCR products. The 
TA of a primer sequence depends on the length of the primer and number of GC 
nucleotides. It can be calculated using the following formula: 
Ta = 64.9°C + 41°C x (number of G’s and C’s in the primer – 16.4)/N  
N = number of nucleotides.  
However, the predicted TA is just an indication and often the best working TA has to 
be found by heuristic testing of different annealing temperatures. The magnesium 
concentration in the reaction is another important factor since the polymerase 
requires magnesium to function. Lower magnesium concentrations give higher fidelity 
than high concentrations. Since each PCR product incorporates both primers, 
modification of the primers by attaching fluorescent tags or short DNA sequences, 
results in the same modification being present in all the PCR products. For this 
reason PCR can be used to prepare DNA sequences for cloning by attaching a DNA 
sequence which will be recognised by a restriction enzyme as well as inserting a 
mutation in the PCR product by changing the primer sequence. The type of 
polymerase being used is also important since not all enzymes contain a so called 
proof reading function for the correction of misincorporation of nucleotides which 
results in single base pair changes. This can be a critical factor to be considered 
when cloning a coding sequence for overexpression experiments as one base pair 
change can result in the production of a mutated protein or a prematured STOP 
codon. Polymerase derived from Thermophilus aquaticus (Taq) has an error rate of 
2.4x10
-5 
whilst polymerase derived from Pyrococcus furiosus (Pfu), has a much lower 
error rate (0.2 x10-5) due to its proof reading capability. For this reason Pfu is a much 
slower enzyme than Taq. Hybrid enzymes based on the Pfu polymerase also exist. 
They possess the proofreading properties of Pfu but are as fast as Taq. In this study, 
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PCR was used to detect the expression of different genes (by using cDNA obtained 
from a reverse transcription of isolated RNA), attaching linkers to a specific sequence 
for cloning purposes and introducing site-specific mutations in a DNA sequence. 
Verification of the PCR target was done by sequencing. The reactions were 
performed in a thermal cycler (ABI Prism 3700). The optimal TA was found using a 
temperature gradient thermal cycler (iCycler) and identifying which temperature gave 
the highest yield with lowest amount of unwanted products. When error-free or 
mutagenesis PCRs were performed, Pfu-based polymerases (Pfu, Bioron; Pfx, 
Invitrogen) or a hybrid system (Expand High FidelityPLUS PCR System, Roche; 
Phusion,  NEB) were used with an extension temperature of 72°C.  
 
Fig. 13   Schematic overview  of the working principle of the polymerase chain reaction 
(PCR). 
PCR starts with the initial denaturation (1) followed by the annealing step (2) and the elongation (3) in 
which the template is amplified. Steps 1-3 are repeated in circles for a exponential amplification. 
(modified from http://en.wikipedia.org/wiki/File:PCR.svg, used under the GNU Free Documentation 
License) 
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2.2.3.2 Real time PCR 
The real time PCR is a variation of the PCR in which the amplification of the PCR 
products is monitored during the amplification process. This can be done by several 
techniques, here the incorporation of a dye, SYBR green, in the PCR products were 
used. SYBR green, similar to ethidium bromide, becomes fluorescent after 
incorporation in double-stranded DNA. Subsequently, as the amounts of PCR 
products increase after each PCR cycle, also the SYBR green fluorescence 
increases and can be measured after each cycle. The SYBR green fluorescence can 
then be drawn as an amplification graph and the cycle number from which the PCR 
enters the exponential phase (CT value) can be determined. The CT value correlates 
antiparalel with the amount of PCR template and in the case of a cDNA in the end 
with the amount of RNA, meaning the lower the CT value, the higher is the RNA 
content of the sample. The PCR was performed with the following settings. First a 
heating to 95°C for 10 minutes was performed as a hot-start. As the polymerase 
used is blocked by a specific antibody to prevent unspecific amplifications at not-
optimized conditions, the PCR-mix was heated to 95°C for 10 minutes to denaturate 
the antibody and releasing the polymerase. Then 44 cycles were performed with a 
denaturation step at 95°C for 15 seconds followed by a annealing/elongation step at 
60°C for 1 minute. 
2.2.3.3 DNA Sequencing  
Automated fluorescent sequencing utilizes a variation of the Sanger chain-
termination protocol. In this method, the DNA to be sequenced acts as a template 
molecule to which a primer will anneal to begin enzymatic extension and amplification 
of a specific region of double-stranded DNA. The newly created fragments will be 
complementary to the template DNA. This process takes place during the cycle 
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sequencing reaction which works after the same principle as a PCR desribed before. 
As the reaction mix contains a mixture of deoxynucleotides (dNTPs) and 
dideoxynucleotides (ddNTPs), at concentrations that create a statistical probability 
that a dideoxynucleotide will be incorporated instead of a deoxynucleotide at each 
nucleotide position in the newly generated fragments, the chain termination occurs 
during the extension step. When a dNTP is incorporated, the new fragment will 
continue to grow. A ddNTP contains a hydrogen atom instead of a hydroxyl group at 
its 3’ end and cannot participate in further extension. Therefore, when a ddNTP is 
incorporated, further chain elongation is blocked and this results in a population of 
truncated products of varying lengths. When separated by electrophoresis, a "ladder" 
of these truncated products will form, each differing in size by one nucleotide, with 
the smallest terminated fragments running fastest on the gel. There are four different 
ddNTPs that correspond to each of the four DNA nucleotides, and each ddNTP has a 
different color. Thus, each truncated fragment will contain a fluorescently labelled 
ddNTP at its 3’ end, and the sequencing ladder will be composed of colored bands. 
The sequence can then be determined by correlating the color of a band on the gel 
with its specific ddNTP, and the order in which they ran on the gel. So, the first and 
smallest band visualized will correspond to the first labeled nucleotide incorporated 
immediately adjacent to the primer. The second band will be the fragments that 
consist of 1 unlabeled dNTP and 1 labeled ddNTP that terminated those particular 
growing chains. The third band will be made up of 2 unlabeled dNTPS followed by 1 
labeled ddNTP, and so on up the gel. Once the sample has been amplified and 
labeled, it must be electrophoresed for separation and visualization of the labeled 
fragments. The dyes attached to ddNTPs are energy transfer dyes and consist of a 
fluorescein energy donor dye linked to an energy acceptor dichlororhodamine dye. 
This energy transfer system is much more sensitive than a single dye system. The 
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dye-labeled fragments are loaded onto the sequencers to allow capillary 
electrophoresis, through a liquid polymer. At the end of the capillary, a laser is placed 
which excites the fluorescent dyes attached to the fragments inducing them to emit 
light. The wavelength of the emitted light is specific for each dye. Wavelength 
separation occurs by a spectrograph onto a cooled, charge-coupled device (CCD). 
The data collection software collects these light intensities from the CCD camera at 
particular wavelength bands and stores them onto the sequencer’s computer as 
digital signals for processing. The analysis software then interprets the fluorescent 
intensity at each data point. For cycle sequencing, the reagents were added, 
vortexed briefly and centrifuged down before placing them into the thermal cycler. 
The PCR products were cleaned from unincorporated dye using the Nucleo Seq 
sequencing clean-up kit (Macherey-Nagel). To prepare the spin columns, the 
powdered silica was collected at the bottom of the tube by centrifugation at 380 g for 
1 minute. The silica powder was hydrated with water and incubated for 30 minutes at 
room temperature. The tubes were then centrifuged again to remove excess water. 
The sequencing PCR product was applied to the silica by pipetting in the middle of 
the tube. The cleaned product was collected by centrifugation at 380 g for 5 minutes 
Table 2 Sequencing mix and sequencing program for the ABI3100 Genetic Analyser and the 
  BigDye Terminator v1.1 
Sequencing mix   
DNA template 100 ng  ~100ng  
BigDye Terminator v1.1  3.0 l   
Sequencing Primer (10 mM)  1 l  
Add water 10 µl  
   
Sequencing program   
temperature Time (min) Cycles 
96°C 1:00 1x 
96°C 0:10 
50°C 0:05 
60°C 4:00 
 
25x 
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and loaded onto a 96-well sequencing plate. The samples were then run on an ABI 
3100 Genetic Analyser. 
2.2.3.4 Agarose gel electrophoresis  
Agarose gel electrophoresis is used to separate DNA strands according to their 
size/weight ratio. The DNA is loaded onto an agarose gel and a current is passed 
through. Since DNA is negatively charged it moves from the negatively charged 
cathode towards the positively charged anode through the pores created by the 
polymerised agarose. As it moves through the gel, the different DNA strands start 
separating according to size with the smallest strands migrating faster than the longer 
strands. The resolution of the gel is determined by size of the pores which are in turn 
determined by the agarose concentration. The gel was prepared by melting agarose 
powder in electrophoresis buffer (1x TAE) until a clear transparent solution was 
achieved. The concentration of agarose depended on the size of the DNA strands to 
be separated. The open ends of the plastic tray supplied with the electrophoresis 
apparatus was sealed and set up horizontally. A comb containing the appropriate 
number of sample slots was chosen and positioned around 0.5 mm above the bottom 
of the gel casting tray. When the gel solution had cooled down to around 55°C, 
ethidium bromide was added to a final concentration of 0.5 g/ml. The solution was 
then poured into the gel casting tray and allowed to harden for 30 minutes. The 
electrophoresis tank was then filled with electrophoresis buffer (1x TAE). The DNA 
samples were mixed with 0.2 volumes of 6X DNA loading buffer and then loaded 
onto the gel. A size standard was used to determine the approximal DNA fragment 
size. The lid of the electrophoresis tank was closed and the electrodes attached such 
that the DNA would migrate from the cathode to the anode. The power supply was 
set to 100 or 120V. After separation, the gel was removed from the tank and viewed 
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using a UV transilluminator connected to a camera. The picture of the gel was then 
printed and labelled.  
Table 3 Agarose gels concentration and their resolution for DNA separation 
Agarose Concentration Gel (% [w/v])  Range of Separation of Linear DNA Molecules (kb)  
0.3  5-60  
0.6  1-20  
0.7  0.8-10  
0.9  0.5-7  
1.2  0.4-6  
1.5  0-2-3  
2.0  0.1-2  
 
2.2.3.5 Restriction digest  
Restriction digest is the process by which DNA molecules are cut into smaller pieces 
by enzymes called restriction endonucleases or restriction enzymes. These enzymes 
recognise a specific DNA sequence and cleave it wherever it occurs inside a DNA 
molecule. In most cases, the recognition sites are short (4-8 nucleotides) and are 
usually palindromic sequences, although also other non-palindromic recognition sites 
are known. Since both strands have the same sequence running in opposite 
directions, the enzymes make a double-stranded break, which, if the site of cleavage 
is off centre, generates fragments with short single stranded tail known as overhangs. 
These tails can hybridise to the tails of other fragments and are thus called “sticky 
ends”. On the other hand, when the cleavage site is in the centre of the palindrome 
no overhangs are generated and the fragments are said to be “blunt”.  
Each enzyme requires particular conditions such as temperature, NaCl and MgCl2 
concentrations and pH. For this reason the right buffer has to be chosen for every 
enzyme.  
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DNA was digested with restriction endonucleases by incubating it in the presence of 
the desired enzyme and the appropriate buffer at 37°C for 1 h. After digestion, the 
DNA was visualised by agarose gel electrophoresis and/or purified for further 
processes such as cloning. The enzymes mentioned are all from New England 
Biolabs (Frankfurt am Main, Germany). 
Table 4 Reaction mix for NEB enzymes 
Restriction Reaction Mix  
DNA up to  1 g  
Enzyme  0.25 units  
10X Buffer  3.0 l  
Water up to  30 l  
 
 
2.2.3.6 DNA ligation  
DNA ligation was used to clone inserts into eukaryotic expression vectors. T4 DNA 
ligase (New England Biolabs) was used for this reaction. Around 50 ng of linearised, 
dephosphorylated vector were added to a 3-fold molar excess of insert and the 
volume adjusted to 10 l with water. The following formula was used to calculate the 
molarity ends:  
 
Molarity of ends: Molarity = [(g/l) ÷ (base pairs X 650 Daltons)] X 2 ends  
 
For convenience, usual 2 µl of vector and 6 µl of insert were used. Then 1 µl of 10x 
ligation buffer was added and the reaction mixed and centrifuged down. After adding 
of T4 DNA ligase (1 l) the reaction was mixed, centrifuged down and incubated for 
25 minutes at room temperature or for 16 h at 16°C and used directly for 
transformation.  
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2.2.3.7 Preparation of chemical competent bacteria 
To produce large amounts of plasmids, bacteria are used to replicate the DNA. For 
this purpose, so called “competent” bacteria are used which make it easy for plasmid 
DNA to be inserted into them. The technique used was based on the one described 
in the Maniatis’ laboratory manual [71].  
A LB plate was streaked with XL-1 Blue or JM109 bacteria from a stock glycerol 
solution stored at -70°C and then incubated overnight at 37°C. Then a colony was 
picked and grown overnight in 5 ml LB medium. The next day, this volume was grown 
in 500 ml LB medium at 37°C for 3 to 4 h until its OD550 was between 0.3 and 0.4. 
The culture then was centrifuged at 1500 g for 15 minutes at 4°C. The supernatant 
was decanted and the pellet resuspended in 5 ml ice cold TSS solution. Aliquots of 
100 l were then prepared on an ice/ethanol bath and the bacteria stored at -70°C 
until use.  
The quality of new stocks of competent bacteria was checked by transforming an 
ampicillin-resistant plasmid into them and plating on to an LB-Amp plate. The number 
of colonies was counted after 16 h incubation at 37°C. 
2.2.3.8 Chemical transformation  
The bacteria were thawed from -70°C on ice and 0.1 g of DNA or 1/3 of ligation mix 
was added whilst stirring gently with the pipette tip. Then, bacteria were incubated on 
ice for 30 minutes and heated to 42°C for 90 seocnds in a water bath. They were 
cooled on ice for 1 minute and 400 l preheated (42°C) SOC medium was added. 
The bacteria were shaken at 225 rpm at 37°C for 60 minutes. The culture was then 
plated onto LB plates coated with the appropriate selective antibiotic (ampicillin 
10 g/ml or kanamycin 10 g/ml) and grown for 16 h at 37°C.  
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The next day, at least one colony was chosen and inoculated in 2 ml LB medium and 
grown for 6 h at 37°C whilst shaking at 225 rpm, after which 1.5 ml of culture was 
used to perform a plasmid mini preparation. After confirming the presence of the right 
plasmid by restriction digest or sequencing, 200 l of culture was grown in 200 ml of 
LB medium for 16 h at 37°C whilst shaking at 225 rpm. Plasmid maxi preparation 
was performed using the Qiagen Plasmid Maxi kit.  
2.2.4 Protein methods  
2.2.4.1 Protein isolation  
Proteins were extracted from cultured cells using different techniques. The 
guandinium thiocyanate-acid phenol extraction used here has the advantage that one 
can obtain RNA and proteins from the same experiment and is based on the 
procedure described in the Maniatis laboratory manual [71].  
Cells were washed with ice cold serum free medium and plates were frozen on liquid 
nitrogen. Cells were then lysed in GT-DTT buffer and total proteins from endothelial 
cells were purified using guanidine thiocyanate-acid phenol extraction, as described 
for purification of total RNA. The proteins which remained in the lower organic phase 
were precipitated overnight at 4°C by addition of 3 ml isopropanol and 600 l of 
ethanol. Thereafter, the protein pellet was washed in 70% ethanol and dissolved in 
PBS containing 1% SDS and 1 mM NaF.  
Alternatively, to detect phosphorylated proteins, cells were lysed in freshly prepared 
phospho-buffer. After scraping of the cells, samples were incubated for 30 minutes 
on ice, centrifuged for 10 minutes at 16000 g to remove cellular debris and stored at -
20°C or -70°C until use.  
As second alternative, cells were scraped directly in 1.5x Laemmli loading buffer, 
boiled at 95°C for 5 minutes and directly used for western blot analysis. 
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2.2.4.2 Subcellular cell fractionation 
Microsomal membrane fraction was isolated as described with some modifications 
[73]. Briefly, cells were harvested in phosphor buffer without detergent and 
homogenized by sonfication (5x 10 seconds burst). The cell homogenate was 
centrifuged at 1000g for 10 minutes at 4°C and the supernatant was further 
centrifuged at 12000g for 15 minutes at 4°C. Subsequently, the supernatant was 
centrifuged at 40.000g for 30 minutes at 4°C to receive the microsomal membrane 
fraction. The pellet was resuspended in 1.5X Laemmli buffer and applied for Western 
blot analysis. 
2.2.4.3 Protein quantification after Bradford 
Total protein quantification was performed after Bradford [74] using the Roti-Quant 
(Carl Roth GmbH) containing Coomassie Brilliant Blue Dye-G250. This dye appears 
in three different states which absorb at varying wavelengths (cationic 470 nm, 
neutral 650 nm, anionic 595 nm). By binding the dye with a protein it changes from a 
cationic to an anionic state and changes its absorption level to 595 nm. This 
absorption change is proportional to the protein concentration over a wide range. 
Coomassie Brilliant Blue-G250 binds primarily to basic amino acids. This accounts 
for the difference in the level of absorption of varying proteins. Therefore we used a 
BSA protein standard for quantification (0, 5, 10, 20, 30, 40, 50, 60 µg/ml). Protein 
cell lysates were diluted 1:100 to 1:300 and 80 µl or protein standard and samples 
were added to the wells of a 96-well microtiterplate. The Roti-Quant solution was 
diluted 1:5 and 200 µl were added to the samples and standard. Absorbance of the 
proteins was analyzed using a microplate reader (Tecan) and protein concentration 
was calculated performing a standard curve from the standard and linear regression 
analysis. 
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2.2.4.4 SDS-PAGE and Western blot analysis 
Western blot is used to detect protein levels. After protein extraction, the proteins are 
loaded onto a denaturing polyacrylamide gel where they are separated according to 
size. They are then blotted onto a membrane which is hybridized with an antibody 
specific for the protein of interest (the primary antibody). The membrane is then 
incubated with another antibody which recognizes the primary antibody (the 
secondary antibody). The secondary antibody is tagged with horseradish 
phosphatase so the protein levels are detected by exposure of photographic films to 
the chemoluminescence given off by the secondary antibody.  
Before performing the electrophoresis, samples were mixed with 3x Laemmli loading 
buffer and boiled at 95°C for 5 minutes. Proteins (50 g) were separated by 8-12% 
SDS polyacrylamide gel electrophoresis (PAGE) in running buffer in a Mini-Protean 3 
System (Biorad) and transferred to nitrocellulose Protran membranes (Schleicher & 
Schuell) using the Mini Trans-blot System (Biorad) in ice cold transfer buffer. After 
transfer, membranes were rinsed in water and incubated in Ponceau S solution for 
several minutes. The membranes were then washed in water to reduce background 
staining and the membranes were scanned for documentation and loading control. 
For reversing the Ponceau S staining, membranes were washed with TBS-T and  
then blocked for 60 minutes in TBS-T containing 5% non-dry milk or 5% BSA and 
then overnight at 4°C with specific antibodies. After incubation with primary 
antibodies, the membranes were washed 3 times for 10 minutes with TBS-T and 
incubated with a horseradish peroxidase-conjugated secondary antibody for 1 h. 
After washing the membranes 3 times for 10 minutes with TBS-T, protein bands were 
visualized by performing luminol-enhanced chemiluminescence. Blots were analyzed 
and quantified using ImageJ software (NIH, USA).  
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2.2.4.5 Stripping and reprobing  
To remove bound antibodies, membranes were incubated in stripping buffer for 30 
minutes at 50°C. Thereafter, membranes were washed 2 times for 30 minutes in 
TBS-T, blocked for 2 h in TBS-T containing 5% non-dry milk and then incubated with 
the appropriate primary antibody.  
2.2.4.6 Coimmunoprecipitation  
Coimmunoprecipitation was used to detect protein-protein interactions [71]. This 
technique can be used to detect interaction of endogenous and/or overexpressed 
proteins. It relies on cellular lysis without denaturing the proteins and whilst 
maintaining all protein interactions. An antibody is then used to precipitate a specific 
protein, which can precipitate some of its interaction partner together with it. The 
precipitate is separated from the remaining lysis product by the addition of beads 
which have a high affinity for the antibody. The whole complex can thus be pelleted 
by centrifugation. Finally the precipitated proteins are denatured and detected by 
Western blot.  
The cells were washed with PBS and scraped in phosphor-buffer supplemented with 
protease inhibitors and samples were incubated on ice for 20 minutes. Then samples 
were centrifuged at 16000 g at 4ºC for 15 minutes and the supernatant was 
transferred to new 1.5 ml reaction tubes. After protein concentration determination 
500 µg protein was used for each immunoprecipitation and the remaining protein 
samples were stored at -20°C. 
For setting the immunoprecipiation mix, per precipitation mix 30 µl of a 50:50 slurry 
sepharose beads solution in PBS were washed 3 times with phospho-buffer and 
resuspended in phospho-buffer. Protein samples were added to the beads and the 
solution was filled up to 500 µl with phosphor-buffer. Finally 4 µg GFP-antibody 
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(Invitrogen) was added and the mixture was incubated overnight at 4°C slowly 
rotating. The samples were then centrifuged for 1 minute. The supernatant was 
dissolved in 2x Laemmli lysis buffer and loaded onto an SDS-PAGE gel for Western 
blot.  
The immunoprecipitate was washed 5 times with phospho-buffer. After the last wash 
the pellets were dissolved in 2X Laemmli buffer and loaded onto an SDS-PAGE gel 
for Western blot.  
2.2.5 Statistical analysis 
Values presented are means ± standard deviation. Results were compared by 
ANOVA for repeated measurements followed by Student–Newman–Keuls t test. 
P < 0.05 was considered statistically significant. 
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3 Results 
3.1 Expression and localization 
Function and expression of the novel NOX2 homologues NOX1, NOX4 and NOX5 
are poorly understood in the vasculature. Their expression and subcellular 
localization were therefore firstly investigated. 
3.1.1 Expression of NOX1, NOX2, NOX4, p22phox in endothelial cells 
As a model for endothelial cells, we used the endothelial cell line Ea.Hy926 and 
human microvascular endothelial cells (HMEC-1). In Ea.Hy926 cells, the expression 
levels of NOX1, NOX2, NOX4 and ,in addition, of the small NADPH oxidase subunit 
p22phox were analyzed by RT-PCR and Western blot analyzes. NOX2, NOX4 and 
p22phox were easily detectable in Ea.Hy926 cells at the mRNA (Fig. 14A) and 
protein levels (Fig. 14B). However, in polymorphonuclear neutrophils, which were 
used as known model cells for the phagocytic NADPH oxidase, NOX2 and p22phox 
proteins appeared to be the only detectable NADPH oxidase subunits (Fig. 14B). 
RT-PCR and Western blot analyzes showed that NOX1 was expressed in Ea.Hy926 
cells (Fig. 14A, B), although detection of NOX1 mRNA levels required increased 
cycle numbers in Ea.Hy926 cells (Fig. 14A). Similarly, qPCR analysis of the NOX1 
RNA level in HMEC-1 and CaCo2 cells, a colon carcinoma cell line known to highly 
express NOX1, showed a higher CT value (cycle of take off) for HMEC-1 cells 
(CT=32) than for CaCo2 cells (CT=25) (Fig. 14C). 
3.1.2 Expression of NOX5 variants in endothelial cells. 
To investigate whether NOX5 is expressed in vascular cells, RT-PCR was performed 
with primers amplifying a region at the 3’ end of the coding sequence which is 
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conserved in all NOX5 variants. A PCR product corresponding to the expected NOX5 
sequence (501 bp) was detected in human microvascular endothelial cells (HMEC-1), 
human umbilical vein endothelial cells (HUVEC), pulmonary artery smooth 
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Fig. 14   NOX1, NOX2, NOX4 and p22phox mRNA and protein are expressed in 
endothelial cells. 
A. RT-PCR was carried out with cDNA reverse transcribed from mRNA derived from Ea.Hy926 cells 
using specific primers for p22phox, NOX1, NOX2, NOX4 (lane 1: cDNA derived from mRNA, lane 2: 
H2O as negative control). B. Western blot analysis was performed with Ea.Hy926 cells and 
polymorphonuclear neutrophils (PMN) lysates using antibodies against human p22phox, NOX1, 
NOX2, NOX4. C. Representative amplification graph for a qPCR analysis of the NOX1 RNA levels in 
HMEC-1 and CaCo2 cells. Amplification graph of GAPDH shown as indicator for equal amounts of 
cDNA for CaCo2 and HMEC-1 cells. All PCR products were condirmed by sequencing. 
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muscle cells (PASMC), and colon carcinoma cells (CaCo2) used as positive control 
(Fig. 15A). Four NOX5 variants have been described so far which differ in the 
sequences of their calcium-binding domains in the N-terminus [45]. To discriminate 
between the different variants and to analyze which of the NOX5 variants were 
present in vascular cells, primers were designed to specifically amplify the α-, β-, γ-, 
and δ-variants of NOX5. RT-PCR followed by sequence analysis of the respective 
PCR products revealed that endothelial cells (HMEC-1 and HUVEC) expressed 
NOX5β and NOX5δ. In contrast, CaCo2 cells expressed NOX5α and NOX5γ and 
PASMC expressed all four variants (Fig. 15B). For detection on protein level, an 
antibody against an epitope in the core region of NOX5 was designed in the lab and 
Western blot analysis of HMEC-1 cells was performed. In addition to a band of 75 
kDa corresponding to NOX5, a band at around 60 kDa was detected whereas no 
corresponding bands were observed in lysates from polymorphonuclear neutrophils, 
which were reported not to express NOX5 (Fig. 16A). Furthermore, after 
preincubation of the antibody with the peptide used for immunization, these bands 
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Fig. 15   Different NOX5 splice variants are expressed in endothelial cells. 
RT-PCR was carried out with mRNA derived from human microvascular endothelial cells (HMEC-1), 
human umbilical vein endothelial cell (HUVEC), pulmonary artery smooth muscle cells (PASMC) and 
colon carcinoma cells (Caco2). A. PCR was performed using specific primer pairs to detect NOX5. 
PCR was performed using specific primer pairs for the calcium-binding domain containing regions of 
NOX5α, NOX5β, NOX5γ or NOX5δ (B). 
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were not detectable anymore suggesting the presence of two different NOX5 variants 
in HMEC-1 cells (Fig. 16A). Previously, a NOX5 variant lacking the calcium-binding 
domains and thus resembling other NOX homologues has been described [75]. To 
test wether the shorter NOX5 protein detected by our antibody resembles the 
reported NOX5 variant we cloned the full length coding sequence of this variant, 
which we termed NOX5S, from HMEC-1 and from CaCo2 cells. Sequence analysis 
confirmed the presence of the complete coding sequence of NOX5S (Genbank 
#DQ413001) leading to a predicted protein of 565 amino acids. To further confirm 
that NOX5 and NOX5S are present in HMEC-1 cells and detected by the antibody, 
NOX5S and NOX5β were overexpressed in HMEC-1 cells. Western blot analysis 
using the NOX5 antibody revealed bands at 60 and 75 kDa (Fig. 16B) similarly to 
non-transfected cells and confirming that the antibody recognized both NOX5 
variants in HMEC-1 cells. In addition, NOX5S and NOX5β were fused to green 
fluorescent protein (GFP) and these fusion proteins were expressed in HMEC-1 cells. 
Western blot analyzes with antibodies against NOX5 and GFP revealed bands at 85 
and 100 kDa corresponding to the respective NOX5 fusion proteins (Fig. 16D), 
further confirming that this antibody recognizes NOX5 and NOX5S and that HMEC-1 
cells express both NOX5 proteins. Densitometric quantification further suggested that 
approximately one third of the total NOX5 content represented NOX5S in HMEC-1 
cells (Fig. 16E). We further investigated the expression of NADPH oxidase subunits 
in the vasculature. Since NOX5 mRNA has been previously described to be 
expressed in spleen [45], immunohistochemistry was performed in archival tissue 
samples from spleen as a positive control and for testing our developed antibody. 
Indeed, positive NOX5 staining was observed in spleen tissue (Fig. 17A). In addition, 
strong staining for NOX5 was detected in spleen vessels in the smooth muscle cell 
layer which was positive for α-actin (Fig. 17A) as well as in the endothelial cell layer 
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(Fig. 17A) which was positive for PECAM-1 [53] confirming the presence of NOX5 in 
the vasculature. To test whether NOX5 protein was present in vessels from non-
lymphoid tissues immunohistochemistry was performed in lung tissue. Consistently 
with the situation in the spleen, NOX5 protein was indeed detected in the wall of 
pulmonary vessels in endothelial as well as in smooth muscle cells (Fig. 17B).  
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Fig. 16   Different NOX5 proteins are expressed in endothelial cells. 
A. Western blot analysis was performed in polymorphonuclear neutrophils (PMN) or in HMEC-1 cells 
using NOX5 antibody (-pep (without peptide)), or NOX5 preadsorbed with the antigenic peptide (+pep 
(with peptide)). B. HMEC-1 cells were transfected with plasmids encoding for NOX5S or NOX5β and 
Western blot analysis was performed using an antibody against NOX5. C. HMEC-1 cells were 
transfected with plasmids encoding GFP, GFPNOX5S or GFPNOX5β, and Western blot analysis was 
performed using antibodies against NOX5 or GFP. D. The relative levels of the 75 kDa band (NOX5) 
and the 60 kDa band (NOX5S) were determined from immunoblots by densitometry using GelDoc 
software. Data are presented as relative amount of NOX5 (75 kDa) and NOX5S (60 kDa) to total 
NOX5 (100%) (n=3). 
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3.1.3 Expression of NOXA1 and NOXO1 in endothelial cells 
In the next step we investigated whether endothelial cells express the p47phox 
homologue NOXO1 and p67phox homologue NOXA1. RT-PCR studies were 
performed with Ea.Hy926 cells and HEPG2 cells, as NOXA1 and NOXO1 are known 
to be expressed in the liver [47], using specific primers for NOXA1 and NOXO1. 
Surprisingly, in both cases longer PCR products were detected. In addition to the 
expected fragments of 214 bp (NOXA1) or 159 bp (NOXO1) longer fragments of 326 
bp (NOXA1) or 270 bp (NOXO1) were amplified. (Fig. 18A, 19A, red arrows). 
Sequencing analysis revealed that both additional PCR products contained NOXA1 
A CTR NOX5 Actin 
B CTR NOX5 Actin 
  
Fig. 17   p22phox and NOX5 are expressed in the vessel wall. 
NOX5 expression was detected in human spleen (A) or human lung (B) using an antibody against 
NOX5. α-actin staining (Actin) was used to mark the smooth muscle cell layer. As negative control, the 
first antibody was omitted (CTR). 
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and NOXO1, respectively, but revealed potential new splice variants of NOXA1 and 
NOXO1. The primers used for NOXA1 were spanning from exon 2 to exon 4. The 
longer PCR product contained additional nucleotides from the intron upstream of 
exon 3 in accordance to the gene bank entry (NT_078083). The transition between 
exon 2 and the novel nucleotides corresponded to the canonical GT-AG splicing rule 
indicating a novel splice variant of NOXA1 (Fig. 18B).  
Assuming no other differences, the partial incooperation of intron 2 into the mRNA of 
NOXA1 would lead to a premature STOP codon at 307 bp resulting in a protein of 
102 amino acids. The primers for NOXO1 were also spanning between exon 2 and 
exon 4 in accordance to the gene bank intron-exon structure (NT_037887). Here, we 
found that the longer PCR product contained the intron between exon 3 and exon 4 
which was not excised in the novel PCR product, whereas the intron between exon 2 
and exon 3 was regularly spliced (Fig. 19B). Therefore this amplificate may be either 
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Fig. 18   NOXA1 mRNA is expressed in endothelial cells and HEPG2 cells. 
A. RT-PCR was carried out with cDNA reverse transcripted from mRNA derived from Ea.Hy926 and 
HEPG2 cells using specific primers for NOXA1. Arrows indicating the predicted and and additional 
PCR product. B. Schematic figure of the novel PCR product. The additional band is a product of a 
novel conical splice site upstream of exon 3 of the NOXA1 gene, which leads to the insertion of 
several nucleotides in the transcript.  
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result of an incomplete splicing or of an alternative splicing. Under the assumption 
that there are no further differences between the novel cDNA and the published 
ones, the inclusion of intron 3 would predict an early STOP codon at 328 bp resulting 
in a protein of 109 amino acids instead of 369 amino acids of the full length NOXO1. 
3.1.4 Localization of NOX2, NOX4, NOX5, but not of NOX1 in the endoplasmic 
reticulum of endothelial cells 
In the next step we investigated the intracellular localization of the NADPH oxidase 
homologues. First, coimmunofluorescence studies for NOX2 and NOX4 were 
performed, which revealed that both NOX2 and NOX4 colocalize in an intracellular 
compartment in the same cell (Fig. 20A). Although NOX2 was suggested to be 
localized in the plasma membrane [21], only a faint peripheral staining for NOX2 (Fig. 
20A, arrow), but not for NOX4, could be detected. However, a strong perinuclear 
staining for both NOX2 and NOX4 was found. Further coimmunofluorescence studies 
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Fig. 19   NOXO1 mRNA is expressed in endothelial cells and  HEPG2 cells. 
A. RT-PCR was carried out with mRNA derived from Ea.Hy926 cells and HEPG2 cells using specific 
primers for NOXO1. Arrows indicating the predicted and and additional PCR product. B. Schematic 
figure of the novel PCR-product, which includes the intron between exon 3 and exon 4. 
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using an Alexa Fluor488-coupled phalloidin against f-actin revealed that NOX2 
shows a faint colocalization with actin at the plasma membrane whereas NOX4 did 
not exhibit this pattern (Fig. 20B). As the perinuclear localization of NOX2 and NOX4 
resembled the ER, further co-immunfluorescence studies were performed for NOX1, 
NOX2 and NOX4 together with calreticulin, a marker protein for the ER (Fig. 21). 
NOX2 and NOX4 showed an intracellular perinuclear localization at least partially 
colocalising with calreticulin. NOX1 showed also an intracellular, perinuclear 
localization, however there was no colocalization with calreticulin (Fig. 21). For 
confirmation of the ER localization of p22phox, NOX2 and NOX4, Ea.Hy926 cells 
were cotransfected with an YFP-tagged p22phox (YFPp22phox), a CFP-tagged 
NOX2 (CFPNOX2) and an YFP-tagged NOX4 (YFPNOX4) together with an ER 
localized CFP or YFP (Fig. 22A, B, C). Furthermore, Western blot analysis 
demonstrated the presence of p22phox, NOX1, NOX2 and NOX4 as well as of the 
ER protein calnexin in microsomal fractions of Ea.Hy926 cells (Fig. 22D). In contrast, 
the transcription factor ARNT and the cytoplasmically located p38 MAP kinase were 
not present in this fraction as expected (Fig. 22D). To determine whether the 
expression pattern observed for p22phox, NOX2 and NOX4 were specific for 
endothelial cells, the intracellular localization in cervix carcinoma cells (HeLa) was 
investigated. HeLa cells were transfected with YFPp22phox, CFPNOX2, YFPNOX4, 
together with an ER-localized fluorescent protein (ERYFP or ERCFP). In contrast to 
the situation in endothelial cells, only p22phox showed a colocalization with the ER-
marker, whereas NOX2 and NOX4 showed a more peripheral membrane staining 
(Fig. 23). To investigate the intracellular localization of NOX5S and calcium binding 
NOX5 variants, Ea.Hy926 cells were transfected with plasmids encoding for GFP-
fusion proteins of NOX5S (GFPNOX5S) and NOX5β (GFPNOX5β) as a 
representative member of the EF-hands containing NOX5 variants (Fig. 24A). Both 
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constructs showed an ER-like localization. We also investigated their intracellular 
localization in HMEC-1 cells. For this, cells were transfected with either GFPNOX5S 
or GFPNOX5β and coimmunofluorescence studies together with calreticulin were 
performed using an anti-GFP- and an anti-calreticulin antibody. Both NOX5 variants 
colocalized with calreticulin (Fig. 24B). Similarly, in Hela cells cotransfected with 
GFPNOX5S together with an ER-localized fluorescent protein (DsRed) showed a 
colocalization of NOX5S with the ER-marker (Fig. 24C). Immunofluorescence studies 
of endogenous NOX5 in HMEC-1 cells, using antibodies against NOX5 and 
calreticulin showed a colocalization of NOX5 with the ER-marker (Fig. 24D). 
NOX2
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60x20x NOX2 NOX4
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Fig. 20   NOX2 and NOX4 colocalize in an intracellular compartment in endothelial cells, 
but only NOX2 colocalizes with f-actin. 
A. Immunofluorescence was performed on Ea.Hy926 cells using antibodies against NOX2 (green) and 
NOX4 (red). Fluorescence images were taken at a 20x magnification (left column) and 60x 
magnification of a representative cell (right column). B. Immunofluorescence was performed on 
Ea.Hy926 cells using antibodies against NOX2 (left column, green) or NOX4 (right column, green) 
together with staining for f-actin (red). All scale bars are 20 µm. 
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3.2 Interaction of NOX2, NOX4, NOX5S and NOX5β with p22phox 
and contribution to basal endothelial ROS generation  
3.2.1 Interaction of NOX2, NOX4, NOXS and NOX5β with p22phox 
In the phagocytic NADPH oxidase, dimerization of NOX2 with p22phox is required for 
functional activity of the enzyme. As NOX4 and the two NOX5 varaints NOX5S and 
NOX5β show a homologous domain structure, we tested the interaction between 
NOX2, NOX4, NOX5S and NOX5β with p22phox in HeLa cells using bimolecular 
fluorescence complementation (BiFC). The BiFC approach is based on the 
complementation of two non-fluorescent fragments of a fluorescent protein due to 
Calreticulin merged
NOX4
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NOX1
Calreticulin merged
Calreticulin merged
  
Fig. 21   NOX2, NOX4 but not NOX1 are intracellularly localized in endothelial cells. 
Ea.Hy926 cells were stained with antibodies against NOX1, NOX2 and NOX4 together with an 
antibody against calreticulin, a marker for the ER. Merged images show overlay of NOX2, and NOX4 
but not NOX1 with calreticulin. All scale bars are 20 µm. 
Results 
 80
protein-protein interaction of potential interacting proteins fused to these fragments 
(Fig. 25A) [76, 77]. Complementary fragments of YFP (YN and YC) were fused to the 
3´-ends of the different NOX proteins and p22phox. Specifically, NOX2, NOX4, 
NOX5S and NOX5β were fused to the YC-fragment (NOX2YC, NOX4YC, 
NOX5SYC, and NOX5βYC) and p22phox was fused to the YN-fragment 
(p22phoxYN). Upon interaction of the proteins of interest, the fluorescent 
chromophore YFP is restored and can be detected by fluorescence microscopy. 
HeLa cells were transfected with the plasmid encoding p22phoxYN with either 
YFP-p22phox ER-CFP merged
CFP-NOX2 ER-YFP merged
YFP-NOX4 ER-CFP merged
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Fig. 22   p22phox, NOX2 and NOX4 are expressed in the endoplasmic reticulum of 
endothelial cells. 
Ea.Hy926 cells were cotransfected with YFP-p22phox (A), CFP-NOX2 (B) or YFP-NOX4 (C) and 
constructs where the ER localization signal was linked to either CFP or YFP. Scale bar is 20 µm for all 
panels. D. Ea.Hy926 cells were fractionated and Western blot analysis was performed using the 
microsomal fraction (MF) or total cell lysate (TCL) and antibodies against p22phox (p22), NOX1 
NOX2, NOX4, calnexin (Cal.), ARNT and  p38 MAP kinase (p38).   
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NOX2YC or NOX4YC. YFP-fluorescence was monitored by fluorescence microscopy 
(Fig. 25B). Both, NOX2 and NOX4 formed complexes with p22phox in a perinuclear 
compartment resembling the ER. No fluorescence was detectable in cells transfected 
with plasmids encoding for NOX2YC or NOX4YC or p22phoxYN and YN or YC 
lacking a fusion, respectively (Fig. 25B). Cotransfection of NOX5βYC or NOX5SYC 
with p22phoxYN resulted in a strong perinuclear fluorescence similar to the pattern 
observed with NOX2 and NOX4, indicating that both NOX5 variants interact with 
p22phox (Fig. 25C). In contrast, transfection of NOX5βYC or NOX5SYC with the YN-
fragment or p22phoxYN with the YC-fragment did not lead to fluorescence 
complementation (Fig. 25C). To confirm that p22phox interacts with both NOX2 and 
NOX4, coimmunoprecipitation studies of p22phox and NOX2 or NOX4 were 
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Fig. 23   p22phox, but not NOX2 and NOX4 are localized in the endoplasmic reticulum of 
cervix carcinoma cells. 
Cervix carcinoma cells (HeLa) were transfected either with CFP-p22phox, CFP-NOX2 and YFP-NOX4 
together with constructs where the ER localization signal was linked to CFP, YFP or DsRed. Merged 
images show overlay of p22phox with ER-marker. Scale bar is 10 µm for all panels. 
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performed (Fig. 26A). HEK293 cells were cotransfected with a plasmid encoding 
human p22phox and plasmids encoding NOX2 or NOX4 fused to either CFP (CFP- 
A GFP-NOX5S GFP-NOX5β
D NOX5                 Calreticulin merged
B GFP-NOX5S             Calreticulin merged
GFP-NOX5β Calreticulin merged
GFPNOX5S ER-DsRed mergedC
 
Fig. 24   NOX5 variants are expressed in an ER like compartment in endothelial cells. 
A. Ea.Hy926 cells were transfected with GFPNOX5S or GFPNOX5β and GFP-fluorescence pictures 
were taken. B. HMEC-1 cells were transfected with either GFPNOX5S or GFPNOX5β and stained with 
antibodies against GFP and calreticulin. C. HeLa cells were transfected with GFPNOX5S and ER-
DsRed and GFP- and DsRed fluorescence pictures were taken. D. Endogenous NOX5 and calreticulin 
were stained in HMEC-1 cells using antibodies against NOX5 and calreticulin. Scale bars are 10 µm. 
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NOX2) or the YC- fragment (NOX4YC). Immunoprecipitation was performed with an 
antibody against GFP. Subsequent Western blot analysis with an antibody against 
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Fig. 25   Bimolecular fluorescence studies show an interaction between NOX2, NOX4, 
NOX5S or NOX5β and p22phox. 
A. Illustration of the principle of the Bimolecular Fluorescence Complementation (BiFC). After 
interaction, the YC and YN fragments form the fluorophore whose fluorescence light can be monitored 
using fluorescence microscopy. B. HeLa cells were transfected with p22phoxYN and either NOX2YC 
or NOX4YC and fluorescence pictures were taken showing an interaction of NOX2 and NOX4 with 
p22phox. C. Cells were transfected with p22phoxYN and either NOX5SYC or NOX5βYC and 
fluorescence pictures were taken showing a interaction of NOX5S and NOX5β with p22phox. No 
fluorescence was observed in negative controls (NOX2YC/YN, NOX4YC/YN, NOX5SYC/YN, 
NOX5βYC/YN and p22phoxYN/YC). Scale bar is 20µm for all panels. 
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p22phox revealed that p22phox was detectable in NOX2- and NOX4-expressing 
cells, but not in control cells expressing only GFP (Fig. 26A), indicating that both 
NOX2 and NOX4 interact with p22phox. For confirmation of the interaction between 
p22phox and NOX5S or NOX5β, coimmunoprecipitation was performed in HEK293 
cells (Fig 26B). Cells were cotransfected with p22phox and GFPNOX5β, GFPNOX5S 
or GFP control vector and immunoprecipitation was carried out with a polyclonal 
antibody against GFP. Western blot analysis using an antibody against p22phox 
showed that both NOX5β and NOX5S can interact with p22phox whereas no specific 
band could be observed in cells transfected with control vector (Fig. 26B). To 
determine whether NOX5 proteins interact with endogenous p22phox, 
immunoprecipitation was performed in HEK293 cells transfected with GFPNOX5β, 
GFPNOX5S, CFPNOX2 or GFP control vector, using an antibody against GFP. As 
expected, Western blot analysis using the p22phox antibody revealed that NOX2 is 
able to interact with endogenous p22phox (Fig. 26C). In contrast, no interaction was 
detectable between overexpressed NOX5 proteins and endogenous p22phox under 
these conditions (Fig. 26C).  
3.2.2 Contribution of p22phox, NOX2, NOX4 and NOX5 to endothelial ROS 
generation  
To determine the functional role of NOX2, NOX4 and NOX5 in endothelial Ea.Hy926 
and HMEC-1 cells, siRNA against NOX2 (siNOX2), NOX4 (siNOX4) and p22phox 
(sip22phox) were designed and cloned into a vector system. Also a siRNA targeting 
all NOX5 variants including NOX5S was designed (siNOX5). A random sequence 
was used as control (siCtr). Transfection of siRNA against NOX2, NOX4, NOX5 and 
p22phox diminished NOX2, NOX4, NOX5 and p22phox mRNA levels (Fig. 27A) as 
well as protein levels (Fig. 27B), respectively. Next, we tested the contribution of 
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NOX2, NOX4, NOX5 and also p22phox to endothelial ROS production. Silencing of 
the expression of NOX2, NOX4 and NOX5 decreased ROS levels in endothelial cells 
to a similar extent indicating that these NOX homologues are involved in basal ROS 
generation in these cells (Fig. 28A). Also the silencing of p22phox decreased the 
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Fig. 26   p22phox coimmunoprecipitates with NOX2, NOX4, NOX5S and NOX5β. 
A./B.HEK293 cells were cotransfected with plasmids encoding for the indicated fusionproteins. CFP-
NOX2 and NOX4YC (A) or GFP-NOX5S and GFP-NOX5β (B), and were precipitated with a polyclonal 
GFP-antibody. WB of the input showed overexpressed p22phox (input). The immunoprecipitates were 
subjected to Western blot analysis using an antibody against p22phox (IP). C. HEK cells were 
transfected only with GFP-NOX5β, GFP-NOX5S, CFP-NOX2 or GFP and immunprecipitation was 
performed with a polyclonal GFP-antibody. Expression of endogenous p22phox is shown in the upper 
panel (INPUT) with actin staining as loading control. Lower panel shows endogenous p22phox in the 
immunoprecipitate. 
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ROS generation (Fig. 28A). Moreover, overexpression of p22phox, NOX2, NOX4, 
NOX5S and NOX5β increased ROS levels to a similar extent (Fig.28B). In order to 
determine whether p22phox is required for ROS production by NOX5 variants, 
p22phox was depleted by specific siRNA in NOX5 overexpressing HMEC-1 cells 
(Fig. 29A). Compared to cells cotransfected with unspecific siRNA (siCtr), no 
difference in ROS levels was detected in cells coexpressing sip22phox with either 
NOX5S or NOX5β (Fig. 29B). In contrast, coexpression of sip22phox significantly 
decreased NOX2-mediated ROS production. In addition, coexpression of p22phox 
with NOX5β or NOX5S did not significantly enhance ROS levels compared to 
coexpression of control vector with NOX5 variants whereas coexpression of NOX2 
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Fig. 27   p22phox, NOX2, NOX4 and NOX5 are downregulated by specific siRNA. 
Endothelial cells were transfected with constructs encoding either for a specific siRNA against 
p22phox (sip22), NOX2 (siNOX2), NOX4 (siNOX4), NOX5 (siNOX5) or a random sequence (siCtr). A. 
24 hours after transfection mRNA levels of p22phox, NOX2, NOX4 and NOX5 were determined by 
RT-PCR using equal amounts of RNA for reverse transcription. B. Protein levels of p22phox, NOX2, 
NOX4 and NOX5 were analyzed by Western blot in comparison with actin, which was used as loading 
control.  
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with p22phox resulted in significantly elevated ROS levels compared to coexpression 
of a control vector (Fig. 29C). Since ROS production by NOX5 has been described to 
be enhanced by calcium [44, 45], HMEC-1 cells overexpressing NOX5S and NOX5β 
were treated with the calcium ionophore ionomycin and ROS levels were determined 
by DCF fluorescence measurements. Whereas in the absence of ionomycin NOX5S 
and NOX5β both contributed to ROS production equally, NOX5β- but not NOX5S- 
dependent ROS levels were increased in the presence of ionomycin, indicating that 
calcium specifically potentiates NOX5β-mediated ROS production (Fig. 30). In 
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Fig. 28   p22phox, NOX2, NOX4 and NOX5 modulate ROS generation of endothelial cells. 
Ea.Hy926 cells were transfected with plasmids encoding for a siRNA against p22phox, NOX2 
(siNOX2), NOX4 (siNOX4), NOX5 (siNOX5) or control siRNA (siCtr) (A) or vectors encoding for 
p22phox, NOX2, NOX4, NOX5S, NOX5β or with control vector (Ctr) (B). ROS levels were evaluated 
24 hours after transfection by performing DCF fluorescence measurements. Data are presented as 
relative change to control (100%) (n=4-6, *p<0.05 vs. cells transfected with control vectors [Ctr. or 
siCtr]). 
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accordance, ionomycin leads to an increase in ROS generation, which was inhibited 
by depletion of all NOX5 variants (Fig. 30B). 
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Fig. 29   p22phox is not required for NOX5S- or NOX5β-mediated intracellular ROS 
production in endothelial cells. 
A. HMEC-1 cells were transfected with control vector (Ctr) or plasmids encoding for p22phox 
(p22phox),a siRNA against p22phox (sip22phox), or control siRNA (siCtr), and Western blot analysis  
was performed with an antibody against p22phox. Reprobing with an actin antibody served as loading 
control. B. HMEC-1 cells were cotransfected with plasmids encoding for NOX2, NOX5S, or NOX5β 
together with plasmids encoding for siRNA against p22phox (sip22phox) or control siRNA (siCtr) and 
ROS levels were evaluated by performing DCF fluorescence measurement. Data are presented as 
relative change to control (100%) (n=3, *p < 0.05 vs. cells cotransfected with NOX2 or siCtr). C. 
HMEC-1 cells were cotransfected with NOX2, NOX5S, or NOX5β together with a plasmid encoding for 
p22phox or control vector (–). ROS levels were determined by performing DCF fluorescence 
measurement. Data are presented as relative change to control (100%) (n=3, *p < 0.05 vs. cells 
transfected with NOX2 and control vector). 
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3.2.3 Contribution of NOX2, NOX4 and NOX5 to basal endothelial proliferation 
Since ROS and NADPH oxidases have been implicated in the regulation of 
endothelial proliferation [72], we determined the contribution of the different NOX 
homologues (NOX2, NOX4 and NOX5) and p22phox to the proliferative response of 
endothelial cells using 5’-bromo-2’-deoxyuridine (BrdU) incorporation assay. 
Depletion of p22phox, NOX2, NOX4 or NOX5 reduced proliferation of endothelial 
cells (Fig. 31A). In contrast, the proliferative activity of Ea.Hy926 cells was 
significantly increased when p22phox, NOX2, NOX4, NOX5S or NOX5β were 
overexpressed (Fig. 31B). Since proliferation is required for formation of capillary like 
structures and angiogenesis, we further performed an in vitro angiogenesis assay 
using Matrigel for determinating the contributing of NOX homologues to the forming 
of capillary-like structures by depletion of NOX2, NOX4 and NOX5 
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Fig. 30   Calcium increases NOX5 dependent ROS generation in endothelial cells. 
HMEC-1 cells were transfected with plasmids encoding for NOX5S, NOX5β, siRNA against NOX5 
(siNOX5) or control siRNA (siCtr) and were exposed for 30 min to 3 µM ionomycin (IM) and 1.25 mM 
Ca2+. ROS levels were evaluated by performing DCF fluorescence measurement. Data are presented 
as relative change compared to respective nontreated cells set on 100% (n=3, *p < 0.05 vs. untreated 
cells transfected with NOX5β or untreated cells transfected with siCtr, #p<0.05 vs. ionomycin-treated 
siCtr-transfected cells). 
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in HMEC-1 cells and observed an reduced capacity of HMEC-1 cells to form 
capillary-like structures (Fig. 31C), indicating that the NOX homologues NOX2, NOX4 
and NOX5 are contributing to endothelial function. 
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Fig. 31 p22phox, NOX2, NOX4 and NOX5 modulate the proliferation of endothelial cells. 
A & B. Endothelial cells were transfected with plasmids encoding for siRNA against p22phox 
(sip22phox), NOX2 (siNOX2), NOX4 (siNOX4), NOX5 (siNOX5) or control siRNA (siCtr) (A) or 
plasmids encoding for p22phox, NOX2, NOX4, NOX5S, NOX5β or with control vector (Ctr) (B). 
Proliferation was assessed 48 h after transfection by using 5-bromo-2´-deoxyuridine (BrdU) 
incorporation. Data are presented as relative change to control (100%) (n=4-6, *p<0.05 vs. cells 
transfected with corresponding control vectors [Ctr or siCtr]). C. HMEC-1 cells were transfected with 
plasmids encoding for siRNA against NOX2 (siNOX2), NOx4 (siNOX4), NOX5 (siNOX5) or control 
siRNA (siCtr). Cells were plated on growth factor reduced matrigel and formation of capillary-like 
structures was allowed for 4 h at 37°C. Pictures were taken by light microscopy using Improvision 
software. Representative images are shown.  
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3.2.4 The p38 MAP kinase contributes to the proliferative response mediated 
by NOX2 and NOX4 
Since we previously showed that p38 MAP kinase is involved in endothelial 
proliferation dependent on p22phox [72], we determined the involvement of this 
kinase in the proliferative response mediated by NOX2 and NOX4. NOX2 and NOX4 
were expressed in Ea.Hy926 cells. Western blot analysis showed that p38 MAP 
kinase was phosphorylated in the presence of either NOX2 or NOX4 (Fig. 32). 
Treatment with the p38 MAP kinase inhibitor SB202190 decreased both NOX2- and 
NOX4-mediated proliferation (Fig. 32) indicating that p38 MAP kinase contributes to 
the proliferative response initiated by NOX2 or NOX4. 
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Fig. 32 The p38 MAP kinase contributes to the proliferative response mediated by NOX2 
and NOX4. 
Ea.Hy926 cells were transfected either with plasmids encoding for NOX2 (A) or NOX4 (B) or with 
control vector (Ctr). Expression of NOX2 and NOX4 and the presence of phosphorylated p38 MAP 
kinase were determined by Western blot analysis. Reprobing with actin served as loading control. 
Cells were treated either with solvent (-SB) or with 20 µM SB202190 (+SB) and proliferation was 
assessed after 12 h by using a BrdU incorporation assay. Data are presented as relative change to 
control without SB202190 (100%; n=3, *p < 0.05 vs. cells transfected with control vector; #p < 0.05 vs. 
untreated cells).  
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3.2.5 Influence on ROS generation and proliferation by NOX1 is limited in 
endothelial cells under basal conditions 
To analyze the involvement of NOX1 in ROS generation of Ea.Hy926 cells, a specific 
siRNA against NOX1 (siNOX1) was designed which downregulated NOX1 protein 
(Fig. 33A). However, in contrast to the other investigated NOX proteins, depletion of 
NOX1 did not significantly alter ROS levels in Ea.Hy926 cells and was also unable to 
significantly downregulate endothelial proliferation (Fig. 33B, C). This indicates that 
NOX1 plays only a minor role in basal endothelial function in contrast to NOX2, 
NOX4 and NOX5. 
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Fig. 33   NOX1 does not contribute to basal ROS generation and proliferation of 
endothelial cells. 
Ea.Hy926 cells were transfected with plasmids encoding for siRNA against NOX1 (siNOX1) or control 
siRNA (siCtr). A. Western blot analysis was performed using an antibody against NOX1. Reprobing 
with an actin antibody served as loading control. B. ROS levels were evaluated 24 hours post-
transfection by performing DCF fluorescence measurement. Data are presented as relative change to 
control (100%; n=3). C. Proliferation was assessed 48 hours post-transfection using a BrdU 
incorporation assay. Data are presented as relative change to control (100%; n=3).  
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3.3 Function and regulation of NADPH oxidases in thrombin and 
endoplasmic reticulum stress activated endothelial cells 
3.3.1 Contribution of NOX2 and NOX5 to thrombin-induced endothelial ROS 
generation and cell proliferation 
It is known that thrombin is an activator of the endothelium and we have previously 
shown that thrombin can induce and activate the NADPH oxidase subunits p22phox 
and NOX4 in the endothelial cell line Ea.Hy926 and in smooth muscle cells [33, 72, 
78]. Therefore, we investigated whether NOX2 and NOX5 are also regulated by 
thrombin and whether they play a role in the thrombin-induced ROS generation and 
proliferation. Cells were stimulated with thrombin (3 U/ml) for 3 hours. Western blot 
analysis using an antibody against NOX5 revealed that thrombin upregulates NOX5 
protein levels including NOX5S (Fig. 34A). This upregulation could be inhibited by 
transfecting siRNA against NOX5 (Fig. 34A), whereas upregulation of NOX5 in cells 
transfected with control siRNA was not affected indicating a de-novo transcription of 
NOX5 upon thrombin stimulation. Also the level of NOX2 protein was increased after 
thrombin stimulation and this upregulation was not decreased by depletion of NOX5, 
excluding cross-reactivity of the NOX5 siRNA and thus indicating a 
NOX5-independent mechanism (Fig. 34B). Then we investigated the contribution of 
NOX2 and NOX5 to thrombin-induced ROS generation. Thrombin-induced ROS 
generation was significantly reduced in NOX5-depleted cells and also depletion of 
NOX2 resulted in a similar reduction of ROS levels (Fig. 35) indicating an 
involvement of both NOX2 and NOX5 containing NADPH oxidase to thrombin-
induced ROS generation. Furthermore, stimulation with thrombin increased 
endothelial cell proliferation. Depletion of both NOX2 and NOX5 decreased the 
proliferative response to thrombin (Fig. 36A). Thrombin also induced the formation of 
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capillary-like structures of HMEC-1 in an in vitro angiogenesis assay using Matrigel 
for simulation of the extracellular matrix. Depletion of NOX2 and NOX5 completely 
abolished the capillary formation under thrombin stimulation (Fig. 36B), confirming a 
role for NOX2 and NOX5 in this response.  
3.3.2 Regulation of NADPH oxidase subunits by endoplasmic reticulum stress 
A redox dysbalance, like an in- or decrease in ROS generation in the ER often results 
in a so called endoplasmic reticulum stress (ER-stress) and subsequently an 
accumulation of unfolded proteins triggering the unfolded protein response (UPR). 
We could demonstrate that the endothelial NADPH oxidase is mainly localized in the 
ER (Fig. 5). We therefore formulated the hypothesis of an involvement of the NADPH 
oxidase in the UPR. First, we investigated whether NADPH oxidase subunits are able 
to colocalize with protein disulfide isomerase (PDI), 
A
B
50 kDa
75 kDa
siCtr siNOX5 siCtr siNOX5
ThrombinThrombin
NOX5
Actin
Ctr Ctr
NOX2
Actin
Thrombin
siCtr siNOX2 siCtr siNOX5 siCtr siNOX5
Thrombin
Ctr Ctr
 
Fig. 34   NOX2 and NOX5 are regulated by thrombin in endothelial cells. 
A. HMEC-1 cells remained untransfected or were transfected with plasmids encoding for siRNA 
against NOX5 (siNOX5) or control siRNA (siRNA) and Western blot analysis was performed under 
control conditions (Ctr) or after stimulation with thrombin (3 U/ml) for 3 hours using a NOX5 antibody. 
Reprobing with actin was performed as loading control. B. HMEC-1 cells were stimulated with 
thrombin (3 U/ml) for 3 hours or transfected either with plasmids encoding for siRNA against NOX2 
(siNOX2), NOX5 (siNOX5) or control siRNA (siCtr) and Western blot analysis was performed using a 
NOX2 antibody. Reprobing with actin was used as loading control.  
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which is highly involved in the cellular answer to ER-stress. For this, 
coimmunofluorescence studies with antibodies against NOX1, NOX4 and PDI were 
performed. PDI colocalized mainly with NOX4 and only weakly with NOX1 (Fig. 37A). 
Interestingly, overexpression of wild-type PDI increased endothelial ROS generation 
whereas overexpression of a nonfunctional PDI-mutant was not able to increase 
ROS generation (Fig. 37B). As PDI is a target gene and mediator of the UPR in the 
ER-stress response, we investigated whether ER-stress itself can induce ROS 
generation. Two common substances which induce ER-stress are tunicamycin (Tm) 
and thapsigargin (Tp). Tunicamycin inhibits N-glycosylation whereas thapsigargin 
inhibits the Ca2+-ATPase of the ER which leads to inhibition of calcium-dependent 
chaperones. First, we evaluated the effects of tunicamycin and thapsigargin on ROS 
generation in endothelial cells. Ea.Hy 926 cells were stimulated with tunicamycin 
(2 µg/ml) or thapsigargin (2.5 nM) and ROS generation was measured by DCF 
fluorescence in a microplate reader. Exposure to tunicamycin or thapsigargin resulted 
in significantly increased ROS generation with a peak at 
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Fig. 35   NOX2 and NOX5 mediates thrombin-induced ROS generation in endothelial 
cells. 
HMEC-1 cells were transfected with plasmids encoding for siRNA against NOX5 (siNOX5), NOX2 
(siNOX2) or control siRNA (siCtr). Cells were stimulated with thrombin (3 U/ml) for 3 hours. ROS 
levels were determined by performing DCF fluorescence measurements. Data are presented as 
relative change to control (100%) (n=3, *p<0.05 vs. unstimulated cells transfected with siCtr, #p<0.05 
vs. thrombin-stimulated cells transfected with siCtr). 
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one hour after thapsigargin or tunicamycin stimulation (Fig. 38A). Since NADPH 
oxidases have been shown to contribute to endothelial ROS production, it 
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Fig. 36   NOX2 and NOX5 mediates thrombin induced proliferation and tube formation in 
endothelial cells. 
HMEC-1 cells were transfected with plasmids encoding for siRNA against NOX5 (siNOX5), NOX2 
(siNOX2) or control siRNA (siCtr) and stimulated with 3 U/ml thrombin for 24 hours. A. Proliferation 
was assessed by performing BrdU incorporation. Data are presented as relative change to control 
(100%) (n=3, *p<0.05 vs. unstimulated cells transfected with siCtr, #p<0.05 vs. thrombin-stimulated 
cells transfected with siCtr). B. Cells were plated on growth factor reduced matrigel and formation of 
capillary-like structures was allowed for 4 h at 37°C. Pictures were taken by light microscopy using 
Improvision software. Representative images are shown. The relative formation of capillary-like 
structures as a measure for angiogenic capacity was quantified by Image J software. Data are 
presented as relative change to control (100%) (n=4, *p<0.05 vs. unstimulated cells transfected with 
siCtr, #p<0.05 vs. thrombin stimulated cells transfected with siCtr).  
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was determined whether elevated ROS production in response to prolonged ER-
stress would be NADPH oxidase-dependent. For this, Ea.Hy926 cells were 
transfected with a plasmid encoding for a specific siRNA against p22phox 
(sip22phox) 48 hours prior to stimulation with tunicamycin for 0.5, 1 and 2 hours and 
subsequent ROS measurements (Fig. 38B). Depletion of p22phox decreased ROS 
generation and the response to tunicamycin was completely abolished, indicating an 
involvement of p22phox in tunicamycin-induced ROS generation. Next, it was 
analyzed whether elevated ROS generation in response to prolonged ER-stress 
would be associated with increased expression of the NADPH oxidase subunit 
p22phox. Ea.Hy926 cells were stimulated with thapsigargin for increasing time 
periods and mRNA and protein levels of p22phox were analyzed by Northern or 
Western blot, respectively. Levels of mRNA for p22phox were increased after one 
hour of ER-stress reaching a plateau phase at two hours up to eight hours ER-stress 
(Fig. 39A) and also p22phox protein was increased by ER-
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Fig. 37  Protein disulfide isomerase is associated with NOX4 and increased ROS 
generation in endothelial cells. 
A. Ea.Hy926 cells were stained with antibodies against NOX1 or NOX4 together with an antibody 
against PDI. Merged images show overlay of NOX4 with PDI. Scale bar is 20 µm for all panels. B. 
Ea.Hy926 cells were transfected with plasmids encoding either for wild-type PDI (PDI), a mutated 
nonfunctional PDI (PDIm) or control vector (Ctr). 24 hours post-transfection, ROS levels were 
measured by performing DCF fluorescence measurement. Data are presented as relative change to 
control cells (100%) (n=3,*p<0.05 vs. cells transfected with control vector (Ctr); #p<0.05 vs. cells 
transfected with wild-type PDI). 
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stress (Fig. 39B). Since ER-stress and UPR increase phosphorylation of eIF2α, 
Western blot analysis of phosphorylated eIF2α was performed to confirm the 
presence of ER-stress or UPR (Fig. 39B). Increased phosphorylation of eIf2α was 
observed up from 0.5 hours. To investigate whether the increase of p22phox mRNA 
is a transcriptional process, Ea.Hy926 cells were pretreated with 
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Fig. 38   ER-stress induces ROS generation via p22phox in endothelial cells. 
A. Ea.Hy 926 cells were stimulated with either 2.5nM thapsigargin (Tp) or 2 µg/ml tunicamycin (Tm) for 
indicated time points and ROS generation was analyzed using DCF fluorescence. Data are presented 
as relative change to control (100%) (n=3, *p<0.05 vs. unstimulated cells). B. Ea.Hy926 cells were 
transfected with a plasmid encoding for a siRNA against p22phox (sip22phox) or control siRNA (siCtr) 
and ROS generation was analyzed using DCF fluorescence after tunicamycin (2 µg/ml) for 0.5, 1 and 
2 hours. Data are presented as relative change to control (100%) (n=3, *p<0.05 vs. unstimulated cells; 
#p<0.05 sip22phox vs. siCtr). 
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actinomycin D (5 µg/ml) 30 minutes prior to stimulation with thapsigargin for 2 and 4 
hours. Northern blot analysis showed that pretreatment with actinomycin D abolished 
thapsigargin-induced increase of p22phox mRNA levels (Fig. 39C), indicating that 
p22phox is indeed upregulated by a transcriptional mechanism. A bioinformatic 
analysis of the potential promoter region of p22phox (MatInspector™ software, 
Genomatix, München) was performed to search for mediators of the UPR. Two 
important transcription factors in the UPR are XBP1 and ATF4. Indeed, several 
potential binding sites for ATF4 and XBP1 were found in the upstream region of the 
p22phox gene (Fig. 40A). In the 6k upstream sequence of p22phox, four distal, but 
closely related XBP1 binding sites were found 
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Fig. 39   ER-stress increases p22phox mRNA and protein levels in endothelial cells. 
A. Ea.Hy926 cells were stimulated with thapsigargin (2.5 nM) for 1, 2, 4 or 8 hours and mRNA levels of 
p22phox were analyzed using Northern blot (n=3 *p<0.05 thapsigargin vs. unstimulated control). B. 
Cells were stimulated with thapsigargin (2.5 nM) for 0.5, 1, 2, 4 or 8 hours. Western blot analysis was 
performed with antibodies against p22phox, phosphorylated eIF2α (p-eIF2α) and actin as loading 
control. C. Ea.Hy926 cells were preincubated with actinomycin D (Act D; 5 µg/ml) for 30 minutes prior 
to thapsigargin stimulation (2.5 nM) for 2 or 4 hours. mRNA level for p22phox was analyzed by 
Northen blot analysis (n=3;*p<0.05 thapsigargin vs. unstimulated control). 
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(-3967 bp, -3838 bp, -3689 bp, -3511 bp). In addition several ATF4 sites (-5847 bp, 
-4190 bp, -3786 bp, -2788 bp, -2568 bp, -2531 bp, -2507 bp, -587 bp) were found by 
bioinformatics analysis. Therefore we investigated whether ATF4 or XBP1 can induce 
ROS generation and p22phox expression. We investigated the role of ATF4 and 
XBP1 in thapsigargin-induced ROS generation and as a first step we investigated the 
activation of ATF4 and XBP1 by thapsigargin. XBP1 activation is characterized by 
splicing by IRE1. We performed RT-PCR studies for XBP1 mRNA using primers by 
which both splice variants were amplified and could be distinguished by their size. 
Indeed we could detect the smaller spliced XBP1 form after one hour of thapsigargin 
stimulation (Fig. 40B). ATF4 activation is characterized by increased protein 
expression and we could detect increased ATF4 protein levels starting from 30 
minutes stimulation with thapsigargin (Fig. 40C). Next, we investigated the role of 
ATF4 and XBP1 on ROS generation in endothelial cells. For this, specific siRNA 
against ATF4 and XBP1 were designed (siATF4 and siXBP1) and Ea.Hy926 cells 
were transfected with these siRNAs 48 hours prior to thapsigargin stimulation for half, 
one and two hours and ROS generation was measured. 
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Fig. 40   Thapsigargin induces XBP1 and ATF4 activation in endothelial cells. 
A. Schematic of the p22phox promoter with potential binding sites for ATF4 (A4, grey) and XBP1 (X1, 
black). B & C. Ea.Hy926 cells were stimulated with thapsigargin (2.5nM) for 0.5, 1 and 2 hours. B. 
RNA was extracted and splicing of XBP1 was analyzed with RT-PCR using primers spanning the 
splice site resulting in unspliced (u) or spliced (s) PCR-product. C. Western blot analysis was 
performed using antibodies against p-eIF2α, ATF4 and actin as loading control.  
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Depletion of ATF4 and XBP1 abolished ROS generation after thapsigargin 
stimulation (Fig. 41A). Accordingly, overexpression of ATF4 or XBP1 incresed ROS 
generation in Ea.Hy926 cells (Fig. 41B). Next the effect of ATF4 or XBP1 on the 
expression of p22phox was analyzed. Overexpression of ATF4 or XBP1 in Ea.Hy926 
cells caused an increase in p22phox mRNA and protein levels (Fig. 42A, B) and 
silencing of XBP1 abolished the upregulation of p22phox protein levels after 
thapsigargin stimulation (Fig. 42C). 
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Fig. 41  ATF4 and XBP1 mediates ROS generation under thapsigargin stimulation in 
endothelial cells. 
A. Ea.Hy926 cells were transfected with plasmids encoding for siRNA against ATF4 (siATF4), XBP1 
(siXBP1) or control siRNA (siCtr) followed by thapsigargin (2.5 nM) stimulation for indicated time 
points. ROS levels were analyzed by DCF fluorescence (n=3,*p<0.05 vs. unstimulated control cells, 
#p<0.05 siATF4 transfected cells vs. control transfected cells,$p<0.05 siXBP1 transfected cells vs. 
control transfected cells). B. Cells were transfected with plasmids encoding for ATF4, XBP1 or control 
vector (Ctr) and 24 hours post-transfection, ROS levels were analyzed by DCF fluorescence (n=3, 
*p<0.05 vs. cells transfected with control vector). 
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3.3.3 Regulation of p22phox upstream enhancer element activity by ATF4, 
XBP1 and ER-stress in endothelial cells 
Since the bioinformatic analysis revealed a potential ATF4 binding site in the 
proximal promoter region and a potential enhancer region with four XBP1 and one 
ATF4 binding site, two reporter constructs were used which were already present in 
the lab. One construct was based on the pGL3-Basic and contained 1179 bp of the 
upstream promoter region including 35 bp of the 5´ untranslated region of the 
p22phox gene creating the pGL3B-p22phox1.2Kluc plasmid (p22phox-1.2K). The 
other construct contained a 520 bp large fragment from -4104 bp and -3584 bp 
upstream of the p22phox coding sequence with three potential XBP1 and one 
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Fig. 42   ATF4 and XBP1 mediates p22phox expression under thapsigargin stimulation in 
endothelial cells. 
A. Ea.Hy926 cells were transfected with plasmids encoding for ATF4 (ATF4), XBP1 (XBP1) or control 
vector. After RNA preparation, Northern blot analysis for p22phox was performed, 18S RNA served as 
loading control. Graph represents the relative ratio of p22phox mRNA to 18S RNA. B. Ea.Hy926 cells 
were transfected with either ATF4, XBP1 or control vector and Western blot analysis for p22phox was 
performed. Reprobing with actin served as loading control. C. Ea.Hy926 cells were transfected with a 
plasmid encoding for a siRNA against XBP1 (+) or control siRNA (-). 24 hours post-transfection cells 
were stimulated with thapsigargin (2.5 nM) for the indicated time points and Western blot analyzes for 
XBP1, p22phox, p-eIF2α were performed. Reprobing with actin served as loading control. 
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potential ATF4 sites and was cloned as enhancer construct into the pGL3-Promoter 
in front of the SV40 promoter creating pGL3E-p22phox-XBPluc (p22phox-XBPluc). 
To test the influence of ER-stress on the function of the p22phox promoter, Ea.Hy926 
cells were transfected with the p22phox-1.2K reporter construct and cells were 
stimulated with thapsigargin for eight hours. Indeed, an increased luciferase activity 
was detected upon stimulation (Fig. 43A). As this construct contains a potential ATF4 
binding site, cotransfection of this construct together with ATF4 showed an increased 
luciferase activity (Fig. 43B) indicating a modulation function of ATF4 on the p22phox 
promoter. The evaluate whether the distal enhancer region can also be modulated by 
ER-stress, Ea.Hy926 cells were transfected with the p22phox-XBP luciferase 
construct and also stimulated with thapsigargin for eight hours and again an 
increased luciferase activity was detected upon stimulation (Fig. 44A). Also 
*
A
Ctr
Tp
0 50 100 150 200 250
Rel. luciferase activity [% control]
B
Ctr
ATF4
0 50 100 150 200
*
Rel. luciferase activity [% control]
luc
ATF4
p22phox-1.2K
luc
ATF4
p22phox-1.2K
 
Fig. 43   ER-stress and ATF4 activates p22phox promoter in endothelial cells. 
A. Ea.Hy926 cells were transfected with p22phox-1.2K promoter construct and stimulated with 
thapsigargin (Tp, 2.5 nM) for 8 hours or remained unstimulated (Ctr) and were subjected to luciferase 
assay. Data represented as change to nontreated cells (100%; n=3,*p<0.05 vs. unstimulated control 
cells). B. Cells were transfected with p22phox-1.2K promoter construct together with a plasmid 
encoding either for ATF4 or empty control vector (Ctr). 24 hours post-transfection cells were subjected 
to luciferase assay. Data are represented as change to cells transfected with control vector (100%, 
n=3, *p<0.05 vs. cells transfected with control).  
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coexpression of ATF4 or XBP1 with this construct resulted in an increased luciferase 
activity (Fig. 44B). Finally, depletion of ATF4 or XBP1 in Ea.Hy926 cells abolished 
the induction of luciferase activity of the p22phox-XBP1 reporter by thapsigargin 
(Fig. 43C). These results indicated that ATF4 and XBP1 could play a role in the 
activation of the p22phox-XBP1 enhancer element, the p22phox promoter and 
subsequently p22phox induction on mRNA as well as protein level. 
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Fig. 44   ER-stress activates a p22phox enhancer element via ATF4 and XBP1 in 
endothelial cells 
A. Ea.Hy926 cells were transfected with p22phox-XBP1 enhancer construct containing XBP1 (X1, 
black) and ATF4 (A4, grey) sites and stimulated with thapsigargin (2.5nM) for 8 hours or remained 
unstimulated (Ctr) and were subjected to luciferase assay. Data are represented as change to 
nontreated cells (100%; n=3,*p<0.05 vs. unstimulated control cells). B. Cells were transfected with 
p22phox-XBP1 enhancer construct together with a plasmid encoding either for ATF4, XBP1 or empty 
control vector (Ctr). 24 hours post-transfection cells were subjected to luciferase assay. Data 
represented as change to cells transfected with control vector (100%, n=3, *p<0.05 vs. cells 
transfected with control). C. Cells were transfected with p22phox-XBP1 enhancer contruct together 
with a plasmid encoding for a siRNA against ATF4 (siATF4), against XBP1 (siXBP1) or control siRNA 
(siCtr). 24 hours post-transfection cells were stimulated with thapsigargin (2.5nM; +Tp) for 8 hours or 
were stimulated with solvent (-Tp) and subjected to luciferase assay. Data are represented as change 
to respective nontreated cells (100%; n=3, *p<0.05 vs. unstimulated cells).
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4 Discussion 
4.1 Expression of NOX2, NOX4, NOX5, p22phox in endothelial cells 
The NOX2 containing NADPH oxidase known from phagocytic cells was the first 
NADPH oxidase discovered in endothelial cells [79]. In the following years several 
homologues of NOX2 were discovered, NOX1, NOX3, NOX4 and NOX5. Whereas 
the expression of NOX3 seems to be limitated to the inner ear and fetal tissues, all 
other NOX homologues were found to be expressed in several adult tissues and cell 
types including vascular cells. From NOX5 several splice variants are predicted, but 
so far little is known about their contribution and function in endothelial cells.  
Therefore, as a first aim, we investigated the expression of different novel NOX 
proteins namely NOX1, NOX2, NOX4 and NOX5 including the EF-lacking variant 
NOX5S in the endothelial cell types Ea.Hy926 and HMEC-1. Briefly, the results show 
that  
(A) Ea.Hy926 cells and HMEC-1 express both NOX2 and NOX4 at mRNA and 
protein levels.  
(B) HMEC-1 cells express mRNA for NOX5β and NOX5δ variants as determined 
by RT-PCR.  
(C) HMEC-1 cells contain NOX5 protein as well as the NOX5S variant which 
lacks the N-terminal calcium-binding domains.  
(D) NOX5 proteins are also present in endothelial and smooth muscle cells in the 
vascular wall of spleen and lung tissue. 
In this study we showed that endothelial Ea.Hy926 cells as well as HMEC-1 cells 
express both NOX2 and NOX4, at the mRNA and protein level. In addition to the 
NADPH oxidase subunit NOX2 (gp91phox) which has been shown to be expressed 
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and functionally active in endothelial cells [32, 79], NOX4 has been recently shown to 
be expressed in endothelial cells suggesting that a NOX4-containing NADPH oxidase 
may play a functional role in these cells [40, 54]. In endothelial cells, we could earlier 
show that NOX2 is envolved in the thrombin-induced ROS generation, proliferation 
and angiogenesis [80]. It was also shown that NOX2 is involved in the migrating 
response of endothelial cells [81]. Furthermore, in porcine cerebral miscrovascular 
endothelial cells, TNFα induced oxidative stress and subsequently apoptosis by 
NOX4 [82] and also in human coronary arterial endothelial cells, NOX4 was involved 
in the TNFα induced ROS generation [83]. Interestingly, NOX2 mediated anti-
inflammatory effects induced by atrial natriuetic peptide in endothelial cells activated 
by TNFα [84], although TNFα is known to mediate the proinflammatory response in 
neutrophils in a NOX2-dependent manner [85].   
We could also demonstrate that vascular cells express NOX5 transcripts, HMEC-1 
cells expressed the EF-hand containing NOX5 variants NOX5β and NOX5δ, whereas 
PASMCs expressed in addition NOX5α and NOX5γ. Previously, the expression of 
NOX5α has been described in the spleen and the expression of NOX5β in testis [45], 
whereas NOX5δ and NOX5γ expression has not been described so far. Other 
findings indicate that NOX5 variants are cell type specifically expressed [37]. In 
addition to the EF-hand containing NOX5 variants, a shorter variant which we now 
termed NOX5S lacking the EF-hands and thus resembling other NOX homologues 
such as NOX1, NOX2 or NOX4, was detected in vascular cells. Initially, a NOX5 
transcript identical to NOX5S has been described to be primarily present in fetal 
tissue and some cancer cell lines including CaCo2 [75]. NOX5 transcripts have been 
subsequently identified in vascular smooth muscle, uterus and bone marrow [45], in 
prostate carcinoma cells [48] and human cardiac fibroblasts [51]. Recently, NOX5 
transcripts have also been detected in the stomach [50]. However, these studies 
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used PCR primers which amplified fragments from the “core region” of NOX5, which 
is common to all NOX5 variants including NOX5S making the discrimination of NOX5 
and NOX5S impossible. To verify the presence of NOX5 variants at the protein level, 
Western blot analysis with an antibody targeted against an epitope within the core 
region of NOX5 was performed. This antibody recognized two proteins of 75 kDa and 
60 kDa with a prevalence of the larger protein which was not present upon addition of 
the immunogenic peptide or after transfection of siRNA targetting NOX5. 
Furthermore, overexpression of NOX5β or NOX5S confirmed that the antibody 
recognizes NOX5S as well as EF-hand containing NOX5 variants indicating that 
NOX5 and NOX5S proteins are present in endothelial cells. Similarly, expression of 
NOX5 has been described in Du145 prostate carcinoma cells and in hairy cell 
leukemic B-cells but not in circulating B-cells [48, 49]. NOX5S was also reported to 
be highly expressed in Barrett esophageal adenocarcinoma cells involved in tumor 
progression [86-88]. 
In addition to the presence of NOX5 variants in cultivated endothelial cells, we could 
clearly demonstrate that NOX5 protein was also present in small vessels of the 
spleen in the endothelial as well as in the smooth muscle cell layer [53]. Although 
NOX5 protein has not been detected in human tissues to date, NOX5 mRNA has 
been found in testis, spleen, and lymph nodes by in situ hybridization and has been 
localized to areas rich in either spermatocytes, or immature B-lymphocytes or T-
lymphocytes, respectively [45]. 
Consistently with these results, we found NOX5 staining for lymphocytes throughout 
the spleen. Although NOX5 protein could also be detected in vessels and in tissue 
from other highly vascularized lymphoid organs such as the tonsil [53], the presence 
of this protein was not restricted to lymphoid tissues since NOX5 was also found in 
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pulmonary vessels. These data suggest that NOX5 protein is expressed in cells of 
the vascular wall. 
4.2 Expression of NOX1, NOXA1 and NOXO1 in endothelial cells 
In addition to NOX2 and NOX4, NOX1 has also been suggested to play a functional 
role in rat basilar and sinusoidal as well as in mouse aortic endothelial cells [41, 42, 
89], although NOX1 mRNA could not be detected in HUVEC [54, 84]. Therefore it 
was also an aim of this study to investigate whether endothelial cells express NOX1 
and its cytosolic factors NOXA1 and NOXO1. Furthermore the contribution of NOX1 
to endothelial ROS generation was investigated. We could demonstrate that  
(A) NOX1 is detectable at mRNA and protein level in Ea.Hy926 cells and HMEC-1 
cells. 
(B) NOX1 is present in a perinuclear compartment and is present in the 
microsomal fraction. 
(C) Ea.Hy926 cells and HepG2 cells express NOXA1 and NOXO1 mRNA. 
Although we could confirm by RT-PCR and Western blot analyzes the presence of 
NOX1 in endothelial cells, detection by RT-PCR required an increased cycle number, 
indicating that only small amounts of NOX1 mRNA are present in endothelial cells. 
However, there is a report showing that a NOX1 short variant termed NOH1-S is the 
result of a template switching during cDNA synthesis [8] indicating that the NOX1 
mRNA and subsequently cDNA is forming secondary structures inhibiting an efficient 
RT-PCR.  
Immunofluorescence analysis further showed that NOX1 was located in a perinuclear 
compartment resembling the ER and NOX1 protein was also present in the 
microsomal fraction, although no colocalization with the ER-marker calreticulin was 
detected. Interestingly, NOX1 also colocalized with NOX2 within one cell (data not 
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shown), indicating that NOX1, NOX2 and NOX4 are co-expressed in endothelial 
cells. However, depletion of NOX1 by different siRNAs did not significantly reduce 
basal ROS levels or proliferation in endothelial cells, indicating that NOX2 and NOX4 
play a major role in basal endothelial ROS production.  
Since NOX1 requires preferentially the p47phox homologue NOXO1 and the 
p67phox homologue NOXA1 for ROS generation [47, 90], we also performed RT-
PCR analysis to identify the expression of NOXO1 and NOXA1 in endothelial cells. 
Indeed, both NOXA1 and NOXO1 mRNA could be detected in endothelial Ea.Hy926 
cells as well as in the hepatoma cell line HepG2, as the expression of NOXA1 and 
NOXO1 was described in the liver [90]. However, additional PCR products could be 
detected in our study. Sequencing and comparison of the two PCR products for 
NOXA1 show the insertion of several nucleotides from the intron upstream of the 5’ 
end of exon 3. The transition of this “extended” exon 3 and exon 2 corresponded to 
the traditional splicing rule, GT at the 5´end and AG at the 3´end of the splice site 
[91], therefore indicating an alternative splicing. In the case of NOXO1, the 
sequencing analysis of the PCR product revealed that the complete short intron 
between exon 3 and exon 4 was amplified leading to a longer PCR product than 
expected. If these observations are the only differences between the newly 
discovered alternative PCR products and the known mRNA of NOXA1 and NOXO1, 
these nucleotide insertions would lead to a premature STOP codon and a very short 
protein. 
For NOXO1, alternative splicing in the region of exon 2, 3 and 4 is reported, but the 
incorporation of the complete intron between exon 3 and 4 has not been previously 
observed [92, 93]. Also for NOXA1 alternative splicing was reported, but at different 
exons than found in our study [94]. Further experimental analyses of our 
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observations are necessary to confirm whether our observed larger PCR products 
are indeed results of an alternative splicing. 
4.3 NOX1, NOX2, NOX4 and NOX5 localization and interaction with 
p22phox 
As we demonstrated that endothelial cells express the NOX homologues NOX1, 
NOX2, NOX4 and NOX5. We further investigated and compared the subcellular 
localization of NOX1, NOX2, NOX4, NOX5 and the EF-hand lacking variant NOX5S 
as well as the localization of p22phox. Furthermore we analyzed whether these NOX 
homologues, similar to the situation in the phagocytic NADPH oxidase, were able to 
interact with p22phox. The following results were achieved:  
(A) NOX2 and NOX4 are simultaneaously expressed within the same endothelial 
cell. 
(B) NOX2, NOX4, NOX5, but not NOX1 are localized in the ER of endothelial 
cells colocalising with the ER-marker calretucilin.  
(C) NOX2 but not NOX4 is also present at the plasma membrane.  
(D) GFP-tagged p22phox, NOX2, NOX4, NOX5S and NOX5β are localized in the 
ER of endothelial cells. 
(E) GFP-tagged p22phox and NOX5 are localized in the ER of HeLa cells, 
whereas GFP-tagged NOX2 and NOX4 are mainly localized in the plasma 
membrane of these cells. 
(F) NOX2 and NOX4 are able to interact with p22phox.  
(G) both NOX5S and NOX5β interact with overexpressed p22phox, although 
p22phox was not essentially required for ROS production by either variant. 
We showed that NOX2 and NOX4 are both present simultaneously within the same 
endothelial cells and that expression of each subunit is not limited to a subpopulation 
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of cells. Although the functional relevance of this observation is not clear to date, 
previous studies suggested that NOX homologues may be present in different cellular 
compartments and may thus have different functions [95]. NOX2 and NOX4 were 
both present in an intracellular, perinuclear compartment and colocalized with 
calreticulin. In addition, GFP-tagged NOX2 and NOX4 as well as p22phox were 
expressed and colocalized with coexpressed ER-localized fluorescent proteins, 
suggesting that NOX2 and NOX4 as well as p22phox, are localized in the ER. 
Interestingly, the intracellular localization of GFP-tagged NOX2 and NOX4 in cervix 
carcinoma cells (HeLa) differs from the localization observed in Ea.Hy926 cells, 
indicating a different localization of NOX2 and NOX4 in different cell lines. Although 
several publications showed a localization of NOX4 in the ER of endothelial cells and 
other cells [54, 96, 97], localization at the focal adhesion together with vinculin in rat 
vascular smooth muscle cells [95] and in the nucleus of human umbilical vein 
endothelial cells, stem cells and cells isolated from rat renal cortex [98-100] were also 
reported. We could not find a difference in the localization of p22phox and NOX5 
between HeLa and endothelial cells. Similarly, GFP-tagged NOX2 and NOX4 showed 
an ER-like expression pattern in HUVEC [54]. Furthermore, in cell fractionation 
experiments we could confirm that NOX2 and NOX4 are present in the microsomal 
fraction. However, preliminary studies did not provide evidence that both proteins 
would interact with each other under the experimental conditions applied. Although 
NOX2 was considered to be mainly localized in leukocytes at the plasma membrane, 
earlier studies showed that NOX2 is also present in intracellular vesicular structures 
in “dormant”, non-activated leukocytes [101]. Consistently, immunofluorescence 
demonstrated that NOX2 and p22phox were expressed in an intracellular, perinuclear 
compartment in an ER-like manner in porcine iliac artery and bovine aortic 
endothelial cells [32]. Similarly, NOX4 has been found in the ER in human aortic 
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smooth muscle cells [55] and fluorescent protein-tagged NOX4 interacted with the 
ER-marker protein-disulfid-isomerase in rabbit vascular smooth muscle cells [56]. In 
contrast, NOX4 protein was found to colocalize with focal adhesions in rat vascular 
smooth muscle cells [95]. Although the reasons for these divergent findings are not 
resolved to date, the functional importance of our observations was further underlined 
by our findings that p22phox was also present in the ER and, more importantly, that 
p22phox interacted with NOX2 and NOX4 in this intracellular compartment as 
determined by BiFC [76, 77]. Importantly, although BiFC was performed in HeLa 
cells, the fluorescent complexes in these cells showed a similar distribution as the 
fusion proteins or the “native” proteins in Ea.Hy926 cells indicating that these studies 
are representative for the situation in intact Ea.Hy926 cells. In contrast to GFP-NOX2 
alone, no clear membrane staining was observed in HeLa cells, indicating that the 
complex of p22phox and NOX2 has a different localization than NOX2 alone. 
Similarly, using FRET, a technique which allows the visualization of proteins located 
in a very close vicinity, the association of transfected rat p22phox with transfected 
NOX2 and NOX4 was demonstrated in HEK293 cells [96]. We could demonstrate the 
presence of smaller amounts of NOX2, but not NOX4 protein at the plasma 
membrane and its colocalization with F-actin whereby actin was found at the inner 
layer and NOX2 at the outer layer of the membrane. Intracellular colocalization of 
NOX2 with parts of the cytoskeleton has been previously described in endothelial 
cells [32, 54]. In addition, a recent study showed that NOX2 can be found at the 
leading edge of migrating HUVEC where it colocalized with actin [81].  
Our immunofluorescence studies revealed that under basal conditions NOX5S and 
NOX5β were localized intracellulary in a perinuclear compartment in both Ea.Hy926 
and HMEC-1 cells and colocalized with calreticulin indicating that they are present in 
the ER. Similarly, we could show that endogenous NOX5 was present in the same 
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compartment. These findings are supported by a previous report where NOX5 was 
shown to be expressed in a perinuclear compartment in prostate carcinoma cells 
[48].  
Interestingly, although NOX5S and NOX5β were able to interact with overexpressed 
p22phox as we could demonstrate by BiFC and co-immunoprecipitation, only NOX2 
was able to interact with endogenous p22phox under these conditions.  
These findings suggest that, in contrast to NOX2, the affinity of NOX5 proteins and 
p22phox may be too low to detect their interaction under the applied conditions. 
Consistently, we found that depletion of endogenous p22phox by siRNA did not 
significantly reduce ROS levels induced by NOX5S or NOX5β, although it diminished 
NOX2 mediated ROS production in HMEC-1 cells. Supporting, depletion of p22phox 
by siRNA did not decrease NOX5β-dependent ROS production in HEK293 cells 
[102]. Furthermore, as expected, when we overexpressed p22phox the NOX2-
stimulated ROS generation was enhanced, but the increased p22phox levels had no 
significant effect on ROS levels in the presence of NOX5S or NOX5β, suggesting 
that, in contrast to NOX2, p22phox is not essentially required for ROS production by 
NOX5 proteins.  
4.4 Contribution of p22phox, NOX2, NOX4 and NOX5 to endothelial 
ROS generation and proliferation 
An intact cytoskeleton and interaction of NOX2 with the actin-binding protein IQGAP1 
have been shown to be required for ROS production and migration of HUVEC [81] 
suggesting that in migrating and possibly also in proliferating endothelial cells, the 
reorganization of the actin cytoskeleton may enable NOX2 to translocate to the 
leading edge, assemble with the actin-binding structures and generate ROS to 
promote migration and proliferation. We therefore investigated the role of the NOX 
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homologues NOX2, NOX4, NOX5 including NOX5S on ROS generation, proliferation 
as well as the formation of capillary-like structures of endothelial cells. Indeed, we 
could demonstrate that 
(A) depletion of NOX2, NOX4 and NOX5 by siRNA reduces ROS production in 
Ea.Hy926 and HMEC-1 cells. 
(B) both NOX5S and NOX5β elevate basal ROS levels while depletion of NOX5 
decrease ROS generation in HMEC-1 cells. 
(C) NOX5β-dependent but not NOX5S-dependent ROS production is enhanced in 
the presence of ionomycin in a calcium-containing buffer. 
(D) depletion of NOX2, NOX4 and NOX5 reduces endothelial proliferation and 
formation of capillary-like structures, indicating angiogenic activity. 
(E) overexpression of NOX2, NOX4 and NOX5β and NOX5S stimulates 
endothelial proliferation and formation of capillary-like structures. 
(F) activation of p38 MAP kinase by NOX2 or NOX4 contributes to the endothelial 
proliferative response. 
These findings indicate that NOX2, NOX4 and NOX5 contribute to ROS generation in 
endothelial cells under basal conditions. A role for NADPH oxidase under stimulated 
conditions could be already demonstrated, although the findings were sometimes 
controversial. It was demonstrated that NOX4 or NOX2 antisense DNA inhibited 
angiotensin-II-induced ROS generation in HUVEC [103]. In addition, NOX4 antisense 
oligonucleotides decreased ROS levels of proliferating rat aortic endothelial cells by 
50% although the contribution of NOX2 to ROS production has not been evaluated in 
that study [40]. On the other hand, ANP-stimulated ROS production was decreased 
by NOX2, but not by NOX4 antisense treatment in HUVEC [84]. Similarly, NOX2 
antisense oligonucleotides reduced VEGF-stimulated ROS production in HUVEC 
[104]. Although the reasons for these controversial
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and may relate to the cell type used and the specific experimental conditions applied, 
we demonstrate that depletion of NOX2 or NOX4 also decreased ROS production in 
HMEC-1 cells, further emphasizing the importance of both homologues for 
endothelial ROS production. 
Moreover, our results show that NOX2, NOX4, NOX5β and NOX5S overexpression 
enhanced ROS levels in Ea.Hy926 cells and HMEC-1 cells further indicating that 
these homologues contribute to endothelial ROS production, and that the amount of 
NOX2, NOX4 and NOX5 present in the cell is limiting the levels of ROS production. 
Consistently, studies in other cellular systems demonstrated that NOX4 
overexpression increased ROS production with no need for concomitant expression 
of other subunits as long as p22phox levels were sufficient and that NOX5β 
overexpression increased ROS generation to a similar extent than NOX4 in HEK293 
cells [102, 105]. In contrast, NOX2 function has been suggested to require p22phox 
as well as cytosolic subunits and Rac [19, 20, 53]. Thus, our findings - demonstrating 
that NOX2 overexpression increases ROS levels - suggest that sufficient cytosolic 
proteins are available in Ea.Hy926 cells or HMEC-1 cells in order to allow functional 
activation of a NOX2-depending NADPH oxidase.  
Moreover, consistent with previous reports [29, 30], we demonstrate that an elevation 
of calcium levels by the addition of ionomycin selectively enhanced NOX5β- but not 
NOX5S-mediated ROS levels. These findings indicate that increased calcium 
concentrations can further stimulate NOX5β-dependent ROS production.  
We previously showed that low levels of H2O2 increase the proliferative activity of 
Ea.Hy926 cells, and that modulation of p22phox levels affect the proliferative 
response of these cells [72]. Here, we demonstrate that overexpression of NOX2, 
NOX4, NOX5β and NOX5S as well as p22phox which lead to increased ROS 
production, also enhanced proliferative activity of Ea.Hy926 and HMEC-1 cells, 
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whereas depletion of NOX2, NOX4, NOX5 and p22phox decreased endothelial 
proliferation to a similar extent. These findings indicate that NOX2, NOX4 and NOX5-
mediated ROS production contributes to endothelial proliferation.  
Consistently, depletion of NOX2 decreased VEGF-induced migration and proliferation 
of HUVEC and depletion of NOX5 by antisense oligonucleotides decreased 
proliferation of prostate carcinoma cells [48, 104]. Furthermore, we showed that 
depletion of NOX2, NOX4 and NOX5 decreased the endothelial tube forming ability 
which is indicative of angiogenic activity. 
Although to date the role of NOX4 in endothelial proliferation has not been fully 
investigated, overexpression of NOX4 has been previously shown to decrease 
proliferation of NIH3T3 cells [106] and depletion of NOX4 prevented the induction of 
apoptosis by 7-ketocholesterol in human aortic smooth muscle cells [55]. In contrast, 
and consistent with our study, recent studies showed that depletion of NOX4 
decreased proliferation of melanoma cells [48], abrogated urotensin-II-stimulated 
proliferation of pulmonary artery smooth muscle cells [107] and increased apoptosis 
of pancreatic cancer cells [108]. Similar to our study it was also shown that NOX4 
promoted proliferation and in vitro angiogenesis of HMEC-1 cells [109], indicating that 
NOX4 has also a pro-proliferative effect. Interestingly, we observed that both NOX2 
and NOX4 activate p38 MAP kinase in Ea.Hy926 cells, and inhibition of this kinase 
prevents the proliferative response by these NOX proteins indicating that p38 MAP 
kinase contributes to the proliferative response induced by NOX2 or NOX4. Several 
other studies confirmed an involvement of NADPH oxidases in the activiation of p38 
MAP kinase [53, 72, 110]. Moreover, p38 MAP kinase was involved in NOX4-
mediated proliferation of pulmonary artery smooth muscle cells in response to 
urotensin-II [107] and in NOX2-mediated proliferation of hepatic stellate cells by 
PDGF [110]. 
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4.5 Regulation of NADPH oxidase subunits NOX2 and NOX5 by 
thrombin 
As we could already show that a prothrombotic state induces ROS generation and 
the expression of p22phox, we further investigated whether NOX5 and NOX2 are 
involved in these processes. We could show that 
(A) thrombin upregulates NOX2, NOX5 and NOX5S protein levels. 
(B) depletion of NOX2 and NOX5 by siRNA diminishes ROS production, 
proliferation, and the formation of capillary-like structures in response to 
thrombin. 
Interestingly, addition of thrombin, which is known to enhance ROS production of 
endothelial cells and of smooth muscle cells involving activation and induction of 
NADPH oxidases [33, 72, 78, 111], also enhanced NOX5 and NOX5S as well as 
NOX2 protein levels, and depletion of NOX5 or NOX2 decreased endothelial ROS 
production by thrombin. Similar to the situation in endothelial Ea.Hy926 cells where 
thrombin induced the NADPH oxidase subunit p22phox thus leading to enhanced 
ROS levels [72], upregulation of NOX5 proteins may also be required for NOX5-
dependent ROS production upon prolonged exposure to thrombin. This hypothesis is 
supported by our findings that ionomycin does not enhance ROS levels in quiescent 
HMEC-1 cells, but effectively enhances ROS levels in response to thrombin [53]. 
Similar to our study, however, ionomycin did not enhance ROS levels in mouse 
microvascular endothelial cells under basal conditions [112], suggesting that NOX5 
levels may be limiting in mediating a response to enhanced calcium levels in resting 
endothelial cells.  
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Since thrombin is known to enhance calcium levels in endothelial cells [113], it is 
tempting to speculate that such a pathway may contribute to ROS generation by 
NOX5 activation. Initial studies in our group using the calcium chelator BAPTA-AM 
showed a decrease in ROS levels in HMEC-1 cells in response to thrombin. 
However, since BAPTA-AM also reduced basal ROS levels, and thrombin also 
upregulated NOX5S and NOX2 which are not activated by calcium, it appears that a 
certain calcium level may be required for signaling processes leading to the activation 
of NADPH oxidase-dependent ROS production. Additional elevation of calcium may 
then specifically lead to the activation of calcium-binding NOX5 variants.  
In contrast, depletion of NOX5 and NOX2 diminished thrombin-stimulated 
proliferation and in vitro angiogenesis, indicating that both proteins are involved in the 
control of the endothelial proliferative response to thrombin. Similarly, ROS derived 
from a NOX2-based NADPH oxidase have been shown to be involved in VEGF-
regulated angiogenesis [48]. 
4.6 Regulation of the NADPH oxidase subunit p22phox by ER-
stress 
It has been previously shown that the NADPH oxidase subunits NOX1 and NOX4 
can interact with PDI [56] and that NOX4 is involved in 7-ketocholesterol-induced ER-
stress and subsequently in the apoptosis of smooth muscle cells [55]. We therefore 
investigated the effect of thapsigargin- and tunicamycin-induced ER-stress [50] on 
the endothelial ROS generation and the expression of p22phox. We could show that  
(A) PDI colocalizes with NOX4 and induces ROS generation in endothelial cells. 
(B) thapsigargin and tunicamycin induces ROS generation in endothelial 
Ea.Hy926 cells. 
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(C) expression of p22phox is induced by ER-stress and depletion of p22phox 
diminishes ER-stress-induced ROS generation.  
(D) depletion of the transcription factors ATF4 and XBP1 reduces not only ER-
stress-induced ROS generation, but - in the case of XBP1 - also p22phox 
induction by ER-stress, whereas overexpression of ATF4 and XBP1 increases 
p22phox expression and ROS generation.  
(E) ER-stress and overexpression of ATF4 increases the luciferase activity of a 
reporter construct containing the p22phox promoter. 
(F) ER-stress increases the luciferase activity of a reporter construct containing 
XBP1 and ATF4 binding sites cloned from a distal upstream region of the 
p22phox gene in a XBP1- and ATF4-dependent manner.  
As we have shown, NOX2, NOX4, NOX5 as well as p22phox were localized in the 
ER of endothelial cells, where also PDI is localized, an ER-localized thiol 
oxidoreductase assisting in redox protein folding [56-58]. 
Similar to the situation in smooth muscle cells [56, 114], we could localize PDI 
together with NOX4 and to a weaker extent also with NOX1. Furthermore, we could 
demonstrate that PDI mediates ROS generation. These results match the 
observation that NOX1, NOX4 as well as p22phox interact with PDI and that PDI 
contributes to ROS generation in smooth muscle cells [56-58]. Interestingly, also in 
phagocytic cells an interaction between PDI and p22phox could be demonstrated 
[115]. Although we could show that a PDI mutant without chaperone function is not 
able to increase ROS generation in endothelial cells, in vascular smooth muscle cells 
the chaperone function of PDI did not seem not to be required to support the NADPH 
oxidase activity [56, 114], indicating a cell-type specific function of PDI. 
Pro-inflammatory stimuli such as angiotensin-II, PDGF [116] or thrombin [53, 72] are 
known to induce NADPH oxidase expression and ROS generation. These stimuli are 
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involved in pathophysiological processes like atherosclerosis or pulmonary 
hypertension which in turn are associated with an increased ROS generation and 
increased expression of NADPH oxidases. On the other hand, pathophysiological 
processes such as atherosclerosis are associated with the accumulation of 
oxysterols which induce ER-stress, triggering the unfolded protein response (UPR) 
[16, 55, 60]. Therefore it is possible that the UPR plays also a role in the regulation of 
NADPH oxidase. The UPR is characterized by a general attenuation in protein 
synthesis with a simultaneous increase in the expression of so-called UPR genes 
such as specific transcription factors like XBP1 and ATF4 [61, 62].  
In this study, we could demonstrate that ATF4 and XBP1 modulate ROS generation 
in endothelial cells. Oxidative stress is a common event upon UPR [62], as the ER 
has an oxidizing environment to promote protein folding [117], which is maintained by 
the ER oxidoreductase 1 (Ero1). It has been reported that Ero1 is upregulated upon 
cellular stress conditions and that Ero1 is able to transfer electrons to molecular 
oxygen to generate H2O2 [118]. Furthermore, it has been shown in Caenorhabditis 
elegans that silencing of Ero1 inhibits tunicamycin-induced ROS generation [119]. 
Interestingly, a constitutively active Ero1 alone was not able to induce ROS 
generation when overexpressed in yeast [120], indicating that other proteins than 
Ero1 are important to induce ROS generation upon ER-stress. We observed a 
complete abolishement of ROS generation in response to thapsigargin-induced ER-
stress upon depletion of p22phox in endothelial cells suggesting the involvement of 
NADPH oxidase in ROS production by ER-stress. In support, it has been reported 
that NOX4 may contribute to ER-stress induced ROS generation in smooth muscle 
cells [55]. 
This assumption was supported by our findings that ER stressors leading to UPR as 
well as ATF4 and XBP1 are able to enhance p22phox expression and p22phox 
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promoter activity. In line, we identified a proximal putative ATF4 binding site in the 
p22phox promoter as well as a distal cluster of potential XBP1 and ATF4 binding 
sites which could serve as an enhancer element. In support, ER-stress and ATF4 or 
XBP1 overexpression increased luciferase activity of a construct driven by this 
putative UPR-responsive element and depletion of ATF4 and XBP1 abolished the 
ER-stress induced activity of this construct. These findings suggest that the NADPH 
oxidase subunit p22phox which is common to most of the NADPH oxidase family 
members, is regulated by a transcriptional mechanism in response to ER-stress 
involving ATF4 and XBP1. This is further supported by our findings that inhibition of 
the transcription abolished p22phox induced mRNA expression upon ER-stress and 
that silencing of XBP1 also decreased ER-stress induced p22phox protein 
expression. 
To date, only little is known about the regulation of the p22phox gene expression. It 
was shown that AP-1 and NFκB, two redox sensitive transcriptions factors, are both 
able to regulate p22phox gene expression [121, 122], which is consistent with our 
previous observation of a redox-sensitive regulation of p22phox mRNA expression 
upon thrombin stimulation [72]. Furthermore, both transcription factors can be 
induced by prolonged UPR [123-125]. However, our study demonstrated a direct 
involvement of the UPR genes ATF4 and XBP1 in the control of p22phox gene 
expression. Although we cannot completely rule out a contribution of AP-1 or NFκB 
on ER-stress-induced p22phox expression, our findings that the distal UPR 
responsive p22phox enhancer element seems not to contain putative binding sites 
for these transcription factors gives a strong hint on the involvement of UPR genes in 
p22phox expression.  
In addition, XBP1 can also induce PDI which can increase ROS generation in 
response to ER-stress, and can have a regulatory function on NADPH oxidases in 
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smooth muscle cells [56]. In line, our preliminary results suggest that XBP1 could 
also modulate NOX4 expression in endothelial cells further emphasizing that UPR 
genes may affect NADPH oxidase expression and activity on multiple levels. Another 
pro-apoptotic transcription factor which is induced by XBP1 and by ATF4 is the 
C/EBP-homologous protein (CHOP). However, we could not find any potential CHOP 
binding site in the upstream region of p22phox and therefore an involvement of 
CHOP appeared to be unlikely in the regulation of p22phox. 
One potential target for the ROS generated during ER-stress is the protein 
phosphatase 1 (PP1). PP1 counteracts PERK which phosphorylates eIF1α during 
UPR by dephosphorylating eIF2α thus restoring protein translation [62]. Consistently 
with our observation that ER-stress induces p22phox levels and subsequently 
increases ROS levels, it was reported that PP1 can be reversibly inhibited by H2O2 
[126]. Another target for increased ROS generation in the UPR is the protein tyrosine 
phosphatase 1B (PTP1B), localized in the ER-membrane. It was reported for 
endothelial cells, that NOX4 is able to interact and subsequently inactivate PTP1B 
[127]. Interestingly, there is evidence that this phosphatase may potentiate the IRE1-
dependent signaling during the UPR as silencing of PTP1B results in reduced 
apoptosis [128]. Interestingly this is controversial to the reported pro-apoptotic 
function of NOX4 upon prolonged ER-stress in smooth muscle cells, where a 
phosphorylation cascade initiated by IRE1 resulted in NOX4-dependent apoptosis 
[55]. Again, different cell types and species could be one reason for the controversial 
observations. Altogether, our observations indicate that NADPH oxidase expression 
and function can be induced by ER-stress and UPR mediators, suggesting a possible 
role of NADPH oxidase-derived ROS generation in the UPR. 
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4.7 Conclusion 
The importance of the various NOX homologues for vascular function is still an open 
question. This present study showed that endothelial cells express at least four of the 
five known NOX homologues as we could show that these cells express in addition to 
NOX2 and NOX4 also NOX1 and NOX5, and that coexpression of various NOX 
proteins in one single cell can take place. However, the contribution of NOX1 to 
endothelial basal ROS generation and proliferation seems to be limited. Still, NOX1 
could be important under specific conditions of endothelial cell activation, the 
elucidation of which needs further investigations.  
The other NOX homologues NOX2, NOX4 and NOX5 contribute equally to basal 
endothelial ROS generation, proliferation and angiogenesis. There are differences in 
the intracellular localization of the NOX homologues in endothelial cells. NOX2, 
NOX4 and NOX5 are mainly localized in the ER, but NOX2 is also partially localized 
to the plasma membrane while the precise localization of NOX1 is still unclear. Stress 
factors such as thrombin and ER-stress are able to induce ROS generation. Here we 
showed that thrombin induces NOX2 and NOX5 expression and that NOX2 and 
NOX5 contribute to endothelial ROS generation, proliferation and angiogenesis upon 
thrombin stimulation. Differences in the fine tuning of NOX2 and NOX5 activation 
could be relevant and the exact role of ROS generation by either NOX2 or NOX5 is 
still not precisely known. However, these novel findings mark NOX2, NOX5 as well 
as ROS in general as novel targets for antithrombotic research in the future. 
Furthermore, the identification of calcium-dependent and –independent NOX5 
variants in endothelial cells is a novel finding. However, activation and embedment of 
NOX5 in calcium-related pathways remains still unclear and constitutes a promising 
topic for future research. 
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The present study also shows for the first time that p22phox, which is required for the 
function of most NOX homologues except NOX5, is induced by ER-stress, and that 
the UPR genes ATF4 and XBP1 enhance ROS generation by upregulating p22phox. 
Although, little is known about the involvement of NADPH oxidases in the UPR, these 
findings suggest that NADPH oxidases may play a role in the this stress response. 
In summary, the results of this study reveal new insights in the role of ROS and novel 
NADPH oxidases in endothelial cells under basal and stress conditions which can 
serve as new background for further research in this field.  
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5 Summary 
Increased levels of reactive oxygen species (ROS) contribute to vascular diseases 
like pulmonary hypertension and atherosclerosis. Although a NOX2-containing 
NADPH oxidase similar to the neutrophil one has been described to be active in 
endothelial cells, the contribution of newly discovered NOX homologues (NOX1-
NOX5) was still unclear. Therefore, the overall aim of this study was to better 
characterize the expression, regulation and function of NOX homologues in different 
endothelial cell models.  
First, we could demonstrate the presence of NOX1, NOX2, NOX4, NOX5 including 
NOX5S as well as p22phox mRNA and protein levels in Ea.Hy926 or HMEC-1 cells. 
Furthermore, NOX5 protein was also present in endothelial and smooth muscle cells 
in the vascular wall of spleen and lung tissue. We found that NOX2, NOX4 and NOX5 
were present in an intracellular perinuclear compartment, whereby NOX2 and NOX4 
could be localized simultaneously in one cell. NOX2, NOX4, NOX5 were able to 
interact with p22phox and overexpression of NOX2, NOX4 and NOX5 increased 
ROS generation, although NOX5-dependent ROS generation did not require the 
presence of p22phox. NOX2, NOX4 and NOX5 also increased endothelial 
proliferation while depletion of NOX2, NOX4 and NOX5 decreased ROS generation, 
proliferation and tube forming ability indicating angiogenic activity under basal 
conditions. NOX2- and NOX4-induced proliferation was mediated by p38 MAP 
kinase.  
Although NOX1 expression as well as the expression of its regulatory subunits 
NOXO1 and NOXA1 was detectable in endothelial cells, depletion of NOX1 did not 
significantly affect basal ROS generation or proliferation of endothelial cells.  
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Second, we could demonstrate the upregulation of NOX2, NOX5 and NOX5S after 
thrombin stimulation in endothelial cells and the modulation of p22phox expression in 
an ATF4- and XBP1-dependent manner under ER-stress conditions. Cellular stress 
either by thrombin or UPR also induced ROS generation of endothelial cells. In 
addition, thrombin induced proliferation and enhanced the tube forming ability of 
endothelial cells. Thrombin-induced ROS generation, proliferation and tube forming 
ability were diminished by silencing NOX2 or NOX5, whereas UPR induced ROS 
generation was inhibited by silencing p22phox as well as by silencing ATF4 or XBP1. 
In summary, this work provides evidence that in endothelial cells, NOX2, NOX4 and 
NOX5, but not NOX1, contribute to basal ROS generation, proliferation and 
angiogenesis and that the NOX proteins NOX2 and NOX5 as well as p22phox play 
an important role in the response to thrombin and ER-stress providing new insights in 
endothelial function and redox signaling. 
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7 Appendix 
7.1 Abbreviations 
Akt   protein kinase B (PKB)      
AngII  angiotensin II      
ARNT  arylhydrocarbon receptor nuclear translocator     
ATF4  activating transcription factor 4      
ATF6  activating transcription factor 6      
BAPTA 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid   
BiFC  bimolecular fluorescence complementation    
BiP  binding protein      
BrdU  5-bromo-2’deoxyuridine      
BSA  bovine serum albumin      
Ca2+  calcium      
CaCo2 carcinom Colon 2       
CFP  cyan fluorescent protein      
CGD  chronic granumaltous disease       
CHOP C/EBP-homologous protein 
DAB Diaminobenzidine 
DCF 5-(and-6)-chloromethyl-2‘,7‘-dichlorodihydrofluorescein diacetate 
(H2DCFDA)   
DEPC diethylpyrocarbonate    
DHE  dihydroethidium         
DMEM Dulbecco's modified Eagle medium      
DMSO dimethylsulfoxide          
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DTT  dithiothreitol      
DUOX dual oxidase      
Ea.Hy926 endothelial alike hybridoma 926       
EC  endothelial cells       
ECAM endothelial cellular adhesion molecules      
eIF2α  eukariotic initiation factor 2 α      
eNOS  endothelial nitric oxide synthase      
EPO  erythropoietin      
ER  endoplasmic reticulum      
ERK  p41/42 extracellular signal regulated kinase     
ET-1  endothelin 1      
ETA  endothelin receptor A      
ETB  endothelin receptor B      
GAPs  GTPase activating proteins      
GDIs  guanine nucleotide exchange inhibitors      
GEFs  guanine nucleotide exchange factors      
GFP  green fluorescence protein      
GPR  G protein-coupled receptors      
GPx  glutathion peroxidase      
GTT  guanidinethiocyanate      
h  hours      
H2O2  hydrogenperoxide      
HAT  hypoxanthine, aminopterin, thymidin      
HBSS  Hank’s balanced salt solution      
HEK293 human embryonic kidney 293 cells      
HIF-1  hypoxia inducible factor-1      
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HMEC human microvascular endothelial cells      
HRE  hypoxia-responsive elements      
hU-II  human urotensin-II       
HUVEC human umbilical vein endothelial cells      
ICAM–1 intercellular adhesion molecule       
IGF-1  insulin-like growth factor      
IL1-α  interleukin-1 α      
IRE1  inositol requiring element 1      
JNK  c-jun N-terminal kinase      
LDL  low density lipoprotein      
L-NAME N-ω-nitro-L-arginine methyl ester       
LPS  lipopolysaccharides      
MAPK  mitogen activated protein kinases      
MEK1  mitogen activated protein kinase kinase 1     
MF  microsomal fracation      
min  minutes  
MOPS 3-(N-morpholino)propanesulfonic acid 
mRNA messenger RNA      
NAC  N-acetyl-cysteine      
NADPH Nicotinamide adenine dinucleotide phosphate     
NO  nitric oxide      
NOX1-5 NADPH oxidase 1 - 5       
NOXA1 NADPH oxidase activator 1       
NOXO1 NADPH oxidase organizer 1       
O2-.  superoxide anion radical      
OH.  hydroxyl radicals      
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ONOO- peroxynitrite       
oxLDL oxidated low density lipoprotein       
PAF  platelet activation factor      
PAGE  polyacrylamide gel electrophoresis      
PASMC pulmonary artherial smooth muscle cells    
PBS  phosphate-buffered saline       
PCR  Polymerase chain reaction     
PDGF  platelet derived growth factor      
PDI  protein disulfide isomerase      
PERK  PKRC endoplasmatic reticulum kinase      
PGI2  prostaglandin I2 or prostacyclin      
PH  pulmonary hypertension       
-phox  phagocytic oxidase      
PI3K  phosphatidyl-inositol-(3) kinase      
PKB  protein kinase B         
PMN  polymorphonuclear leukocytes 
PP1  protein phosphatase 1 
PTP1B protein tyrosine phosphatase 1 B      
qPCR  quantitative PCR      
RH123 rhodamine123      
ROS  reactive oxygen species      
RT-PCR reverse transcription polymerase chain reaction    
SDS  Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siCtr  nonspecific siRNA       
siRNA  small interfering RNA      
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SOD  superoxide dismutase      
TCL  total cell lysate  
TEMED Tetramethylethylenediamine     
TF  tissue factor      
TGF-β transforming growth factor β      
TMB  tetramethyl-benzidine      
TNFα  tumor necrosis factor α      
Tris  tris(hydroxymethyl)aminomethane 
UPR  unfolded protein response      
VEGF  vascular endothelial growth factor      
VSMC vascular smooth muscle cells       
XBP1  X-box binding protein 1      
YFP  yellow fluorescent protein  
 
Appendix 
 139
7.2 List of figures 
Fig. 1  Schematic overview about the progression of atherosclerosis. 3 
Fig. 2  Reactive oxygen and reactive nitrogen species in vascular cells. 5 
Fig. 3  Schematic overview of the structure and activation of the phagocytic 
NADPH oxidase. 6 
Fig. 4  Schematic overview of the NOX homologues NOX1 to NOX5. 8 
Fig. 5  Schematic overview of NOXO1 and NOXA1 in comparison with their 
homologues p47phox and p67phox. 9 
Fig. 6  Schematic overview of the unfolded protein response (UPR). 10 
Fig. 7  Activation of ATF4 and XBP1 by unfolded protein response. 11 
Fig. 8  Luciferase reporter plasmid maps. 24 
Fig. 9  Principle of gene silencing using the siStrike system. 25 
Fig. 10  Schematic overview over the TOPO cloning principle. 30 
Fig. 11  Structure of 5-(and-6)- chloromethyl-2',7'- dichlorodihydrofluorescein 
diacetate, acetyl ester (CM-H2DCFDA). 45 
Fig. 12  Structure of the dihydroethidium. 46 
Fig. 13  Schematic overview  of the working principle of the polymerase chain 
reaction (PCR). 56 
Fig. 14  NOX1, NOX2, NOX4 and p22phox mRNA and protein are expressed in 
endothelial cells. 70 
Fig. 15  Different NOX5 splice variants are expressed in endothelial cells. 71 
Fig. 16  Different NOX5 proteins are expressed in endothelial cells. 73 
Fig. 17  p22phox and NOX5 are expressed in the vessel wall. 74 
Fig. 18  NOXA1 mRNA is expressed in endothelial cells and HEPG2 cells. 75 
Fig. 19  NOXO1 mRNA is expressed in endothelial cells and  HEPG2 cells. 76 
Appendix 
 140
Fig. 20  NOX2 and NOX4 colocalize in an intracellular compartment in endothelial 
cells, but only NOX2 colocalizes with f-actin. 78 
Fig. 21  NOX2, NOX4 but not NOX1 are intracellularly localized in endothelial  
 cells. 79 
Fig. 22  p22phox, NOX2 and NOX4 are expressed in the endoplasmic reticulum of 
endothelial cells. 80 
Fig. 23  p22phox, but not NOX2 and NOX4 are localized in the endoplasmic 
reticulum of cervix carcinoma cells. 81 
Fig. 24  NOX5 variants are expressed in an ER like compartment in endothelial 
cells. 82 
Fig. 25  Bimolecular fluorescence studies show an interaction between NOX2, 
NOX4, NOX5S or NOX5β and p22phox. 83 
Fig. 26  p22phox coimmunoprecipitates with NOX2, NOX4, NOX5S and NOX5β. 85 
Fig. 27  p22phox, NOX2, NOX4 and NOX5 are downregulated by specific siRNA. 86 
Fig. 28  p22phox, NOX2, NOX4 and NOX5 modulate ROS generation of endothelial 
cells. 87 
Fig. 29  p22phox is not required for NOX5S- or NOX5β-mediated intracellular ROS 
production in endothelial cells. 88 
Fig. 30  Calcium increases NOX5 dependent ROS generation in endothelial cells. 89 
Fig. 31 p22phox, NOX2, NOX4 and NOX5 modulate the proliferation of endothelial 
cells. 90 
Fig. 32 The p38 MAP kinase contributes to the proliferative response mediated by 
NOX2 and NOX4. 91 
Fig. 33  NOX1 does not contribute to basal ROS generation and proliferation of 
endothelial cells. 92 
Fig. 34  NOX2 and NOX5 are regulated by thrombin in endothelial cells. 94 
Appendix 
 141
Fig. 35  NOX2 and NOX5 mediates thrombin-induced ROS generation in endothelial 
 cells. 95 
Fig. 36   NOX2 and NOX5 mediates thrombin induced proliferation and tube 
formation in endothelial cells. 96 
Fig. 37  Protein disulfide isomerase is associated with NOX4 and increased ROS 
generation in endothelial cells. 97 
Fig. 38  ER-stress induces ROS generation via p22phox in endothelial cells. 98 
Fig. 39  ER-stress increases p22phox mRNA and protein levels in endothelial  
 cells. 99 
Fig. 40  Thapsigargin induces XBP1 and ATF4 activation in endothelial cells. 100 
Fig. 41  ATF4 and XBP1 mediates ROS generation under thapsigargin stimulation in 
endothelial cells. 101 
Fig. 42  ATF4 and XBP1 mediates p22phox expression under thapsigargin 
stimulation in endothelial cells. 102 
Fig. 43  ER-stress and ATF4 activates p22phox promoter in endothelial cells. 103 
Fig. 44  ER-stress activates a p22phox enhancer element via ATF4 and XBP1 in 
endothelial cells 104 
Appendix 
 142
7.3 Curriculum vitae 
Persönliche Daten    
Name Andreas Petry 
Geburtsdatum 06. Dezember 1978     
Geburtsort Berlin 
Staatsangehörigkeit deutsch 
Familienstand ledig 
 
Hochschule 
2004-2009 Dissertation zum Dr. rer. nat. am Lehrstuhl für 
Pharmazeutische Biologie an der Ludwig-Maximilians-
Universität München, unter der Betreuung von Frau 
Prof. Dr. Angelika Vollmar, in der Experimentellen 
Kinderkardiologie bei Frau Prof. Dr. Agnes Görlach am 
Deutschen Herzzentrum München des Freistaates 
Bayern, Klinik an der Technischen Universität 
München 
2002-2003 Diplomarbeit im Fach Genetik am 
Chemotherapeutischen Forschungsinstitut  
 Georg-Speyer-Haus, Frankfurt am Main 
09/2002 Diplomprüfung Biologie 
09/2000 Vordiplomprüfung Biologie 
1998-2003 Studium der Biologie an der Johann Wolfgang Goethe-
Universität Frankfurt am Main 
Appendix 
 143
1998-2003 Studium der Informatik an der Johann Wolfgang 
Goethe-Universität Frankfurt am Main 
 
Schule 
1989-1998 Gymnasium Bischof-Neumann-Schule, Königstein im 
Taunus, Abschluss: Allgemeine Hochschulreife 
1985-1989  Grundschule Max-von-Gagernschule, Kelkheim am 
Taunus 
 
Berufsausbildung und Tätigkeiten 
seit 09/2003 wissenschaftlicher Mitarbeiter in der Experimentellen 
Kinderkardiologie bei Frau PD Dr. Agnes Görlach am 
Deutschen Herzzentrum München des Freistaates 
Bayern, Klinik an der Technischen Universität 
München 
 
Auszeichnungen und Förderungen 
2009 Reisestipendium der GlaxoSmithKline Stiftung für „88th 
Annual Meeting of the German Physiological Society 
2009”, Gießen, 22.03.2009 – 25.03.2009 
2008  Reisestipendium der GlaxoSmithKline Stiftung für 
“Annual Meeting of the Society for Microcirculation & 
Vascular Biology (GfMVB) 2008”, Aachen, 25.09.2008 
– 27.09.2008 
2006-2007 Stipendiat im Graduiertenkolleg 438 „Vaskuläre 
Biologie in der Medizin“ 
Appendix 
 144
03/2006    Finalist bei der “YOUNG FEPS poster award session” 
auf dem “Joint Meeting of The German Physiologic 
Society and The European Federation of Physiologic 
Societies 2006” in München. Titel der 
Posterpräsentation: “Multiple NOX proteins mediate 
the proliferative response in endothelial cells”. 
Publiziert in: Journal of Vascular Research 2006;43: 
571-571 
2005  Reisestipendium der GlaxosmithKline Stiftung für „3rd 
European Meeting on Vascular Biology and Medicine 
2005”, Hamburg, Germany, 28.09.2005 – 30.09.2005 
2004-2005   Stipendiat im Graduiertenkolleg 438 “Vaskuläre 
Biologie in der Medizin” 
2004-2007 Kollegiat im Graduiertenkolleg 438 “Vaskuläre Biologie 
in der Medizin” 
2004  Reisestipendium der GlaxoSmithKline Stiftung für 
“American Heart Association - Scientific Sessions 
2004”, New Orleans, LA, 07.11.2004 – 10.11.2004 
09/2000 Vorgeschlagen als Stipendiant zur Förderung durch 
die „Studienstiftung des deutschen Volkes” aufgrund 
der erbrachten Leistungen in der Vordiplomprüfung 
Biologie
Appendix 
 145
7.4 Publications 
Manuscripts 
 
Petry A, Djordjevic T, Weitnauer M, Kietzmann T, Hess J, Görlach A. NOX2 and 
NOX4 mediate proliferative response in endothelial cells. Antioxidants & Redox 
Signaling, 8:1473-1484, 2006 
  
 BelAiba RS*, Djordjevic T*, Petry A*, Diemer K, Bonello S,Banfi B, Hess 
J,Pogrebniak A, Bickel C,Görlach A. NOX5 variants are functionally active in 
endothelial cells. Free Radical Biology & Medicine, 42:446-459, 2007, 
*contributed equally to this manuscript. 
 
Diebold I, Djordjevic T, Petry A, Hatzelmann A,Tenor H, Hess j,Görlach A. 
Phosphodiesterase 2 mediates redox-sensitive endothelial cell proliferation and 
angiogenesis by thrombin via Rac1 and NADPH oxidase 2. Circulation Research, 
104:1169-1177, 2009 
 
Published Abstracts 
 
Djordjevic T, BelAiba R, Diebold I, Bonello S, Petry A, Bickel C, Kietzmann T, 
Hess J, Görlach A: Rac controls the expression of the HIF target gene PAI-1 in 
response to thrombin in vascular cells. Pflugers Archiv-European Journal of 
Physiology, 447:S69, 2004 
  
Bickel C, Pogrebniak A, Diemer K, Bonello S, Petry A, BelAiba R, Acker H, Hess 
J, Görlach A: Human vascular cells express a distinct NOX5 isoform: Role in the 
generation of reactive oxygen species and the proliferative response. Cardiology 
in the Young, 14:50, 2004 
  
Bickel C, Petry A, Djordjevic T, Diemer K, Pogrebniak A, Bonello S, BelAiba RS, 
Hess J, Acker H, Görlach A: Human vascular cells express a distinct NOX5 
isoform: Role in the generation of reactive oxygen species and the proliferative 
responses. Circulation, 110; III-157, 2004 
 
Djordjevic T, Petry A, Bickel C, Bonello S, BelAiba RS, Hess J, Acker H, 
Pfeilschifter J, Görlach A: Interaction of p22phox with NOX2 or NOX4 results in 
ROS production and proliferation of endothelial cells. Circulation, 110:III-284, 
2004 
 
Bonello S, Petry A, Belaiba RS, Zaehringer C, Hess J, Djordjevic T, Görlach A: 
Human HIF-3α is an inhibitor of the HIF pathway in endothelial cells. Circulation, 
110:III-214, 2004 
 
Petry A, Djordjevic T, Bickel C, Bonello S, BelAiba RS, Pfeilschifter J, Hess J, 
Görlach A. Interaction of p22phox with NOX2 or NOX4 results in ROS production 
and proliferation of endothelial cells. Pflugers Archiv-European Journal of 
Physiology, 449, S1, S26, 2005 
 
 
Appendix 
 146
Bickel C, Petry A, Djordjevic T, Diemer K, Pogrebniak A, Bonello S, BelAiba RS, 
Acker H, Hess J, Görlach A. Endothelial cells express a distinct, functionally 
active NOX5 isoform.  Pflugers Archiv-European Journal of Physiology, 449, S1, 
S26, 2005 
 
Bonello S, Petry A, BelAiba RS, Djordjevic T, Zähringer C, Hess J, Görlach A. 
HIF3alpha inhibits the hypoxic response in vascular cells. Pflugers Archiv-
European Journal of Physiology, 449, S1, S40, 2005 
 
Petry A, Djordjevic T, Bickel C, Bonello S, BelAiba RS, Pfeilschifter J, Hess J, 
Görlach A: Reactive oxygen species upregulate NOX4, but not NOX2, in 
endothelial cells. Journal of Vascular Research, 42/S2, 2005 
 
Görlach A, Bickel C, Petry A, Djordjevic T, BelAiba RS, Diemer K, Bonello S, 
Acker H, Pogrebniak A, Hess J. A NOX5 isoform is functionally active in human 
endothelial cells”. Journal of Vascular Research 42, II/39, 2005 
 
Bonello S, Petry A, Belaiba RS, Zaehringer C, Djordjevic T, Hess J, Görlach A. 
Human HIF-3α is a novel inhibitor of angiogenesis. Journal of Vascular Research 
42, II/46, 2005 
 
Petry A, Djordjevic T, Weitnauer M, BelAiba RS, Hess J, Görlach A. Multiple NOX 
proteins mediate the proliferative response in endothelial cells. Acta 
Physiologica, 86, 1, 141, 2006 
 
Djordjevic T, Petry A, Weitnauer M, BelAiba RS, Hess J, Görlach A. Endothelial 
proliferation is mediated by multiple NOX proteins. Cardiology in the Young, 
16/2,32, 2006 
 
Petry A, Djordjevic T, Weitnauer M, BelAiba RS, Diemer K, Hess J, Görlach A. 
Multiple NOX Proteins Mediate the Proliferative Response in Endothelial Cells. J 
Vasc Res 43:533-580, 2006 
 
Bonello S, BelAiba R, Petry A, Djordjevic T, Zahringer C, Görlach A. HIF3 α is a 
negative modulator of the hypoxic response in endothelial cells. J Vasc Res 
43(1):49-50, 2006  
 
Djordjevic T, Petry A, BelAiba RS, Hess J, Görlach A. Urotensin-II stimulates 
NOX2- and NOX4-dependent angiogenesis. Acta Physiologica, 191, 2007 
 
Diebold I, Petry A, Burger M, Djordjevic T, Hess J, Görlach A. FoxO3 Mediates 
Urotensin-II-induced MMP2 Expression In Pulmonary Artery Smooth Muscle 
Cells. Circulation, 116: II_109, 2007 
 
Djordjevic T, Petry A, Schäfer N, Weitnauer M, Hess J, Görlach A. Urotensin-II 
activates Rac and ROS production in pulmonary artery smooth muscle cells 
involving GPR14 and Gai proteins. Circulation, 116: II, 2007 
 
Diebold I, Petry A, Burger M, Hess J, Görlach A. FoxO3 mediates MMP-2 
expression by urotensin-II.  Acta Physiol, 192, S663, 2008 
 
Appendix 
 147
Diebold I, Petry A, Burger M Hess J, Görlach A. FoxO3 regulates urotensin-II 
induced MMP2 expression in pulmonary artery smooth muscle cells. European 
Heart Journal, 29, 235, 2008. 
 
Diebold I, Petry A, Weitnauer M, Hess J, Görlach A.  Urotensin-II activates Rac1 
and ROS production in pulmonary artery smooth muscle cells involving Gai 
proteins. Cardiology in the young,18 (1):20.2008. 
 
Diebold I, Petry A, Burger M, Hess J, Görlach A. FoxO3 mediates urotensin-II-
induced matrix metalloproteinase-2 (MMP-2) in pulmonary vascular smooth 
muscle cells, Cardiology in the young, 18(1), 2008 
 
Diebold I, Djordjevic T, Petry A, Hatzelmann A, Tenor, H, Hess J, Görlach A. 
PDE2 mediates redox-sensitive endothelial cell proliferation and angiogenesis by 
thrombin via Rac1 and NOX2 Acta Physiol, 193, 2009 
 
Petry A, Diebold I, Schäfer N, Hess J, Görlach A. Thrombin activates NOX1 
involving Gαi and Rac1 in pulmonary artery smooth muscle cells Acta Physiol, 
193, 2009 
 
Presentations at international conferences  
 
Oral communications 
 
Petry A, Djordjevic T, Bickel C, Bonello S, BelAiba RS, Pfeilschifter J, Hess 
J, Gorlach A. Interaction of p22phox with NOX2 or NOX4 results in ROS 
production and proliferation of endothelial cells. 84th Annual Meeting of the 
German Physiological Society, Göttingen, 06.03-09.03.05. 
 
Petry A, Djordjevic T, Bickel C, Bonello S, BelAiba RS, Pfeilschifter J,Hess 
J, Gorlach A. Interaction of p22phox with NOX2 or NOX4 
Graduiertenkollegs “Vascular Biology in Medicine”, Herrsching a. 
Ammersee, 12.03. – 13.03.05. 
  
Petry A, Djordjevic T, Bickel C, Bonello S, BelAiba RS, Pfeilschifter J, Hess 
J, Görlach A. Reactive oxygen species upregulate NOX4, but not NOX2, in 
endothelial cellc. Journal of Vascular Research, Vol. 42/S2, 2005. 3rd 
European Meeting on Vascular Biology and Medicine, Hamburg, Germany, 
28.09.05 – 30.09.05. 
 
Petry A, Djordjevic T, Weitnauer M, BelAiba RS, Hess J, Görlach A. 
Multiple NOX proteins mediate the proliferative response in endothelial 
cells. 4. Symposium des DFG Graduiertenkollegs “Vascular Biology in 
Medicine”, Herrsching a. Ammersee, 10.11. – 11.11.07. 
  
Petry A, Djordjevic T, Weitnauer M, BelAiba RS, Hess J, Gorlach A. 
Multiple NOX proteins mediate the proliferative response in endothelial 
cells. Acta Physiologica 2006; Volume 186, Supplement 650 :PM07A-7. 
Joint Meeting of The German Society of Physiology and The Federation of 
European Physiological Societies 2006, Munich, 26.03.2006-29.03.2006 
 
Appendix 
 148
Petry A, Diebold I, Schafer N, Hess J, Gorlach A. Thrombin actvates NOX1 
involving Gi and Rac1 in pulmonary artery smooth muscle cells. The 88th 
Annual Meeting of The German Physiological Society, Giessen, 
22.03.2009-25.03.2009 
 
Petry A, Diebold I, Schäfer N, Hess J, Görlach A. Thrombin activates 
NOX1 involving Gαi and Rac1 in pulmonary artery smooth muscle cells. 75. 
Jahrestagung der Deutschen Gesellschaft für Kardiologie, Mannheim, 
16.04.2009 – 18.04.2009 
 
Poster presentations 
 
Petry A, Djordjevic T, BelAiba RS, Bonello S, Acker H, Hess J, Görlach A: 
The NADPH oxidase subunit p22phox is regulated by a redox-sensitive 
pathway in endothelial cells. 4th International Conference on Peroxynitrite 
and Reactive Nitrogen Species in Biology and Medicine, University of 
Konstanz, 27.07.04 – 31.07.04. 
 
Djordjevic T, Petry A, Bickel C, Bonello S, BelAiba RS, Acker H, 
Pfeilschifter J, Gorlach A: Interaction of P22phox With NOX2 Or NOX4 
Results in ROS Production And Proliferation Of Endothelial Cells. 
Supplement to Circulation Vol. 110/17; American Heart Association, 
Scientific Sessions 2004, New Orleans LA, 07.11.04 – 10.11.04. 
 
Petry A, DjordjevicT, Weitnauer M, BelAiba RS, Hess J, Görlach A: 
Multiple NOX proteins mediate the proliferative response in endothelial 
cells. The German Society of Physiology, Joint Meeting, München, 26.03 - 
29.03.06. 
 
Petry A, Djordjevic T, Weitnauer M, BelAiba RS, Diemer K, Hess J, 
Görlach A. Multiple NOX Proteins Mediate the Proliferative Response in 
Endothelial Cells. J Vasc Res 2006;43:533-580; Annual Meeting of the 
German Society for Microcirculation and Vascular Biology. Munich, 
Germany,12.10. – 14.10.06. 
 
Petry A, Diebold I, Schäfer N, Hess J, Görlach A: Thrombin activates 
NOX1 involving Gai and Rac1 in pulmonary artery smooth muscle cells. 
Annual Meeting of the German Society for Microcirculation and Vascular 
Biology. Aachen, Germany, 25.09.08 – 27.09.08. 
 
Invited talks 
 
A. Petry, T. Djordjevic, M. Weitnauer, R.S. BelAiba, J. Hess, A. Görlach: 
Multiple NOX proteins mediate the proliferative response in endothelial 
cells. I.Beritashvili Physiological Institute, Georgian Academy of Sciences, 
Tbilisi, Georgia, 04.04.07. 
Appendix 
 149
7.5 Acknowledgements 
First and foremost, I want to thank Prof. Dr. Agnes Görlach for providing the 
opportunity to perform this PhD thesis in her laboratories in Munich at the German 
Heart Center Munich. I am very thankful for her professional and personal support 
and the long, fruitful and inspiring discussions.  
 
I am also very grateful to my supervisor at the Ludwig-Maximilians-Universität 
München, Prof. Dr. Angelika Vollmar who accepted me as an external PhD student. 
To her go many thanks for support and discussions during the different progress 
stages of my thesis. 
 
I am very grateful to my former colleague Dr. Talija Djordjevic for her guiding, advice, 
kind support and motivating discussions especially in the initial stage of my work who 
initiates me in the art of ROS measurements as well as many other methods. I am 
indebted to her as well as to my former colleagues Dr. R. Siham Bel Aiba and Kerstin 
Diemer for kindly performing NOX5 RT-PCRs, angiogenesis assays and especially 
the immunohistochemistry assays.  
 
All the work of my thesis could not be done without all the grateful help and hard work 
of all the other current and former members of the research group of Prof. Dr. A. 
Görlach. Many thanks go to all of the ExKK for their collaborative support and 
stimulating discussions: Sabine Becht, Christian Bickel, Steve Bonello, Karel 
Chalupsky, Isabel Diebold, Johanna Ebner, Monika Fuchs, Korinna Griesser, Shang 
You He, Damir Kracun, Renaud Quillet, Florian Rieß, Gaby Römer, Michaela 
Appendix 
 150
Rößner, Tomasz Rzymski, Karim Sabrane, Thomas Schwend, Amrei Steinhoff, 
Michael Weitnauer, Stefan Würth and Christian Zähringer. 
 
I am also thankful to the AG Maßberg for helpful support of supplies, to the members 
of AG Koch for nice discussions to bring one on other thoughts and to the “morning-
coffee round” Monika, Birgit, Sabine and Christina. 
 
Deepest thanks go to all who invested time and effort in helping me in correcting and 
finalizing this work, especially Cristina Valcu, Katharina Reger, Andrea Buchstaller 
and my dear friend Silke Karl, without your help this work would never be done, thank 
you all so much! Many thanks also for all the chocolates, cookies and strange fruits! 
 
I also want to thank my friends for their encouragement, especially Patrick, Eva, Steffi 
and Claudia for giving moral support and always having an open ear, and of course I 
want to thank the little “Quälgeist” Karin for motivating and for her friendship. 
 
Eventually, I want to thank my family for all their love and constant support provided 
throughout my entire life. 
 
 
 
 
 
 
 
Appendix 
 151
7.6 Overview of used cloning PCR programs 
p22phoxYN: 
Enzyme Pfu (Bioron) 
Total  volume 50 µl 
Buffer (10x) 5 µl 
F-primer (10pmol/µl) 1 µl 
R-primer (10pmol/µl) 1 µl 
dNTP (5mmol/µl) 2 µl 
Template 25 ng 
Enzyme 1 µl 
Add H2O 50 µl 
Template pcDNA6CFPp22phox 
   
Temperature (°C) Time (min) Cycles 
94 1:00 1 
94 1:00 
27 55 1:00 
72 1:00 
72 5:00 1 
8 ∞ 1 
 
NOX2YC, NOX5SYC 
Enzyme HF Kit (Roche) 
Total  volume 25 µl 
Buffer (10x) 5 µl 
F-primer (10pmol/µl) 0.5 µl 
R-primer (10pmol/µl) 0.5 µl 
dNTP (5mmol/µl) 1.5 µl 
Template 25 ng 
Enzyme 0.4 µl 
Add H2O 25 µl 
Template pcDNA6CFPgp91phox 
 pGEX3xNOX5S 
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Temperature (°C) Time (min) Cycles 
95 1:00 1 
95 1:00 
27 59 1:00 
72 1:45 
72 7:00 1 
8 ∞ 1 
 
pEGFP-NOX4, pEYFP-NOX4 
Enzyme HF Kit (Roche) 
Total  volume 25 µl 
Buffer (10x) 5 µl 
F-primer (10pmol/µl) 0.5 µl 
R-primer (10pmol/µl) 0.5 µ 
dNTP (5mmol/µl) 1.5 µ 
Template 0.3 µg 
Enzyme 0.4 µ 
Add H2O 25 µl 
Template pCMV-NOX4YC 
   
Temperature (°C) Time (min) Cycles 
95 1:00 1 
95 1:00 
26 59 1:00 
72 2:10 
72 7:00 1 
8 ∞ 1 
 
